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During my PhD studies, I have worked with two enzymatic targets having 
diverse functions and so, different physiological/pathological features.  
The first part focused on the design and synthesis of human carbonic anhydrase 
inhibitors, which were tested against four hCA isoforms, the ubiquitous CA I and 
CA II and the tumor-associated ones CA IX and CA XII, thanks to the precious 
collaboration of Prof. Claudiu T. Supuran and colleagues. 
I have spent the last part of my PhD for the discovery of human monoamine 
oxidases inhibitors, which were tested against hMAOs and cortex synaptosomes 
thank to the valuable collaboration of Prof. Jacobus P. Petzer and Prof. Claudio 
Ferrante. 
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Chapter 1 
Carbonic anhydrases: functions and dark side 
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1.1 Introduction 
Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous enzymes found in numerous 
organisms across the tree of life, encoded by seven genetically distinct CA families: α-
, β-, γ-, δ-, η-, ζ- and the last discovered family θ-CAs [1–9]. Carbonic anhydrases are 
metalloenzymes and they are catalytically effective only with one metal ion bound 
within the active site cavity, the apoenzymes being devoid of any catalytic action [10–
16]. The active centre contains three amino acid residues which act as ligands, 
coordinating in a tetrahedral geometry the central divalent ion M(II). All the seven 
genetic families of CA may contain Zn(II) as metal ion, although it is substitutable with 
Cd(II) in the ζ-CAs [10]. γ-CAs seem to be endowed with Fe(II) ion, at least in 
anaerobic conditions [4,17], whereas Co(II) may substitute the zinc ion in many α-CAs 
without significant loss of the catalytic activity [1,18–20].  
Carbonic anhydrases catalyse reversible hydration of CO2 (eq.1) transforming two 
neutral molecules, CO2 and water, into a weak base (bicarbonate) and a strong acid (H+ 
ions). This very simple reaction is particularly slow at the physiological pH, while it 
becomes very effective at higher pH values, being instantaneous at pH > 12 [12,19,21–
23].  
 
 
 
Carbonic anhydrases make faster this reaction in physiological condition that is 
important for pH regulation, as well as for other crucial physiological processes like 
respiration, photosynthesis, pH homeostasis, CO2 transport and electrolyte secretion, 
virtually in all tissues in organisms [5,6,9–11,13,24–34].   
To date, fifteen isoforms of human carbonic anhydrase (hCAs) have been discovered 
(hCAI-XIV). They belong to the α-class and share a common organization of the active 
site, located in a deep cleft and containing a central zinc ion (Zn2+), coordinated by 
8 
 
three histidine residues (His94, His96 and His119) and a water molecule/hydroxide 
ion (Figure 1.1) [5,19,32,35]. 
 
 
Figure 1.1 Active site of hCA II, showing the network of interactions in the active site. Water 
molecules are indicated as red circles. The side chain of His64 is shown in both the “in” and 
“out” conformations [19]. 
 
The zinc-bound water molecule/hydroxide ion establishes hydrogen bond network 
with the hydroxyl group of Thr residue (Thr 199), and with two water molecules 
positioned on two opposite side: the first called “deep water” is located in a 
hydrophobic cavity, while the second is in a hydrophilic environment toward the 
entrance of the active site (Figure 1.1) [19,36]. All these interactions are able to increase 
zinc bound water molecule nucleophilicity. As a consequence, the proton transfer 
occurs leading to the production of the catalytically active form of the enzyme 
containing zinc-bound hydroxide ion. The hydration of carbon dioxide proceeds 
through a two-step catalytic mechanism (eq.2 and 3).  
The first step (eq.2) is the nucleophilic zinc-bound hydroxide ion attack on the CO2 
molecule located in a hydrophobic binding pocket, to obtain metal coordinated 
bicarbonate. The interaction between bicarbonate and central zinc ion is fairly weak; 
so, it is displaced by a water molecule and released in solution forming water 
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coordinated Zn2+, which is the acidic and inactive form of the enzyme (catalytically 
inactive enzyme, eq.2).  
 
 
 
The second step is the rate limiting one in which enzyme’s active form (eq.3)  is 
regenerated by the proton transfer directly to the buffer or assisted by His 64, which 
serves as a proton shuttle between the metal center and buffer molecules of the 
medium [37]. The presence of His 64 that works as a “proton-shuttle” affects positively 
the catalytic activity. Indeed the absence of this system in enzymes as CAIII, impaires 
activity about 500-fold [29,38–40].  
This working machinery based on a “ping-pong” mechanism,  makes some of the 
members of the CA superfamily among the most effective enzymes known in nature, 
with kcat/KM values close to the limit of the diffusion-controlled processes [25]. How 
anticipated, human carbonic anhydrases exist in fifteen isoforms which differ by 
molecular features, oligomeric arrangement, cellular localization, distribution in 
organs and tissues, expression levels, kinetic properties and response to different 
classes of inhibitors [5,34,35,41].  
Five of these enzymes are cytosolic (hCA I-III, hCA VII and hCA XIII), two are 
mitochondrial (CA VA and VB), four are membrane bound (hCA IV, hCA IX, hCA XII 
and hCA XIV), one is secreted (hCA VI) and three are acatalytic hCA-related proteins 
(CARPs, hCA VIII, X and XI) (Figure 1.2). Even if CARPs are acatalytic isozymes 
because of the absence of metal ion (these proteins not possess histidine residues 
required for the coordination of the zinc atom) [42],  they still possess significant 
functions in physiologic and pathologic processes as well as the other hCA isoforms 
(Table 1.1) [43]. 
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Figure 1.2. Domain composition and subcellular localization of catalytically active human α-
Cas [19]. 
 
CA I is the major isozyme found in human erythrocytes with a concentration of about 
6-fold higher than CA II, also found in erythrocytes. However, the specific activity of 
CA I in erythrocytes is 2 x 105 s-1, whereas the specific activity of CA II in erythrocytes 
is 106 s-1. Although CA I has been found to be expressed in a variety of tissues, its 
physiological role is not completely clear [19]. Feeener’s group demonstrated that this 
enzyme is involved in retinal and cerebral edema, and its inhibition may be a valuable 
tool for fighting these conditions [44]. CA II is the high activity or “rapid” isozyme in 
order to distinguish it from the low activity or “slow” one, hCA I. It is expressed in the 
cytoplasm of many cell types and it is involved in processes spanning from bone 
resorption to respiration and pH regulation. Other functions include urine formation 
and bicarbonate reabsorption in the kidney tubules, biosynthetic reactions such as 
gluconeogenesis, lipogenesis and ureagenesis, bone resorption and calcification, and 
probably many other less well understood physiologic/pathologic processes [19,45,46]. 
Deficiency of hCA II is characterized by renal tubular acidosis, osteopetrosis, cerebral 
calcification, and growth retardation [47]. hCA III is known as muscle isoform because 
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it is found in high levels in red skeletal muscle, even if this isoform is present also in 
adipocytes. The activity of hCA III is only 3% that of hCA II and is thought that its 
physiological importance is beyond its catalytical activity.  In fact, this enzyme 
possesses two reactive sulfhydryl groups able to reversibly bind glutathione, 
protecting cells from irreversible protein oxidation [48–50]. hCA IV is found in heart 
[51], brain [52], capillary bed of the eye [53], and erythrocytes [54] and is a possible 
drug target for several pathologies, including glaucoma (together with CA II and XII), 
retinitis pigmentosa and stroke [55,56]. The two mitochondrial isoforms hCA VA and 
hCA VB are implicated in metabolism. hCA VA is found in the mitochondria of the 
kidney, heart, lung, spleen and intestines; it provides bicarbonate for gluconeogenesis 
and fatty acids for pyrimidine base synthesis [57]. On the other hand, hCA VB is found 
in pancreas, kidney and salivary glands mitochondria, showing intermediate role in 
metabolism [58]. These two isoforms could be useful targets for antiobesity agents [59]. 
CA VI, the secreted isoform, is implicated in cariogenesis [60,61]. hCA VII has been 
implicated in neuronal excitation, contributing to epileptiform activity together with 
CA II and XIV [60–62]. Although hCAVIII not possess catalytic activity, its role has 
been documented in various pathologies. Indeed, has been associated with 
neurodegenerative diseases with studies conducted in mice and then in human, 
showing how mutations in CA8 gene cause mental retardation and ataxia. CARP VIII 
is known to be also involved in tumors, being upregulated in colorectal, lung and 
several other cancers [63]. The precise physiological/pathological roles of the 
remaining two acatalytic isoforms CA X and XI are poorly known, albeit ongoing 
studies are trying to shed light on these proteins. 
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Table 1.1. hCA isoforms, their organ/tissue distribution, subcellular localization, relative CO2 
hydratase activity and diseases in which they are involved. 
 
 
hCA XIII was localized in several tissues as the thymus, kidney, submandibular gland, 
small intestine, and notably in reproductive organs, accounting for its involvement in 
the sperm motility processes (probably together with CA XIV) [64]. hCA XIV is 
involved in epileptogenesis and has been localized to the apical and basal membranes 
of the retinal pigment epithelium. This implies that CA XIV have specific and unique 
functions in the context of acid-based balance in the retina. 
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1.2 Involvement of carbonic anhydrase IX and XII isoforms in tumors: the 
dark side of the enzyme 
The two remaining isoforms are the established tumor-related enzymes IX and XII 
[58,65,66]. These membrane-bound isoforms show a limited expression in normal 
tissues, unlike hCA I and hCA II [67]. hCA IX is a dimeric transmembrane glycoprotein 
possessing the catalytic domain oriented toward the extracellular milieu, working at 
the outer side of the cells [65,68–70]. It is overexpressed mainly in hypoxic tumours, 
being regulated by hypoxia and facilitate also the metastatic spread of solid tumors 
[69]. The extracellular acidosis is known to negatively affect drug uptake and radiation 
damage, so the overexpression of hCA IX is associated to radio- and chemotherapy 
resistance [71]. hCA XII shares common features with hCA IX, as the secondary 
structure, orientation and hypoxia induced expression; however, it is a monomer and 
lacks the proteoglycan-like domain [72]. It has a wider tissue distribution compared 
with isoform IX, including kidney, lung, prostate, ovaries, uterine endometrium, 
breast.  Unlike isoform hCA IX, hCA XII is regulated by estrogens and in breast cancer 
patients, hCA XII expression correlates with positive prognosis [73,74]. hCA XII 
possesses catalytic activity lower than hCA IX [75], and is generally associated with 
less-aggressive, well-differentiated tumor phenotypes, compared to the hCA IX- 
expressing tumors [67,76,77]. hCA IX mainly, but probably also hCA XII, regulates 
intra- and extracellular pH variations which take place in cellular metabolism 
stimulated by hypoxia. In fact, hypoxia is able to affect genes regulation through 
hypoxia-inducible factor 1, (HIF-1) favouring cellular adaptation to an anaerobic 
metabolism [78,79]. HIF-1 is a transcriptional factor protein constituted by two 
subunits: HIF-1α and HIF-1β. HIF-1β subunit is constitutively expressed and is located 
inside the nucleus. HIF-1α is an oxygen-regulated subunit working as “O2 sensor” 
system. During normoxia condition its concentration is influenced by degradation 
mechanism controlled by oxygen availability. Prolyl-4-hydroxylase (PHD), is able to 
hydroxylates the P564 on HIF-1α. This modification works as a signal for the von 
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Hippel-Lindau protein that binds HIF-1α and targets it for degradation by the 
ubiquitin–proteasome system (Figure 1.3, a) [80–88].  
 
 
Figure 1.3 (a) Mechanism of hypoxia-induced gene expression mediated by the HIF 
transcription factor [88]; (b) Proteins involved in pH regulation within a tumour cell [23]. 
 
On the other hand, the lack of oxygen under hypoxia inhibits the PHD activity leading 
to the absence of HIF-1α hydroxylation which cannot be recognized by the VHL 
protein. So, HIF-1α translocates to the nucleus where dimerizes with the HIF-1β, 
constituting the active form of the transcription factor that binds the hypoxia response 
element (HRE) in target genes and activate their transcription. Target genes include 
glucose transporters (GLUT1 and GLUT3) that increase glucose caption and take part 
in glucose metabolism, vascular endothelial growth factor (VEGF) that triggers 
neoangiogenesis, erythropoietin (EPO1) involved in erythropoiesis, carbonic 
anhydrase (CA) IX involved in pH regulation and tumorigenesis, and additional genes 
with functions in cell survival, proliferation, metabolism and other processes. The final 
effect of this transformation is a cell ready to face hypoxic condition switching the 
metabolism to anaerobic route. In normal tissues glucose follows the normal aerobic 
b a 
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processes (glycolysis, Krebs-cycle and oxidative phosphorylation) until its complete 
oxidation to carbon dioxide and water. Cancer cells in hypoxic conditions produce 
energy from glycolysis and lactic acid fermentation in the cytosol, completely 
changing its metabolism (the so-called Warburg effect). In this condition cells organize 
a complex machinery system constituted by transporters, pumps and carbonic 
anhydrases, able to cope the new state (Figure 1.3 b). The new system encourages the 
extracellular acidification and the maintaining of a weakly alkaline pH, which is 
optimal for cell proliferation and tumour survival as well as metastatic behaviour 
[66,89,90]. 
 
1.3 Carbonic anhydrase inhibition 
Since the discovery of Mann and Keilinin in 1940 about the capability of sulfanilamide 
to inhibit carbonic anhydrase, the researchers have discovered a huge number of 
molecules which effectively inhibit hCAs isoforms.  
Up to day, five inhibition mechanism have been discovered [91]: 
1. CAIs anchoring to the central zinc ion: this kind of inhibition mechanism belong 
to most of the inhibitors discovered up to day. Compounds exercising this 
mechanism have a scaffold endowed with an anchoring group (AG) which works 
as zinc binder group (ZBG) [92–95]. The most used ZBG is the primary 
sulfonamide moiety, although other groups are able to coordinate central zinc ion 
(e.g. sulfamates, and sulfamides, which are in fact sulfonamide isosters) [96].  
Although these inhibitors are very effective, inhibiting hCAs in the low nanomolar 
range, they lack of selectivity due to the common active site organization of the 
fifteen isoforms. With the aim to increase selectivity, these inhibitors are designed 
using the “tail approach” [97], which takes advantage from the insertion of 
functional groups able to interact fairly away from the Zn2+ ion, where more 
differences among the isoforms occur (Figure 1.4).  
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Figure 1.4. CAIs anchoring to the central zinc ion. 
 
2. CAIs anchoring to the zinc-coordinated water/hydroxide ion:  belong to this 
class compounds able to anchor the zinc-coordinated water 
molecule/hydroxide ion. This mechanism was observed for the first time with 
phenol, but other compounds showing this kind of inhibition contain primary 
amine, carboxylic acids or esters, and sulfonic acids [98–100]. The scaffold of 
these compounds can be aromatic, aliphatic, heterocyclic, or sugar-based type 
and could be designed keeping in mind the “tail approach” (Figure 1.5). 
 
 
Figure 1.5. CAIs anchoring to the zinc-coordinated water/hydroxide ion. 
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3. CA inhibition by occlusion of the active site entrance: the first compound with 
this interesting CA inhibition mechanism was a natural compound with 
coumarin structure [101]. The de facto inhibitor is in this case the hydrolysed 
form of coumarin, produced because of the esterase activity of hCAs. Other 
compounds endowed with “sticky group” showed similar activity [102]. The 
most notable aspect of this inhibition mechanism is that the inhibitors bind the 
active site region, which is the most variable between the various isoforms, i.e. 
the entrance to the cavity (Figure 1.6).  
 
 
Figure 1.6. CA inhibition by occlusion of the active site entrance 
 
4. Out of the active site binding as a CA inhibition mechanism: this is the last 
mechanism discovered with crystal structure obtained between hCA II and 2-
(benzylsulfonyl)-benzoic acid [103]. The electronic density of the inhibitor was 
not observed within the active site but in a binding pocket next to to the active 
site. The compound inhibits hCA blocking the proton-shuttling residue His64 
in the “out” conformation, interfering with the transfer of a proton from the 
zinc-coordinated water molecule to the environment. In this way it prevents the 
formation of zinc-coordinated hydroxide ion, the active form of the enzyme 
(Figure 1.7). 
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Figure 1.7. Out of the active site binding CA inhibition mechanism. 
 
5. Compounds acting as CAIs with an unknown mechanism of action: finally, 
there are a series of compounds whose inhibition mechanism has not been 
discovered, due to the absence of their co-crystal with hCA enzymes. 
Compounds based on saccharin scaffold, belong to this class. 
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1.4 Development of new saccharin inhibitors 
Saccharin derivatives have been documented as good inhibitors of hCA by various 
research groups, that in the last years focused their attention towards the development 
of new molecules based on this scaffold [104–109]. By analysing the structure and 
substitution pattern of published compounds possessing saccharin scaffold, it is 
possible to find that for the design of new molecules two general approach have been 
exploited (Figure 1.5). The first is relative to compounds obtained through the 
substitution of benzene ring of saccharin, with various substituents, maintaining the 
secondary sulfonamide functional group free (Figure 1.5, I and II). Compounds 
containing secondary sulfonamides, have been extensively studied for their ability to 
inhibit hCAs [110–112]. In fact, this approach produced molecules endowed with 
activity in the nanomolar range against isoforms IX and XII, although residual activity 
against the off-targets hCA I and hCA II was unfortunately observed [107,113].  
 
 
Figure 1.5 The two different approaches for the synthesis of hCAs inhibitors based on 
saccharin scaffold.  
20 
 
 
The second approach was based on the substitution of saccharin nitrogen with 
different groups, in order to obtain N-substituted saccharins (Figure 1.5, III). Tertiary 
sulfonamides have been investigated for the atypical mechanism that these substances 
must possess, because they are not able to coordinate zinc ion due to the absence of 
deprotonable nitrogen atom [114–117]. N-substituted saccharins were effective 
inhibitors of hCA IX and XII, even if some of them retained activity against off-targets 
[106,109].  
 
 
 
 
 
Here I report two approaches used to increase activity and selectivity of saccharin-based 
inhibitors of the two tumor-related isoforms hCA IX and XII. The outcomes of these strategies 
were the open saccharin-based secondary sulfonamides and the saccharin/isoxazole - 
saccharin/isoxazoline derivatives. 
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Chapter 2 
Open saccharin-based secondary sulfonamides as potent and selective 
inhibitors of cancer-related carbonic anhydrase IX and XII isoforms 
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2.1 Open saccharin-based secondary sulfonamides: aim of the work 
In a recent publication, Ivanova et al. reported on the spontaneous ring opening of 
cyclic tertiary sulfonamides under basic (pH= 9) crystallization conditions [118]. Since 
hCAs do not possess any peptidase activity, they concluded that the base-catalysed 
hydrolysis of the saccharin isothiazolone ring happened before the inhibitor entered 
the active site, and proved their hypothesis by testing both open and closed analogues 
against a panel of hCAs (hCA I, hCA II, hCA IX and hCA XII) [119]. In particular, these 
open saccharin derivatives determined an increased inhibition of hCA IX, while 
retaining high activity against hCA II. I used a reductive ring opening approach to 
induce the 5-membered isothiazolone ring of saccharin to collapse into its 
corresponding secondary sulfonamide and benzyl alcohol (Figure 2.1) [120]. 
 
 
Figure 2.1. Design of new open-saccharin based inhibitors. 
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 The rationale behind this choice could be found in the opportunity of generating two 
new potential anchoring points for the zinc ion, while introducing several degrees of 
freedom to the bonds connecting the two hydrophobic phenyl substituents to the polar 
core of the molecule. In general, the newly synthesized compounds (1-21) proved to 
be as potent as or slightly less potent than parent inhibitors (I-XXI), while the 
selectivity for the cancer-related isoforms (hCA IX and XII) over the off-target hCA I 
and II improved dramatically. In fact, none of the reported compounds inhibited hCA 
I and II isoforms at concentrations lower than 10 nM, while Ki values spanned from 20 
to 298 nM against hCA IX and from 4.3 to 382 nM against hCA XII. 
 
2.2 Chemistry 
Saccharin (1.0 eq.) was activated using freshly ground anhydrous potassium carbonate 
and the corresponding salt was then directly reacted with a proper electrophile (2 eq. 
of substituted benzyl halide or α-haloacetophenone) by stirring the reaction mixture 
in N,N-dimethylformamide at 80 °C overnight (Scheme 1). Following these optimized 
conditions (polar aprotic solvent), we strictly obtained only the more stable 
regioisomers (N-substituted saccharin derivatives) limiting the Chapman-Mumm 
thermal rearrangement to the less stable O-substituted counterparts [121]. N-
substituted saccharin (the parent drugs) derivatives were then subjected to reductive 
ring opening with an excess of NaBH4 in dry methanol at room temperature for 2-8 hrs 
to give the corresponding secondary sulfonamide compounds 1-21 in discrete yields 
following a previously reported procedure with slight modifications [120]. 
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Scheme 2.1. Synthesis and structure of compounds I-XXI and 1-21. For R substituents see 
Table 2.1 and 2.2. 
 
The choice of NaBH4 as a reducing agent was influenced by preliminary experiments 
which suggested that (i) the sulfone group was not affected by these mild reducing 
conditions leading to the carbonyl group reduction to the alcohol level only with 
saccharin ring cleavage and that (ii) similar results were obtained for the preparation 
of o-hydroxymethyl-N-alkyl-benzamides starting from N-alkyl-phthalimides [120]. 
In their IR spectra, I usually registered for the open saccharin derivatives new but 
expected signals for the OH and NH stretching at 3240 and 3470 cm-1, respectively, and 
the disappearance of the C=O stretching at 1735 cm-1. 
 
2.3 Biological evaluation 
All the synthesized compounds were tested to evaluate their inhibitory activity 
towards the ubiquitous off-target isoforms, hCA I and II, and the cancer-related ones, 
hCA IX and XII, by a stopped-flow, CO2 hydrase assay method and their CA inhibition 
data (Ki) are summarized in Table 2.1 and Table 2.2. 
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2.4 Results and discussion 
2.4.1 Inhibition of hCA I, II, IX, and XII.  
The analysis of the biological data was accomplished comparing the open saccharin-
based derivatives (Table 1) with their corresponding parent compounds (activities 
reported in Table 2) in order to evaluate if the ring opening enhanced or reduced their 
biological activity. All the tested compounds had no affinity for the common off-target 
hCA I and II isoforms (Kis> 10000 nM) compared to their corresponding parent drugs. 
Moreover, our molecules with a benzyl alcohol group, instead of a carboxylic acid one 
[118], abolished completely this inhibitory activity improving the biological profile of 
this scaffold. The inhibition profile of the open saccharin-based derivatives against the 
two tumor-related hCA IX and XII isoforms also displayed some important changes 
compared to parent drugs. Among the new open saccharin derivatives reported here, 
the best activity was obtained toward hCA XII isoform by compounds 1, 5, 6, 10 and 
11, all provided of CH3 or CF3 groups. These molecules exhibited a slightly preference 
for hCA XII respect to hCA IX isoform, although the inhibition of the latter was also in 
the nanomolar range. Compound 5, containing a phenyl ring substituted with methyl 
group in meta position, had the highest inhibitory activity against hCA XII (Ki = 4.3 
nM), but also compound 6, containing a meta trifluoromethyl substituent on phenyl 
ring, exhibited similar inhibitory activity (Ki = 4.4 nM). Comparable profile against 
hCA XII was observed for compounds 10 (Ki = 5.7 nM) and 11 (Ki = 7.2 nM), which are 
para substituted regioisomers of 5 and 6, respectively. Compound 1, which had a 
methyl group at ortho position of phenyl ring, showed similar inhibitory activity (Ki 
hCA XII = 4.7 nM) with respect to 5 and 6. Other compounds with strong selectivity 
between hCA IX and XII were 9 (Ki hCA IX = 267 nM, Ki hCA XII = 64 nM) with bromine 
in meta position of phenyl ring, 12 (Ki hCA IX = 126 nM, Ki hCA XII = 57 nM) containing 
a cyano group in para position, 15 (Ki hCA IX = 154 nM, Ki hCA XII = 48 nM) which had 
a para chloro-substituted phenyl ring, 17 and 18 with, respectively, 2,6-difluoro and 
3,4-dichloro-substituted phenyl rings. 
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Conversely, some compounds displayed a good selectivity towards hCA IX isoform. 
Compounds with nitro substituents in ortho (3), meta (7) or para (13) position of the ring 
had potent inhibitory activity preferentially against this overexpressed isoform in the 
hypoxic tumoral niche. 
For compounds 20 (Ki hCA IX = 224 nM, Ki hCA XII = 64 nM) and 21 (Ki hCA IX = 31 
nM, Ki hCA XII = 355 nM), the reaction with NaBH4 led to the further reduction of 
exocyclic carbonyl moiety. The presence of this additional group maintained the 
biological profile with a loss of inhibitory activity against hCA I and II and a 
preferential selectivity against the cancer-related isoforms. 
Collectively, these promising data showed that the reductive ring opening of the 
saccharin nucleus improved the hCA inhibitory activity with a better selectivity with 
respect to the off-target isoforms. From the above, we also observed that the inhibition 
profile was affected positively or negatively by the substitution pattern. 
 
Table 2.1. Inhibitory activity of the saccharin parent drugs I-XXI and acetazolamide as a 
reference drug, against selected hCA isoforms by a stopped-flow CO2 hydrase assay. 
 
Compound R 
Ki (nM)* 
hCA I hCA II hCA IX hCA XII 
I 2-CH3 1368 > 10000 221 16 
II 2-CF3 3579 > 10000 616 15 
III 2-NO2 > 10000 40.9 91 28.1 
IV 2-Br > 10000 43.5 > 10000 25.1 
V 3-CH3 1503 > 10000 184 26 
VI 3-CF3 > 10000 > 10000 19 17 
VII 3-NO2 > 10000 39.1 11 24.6 
VIII 3-F > 10000 91 380 2690 
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IX 3-Br > 10000 86.8 360 21.1 
X 4-CH3 > 10000 > 10000 234 5.1 
XI 4-CF3 1347 > 10000 51 4.7 
XII 4-CN > 10000 47.6 240 150 
XIII 4-NO2 324 > 10000 1169 29 
XIV 4-F 2479 > 10000 539 41 
XV 4-Cl 2361 > 10000 19 4.4 
XVI 4-Br > 10000 > 10000 22 4.3 
XVII 2,6-diF >10000 460 > 10000 1310 
XVIII 3,4-diCl > 10000 > 10000 390 2760 
XIX 
-CH=CH-
CH=CH- 
> 10000 > 10000 > 10000 2540 
 
XX H > 10000 > 10000 > 10000 1780 
XXI 3-OCH3 1342 > 10000 1570 6.0 
AAZ (acetazolamide) 250 12 25 6.0 
*Mean from 3 different assays (errors were in the range of ±5–10% of the reported values). 
 
Table 2.2. Inhibitory activity of the open saccharin-based derivatives 1-21 and acetazolamide 
as a reference drug, against selected hCA isoforms by a stopped-flow CO2 hydrase assay. 
 
Compound R 
Ki (nM)* 
hCA I hCA II hCA IX hCA XII 
1 2-CH3 >10000 >10000 218 4.6 
2 2-CF3 >10000 >10000 200 54 
3 2-NO2 >10000 >10000 104 383 
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4 2-Br >10000 >10000 113 323 
5 3-CH3 >10000 >10000 223 4.3 
6 3-CF3 >10000 >10000 238 4.4 
7 3-NO2 >10000 >10000 176 382 
8 3-F >10000 >10000 268 247 
9 3-Br >10000 >10000 267 64 
10 4-CH3 >10000 >10000 120 5.7 
11 4-CF3 >10000 >10000 253 7.2 
12 4-CN >10000 >10000 126 57 
13 4-NO2 >10000 >10000 20 54 
14 4-F >10000 >10000 26 63 
15 4-Cl >10000 >10000 154 48 
16 4-Br >10000 >10000 145 432 
17 2,6-diF >10000 >10000 296 45 
18 3,4-diCl >10000 >10000 298 40 
19 
-CH=CH-
CH=CH- 
>10000 >10000 294 345 
 
20 H >10000 >10000 224 64 
21 3-OCH3 >10000 >10000 31 355 
AAZ (acetazolamide) 250 12 25 6.0 
*Mean from 3 different assays (errors were in the range of ±5–10% of the reported values). 
 
2.4.2 Docking studies into the active site of hCA XII 
The open saccharin analogs (compounds 1–21) were endowed with inhibition values 
in the nanomolar range against hCA XII isoform (Ki values: 4.3–432 nM, Table 1, 
approximately 100-fold difference between lowest and highest Ki values). The 
interaction of compound 6 with the active site of hCA XII was shown as an example 
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(Figure 2.2). Docking studies indicated that the hydroxymethyl group and one of the 
sulfonamide oxygen atoms could interact simultaneously with the Zn2+-ion, whereas 
the other sulfonamide oxygen atom was water accessible. This oxygen might also form 
hydrogen bonds with the backbone of Thr199. The other polar substituents of the 
molecule were water accessible. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Docked pose of compound 6 in the active site of hCA XII. Hydrogen bonds and 
interactions to the Zn2+-ion are depicted in red dashed lines. The Zn2+-ion is depicted as a 
turquoise sphere. The three zinc-binding Histidines (H94, H96 and H119) are depicted in light 
grey for clarity. 
 
2.5 Conclusions 
The design, synthesis, characterization and in vitro pharmacological evaluation of 
several new secondary sulfonamides based on the open saccharin scaffold as selective 
inhibitors of human carbonic anhydrase, have been proposed. They were shown to be 
inactive against the two cytosolic off-target hCA I and II (Kis > 10 µM); conversely, all 
these compounds inhibited hCA IX and XII in the low nanomolar range with Kis 
ranging between 4.3 and 432 nM. The analysis of the Ki values showed as the 
H119 
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Q92 
K67 
H64 N62 
W5 
P202 
T200 
P201 
T199 
V121 
L198 
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substituent on phenyl moiety that gives the best outcomes relative to inhibition of hCA 
XII isoform are methyl and trifluoromethyl groups. The results were also rationalized 
by means of docking studies into the active site of hCA XII. Since these two cancer-
related hCA isoforms were recently validated as drug targets, these results provided 
the development of new anticancer candidates. 
 
2.6 Experimental section 
General 
Solvents and reagents were used as supplied without further purification. Where 
mixtures of solvents are specified, the stated ratios are volume:volume. Acetazolamide 
was purchased by Sigma-Aldrich (Italy) and used in the biological assays without 
further purification. All synthesized compounds have been fully characterized by 
analytical and spectral data. Column chromatography was carried out using Sigma-
Aldrich® silica gel (high purity grade, pore size 60 Å, 200-425 mesh particle size). 
Analytical thin-layer chromatography was carried out on Sigma-Aldrich® silica gel on 
TLA aluminum foils with fluorescent indicator. Visualization was carried out under 
UV irradiation (254 nm). 1H-NMR spectra were recorded on a Bruker AV400 (1H: 400 
MHz, 13C: 101 MHz). 19F-NMR spectra were recorded on a Bruker AVANCE 600 
spectrometer (19F: 564.7 MHz). Chemical shifts are quoted in ppm, based on 
appearance rather than interpretation, and are referenced to the residual non 
deuterated solvent peak. In the case of 19F, chemical shifts are referenced to an external 
standard (CF3COOH, δ -76.55 ppm). Infra-red spectra were recorded on a Bruker 
Tensor 27 FTIR spectrometer equipped with an attenuated total reflectance attachment 
with internal calibration. Absorption maxima (νmax) are reported in wavenumbers (cm-
1). All melting points were measured on a Stuart® melting point apparatus SMP1 and 
are uncorrected. Temperatures are reported in °C. Where given, systematic compound 
names are those generated by ChemBioDraw Ultra® 12.0 following IUPAC 
conventions. 
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Synthesis and characterization data of compounds I-XXI and 1-21 
 
 
2-(2-Methylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (I): anhydrous 
potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. 2-Methylbenzyl bromide (1.1 eq.) was added and 
the reaction stirred at 80 °C for 48 h. The mixture was poured on ice and the resulting 
suspension was filtered. Purification via column chromatography on silica gel (ethyl 
acetate:n-hexane, 1:2) gave the title compound as a white solid (72% yield); mp 153-
155 °C; IR νmax 3073 (ν Csp2-H), 1726 (ν C=O), 1335 (νas S=O), 1244 (ν C-N), 1181 (νs S=O), 
754 (δ Csp2-H), 676 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.50 (3H, s, CH3), 4.98 
(2H, s, CH2), 7.21-7.25 (m, 3H, Ar), 7.44 (d, J = 7.2 Hz, 1H, Ar), 7.83-7.91 (m, 2H, Ar), 
7.95 (d, J = 6.8 Hz, 1H, Ar), 8.10 (d, J = 8.0 Hz, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 
19.3 (CH3), 40.6 (CH2), 121.0 (Ar), 125.3 (Ar), 126.3 (Ar), 127.3 (Ar), 128.3 (Ar), 128.7 
(Ar), 130.5 (Ar), 132.1 (Ar), 134.4 (Ar), 134.9 (Ar), 136.3 (Ar), 137.9 (Ar), 159.0 (C=O). 
Anal. Calcd for C15H13NO3S: C, 62.70; H, 4.56; N, 4.87. Found: C, 62.52 ; H, 4.81; N, 5.06. 
 
 
2-(2-Trifluoromethylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (II): anhydrous 
potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. 2-Trifluoromethylbenzyl bromide (1.1 eq.) was 
added and the reaction stirred at 80 °C for 48 h. The mixture was poured on ice and 
the resulting suspension was filtered. Purification via column chromatography on 
silica gel (ethyl acetate:n-hexane, 1:2) gave the title compound as a white solid (60% 
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yield);  mp 142-143 °C; IR νmax 3095 (ν Csp2-H), 1733 (ν C=O), 1336 (νas S=O), 1241 (ν C-
N), 1171 (νs S=O), 749 (δ Csp2-H), 676 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 5.20 
(2H, s, CH2), 7.41-7.45 (t, 1H, Ar), 7.51-7.57 (m, 2H, Ar), 7.72 (d, J = 8.0 Hz, 1H, Ar), 7.87-
7.95 (m, 3H, Ar), 8.13 (d, J = 7.6 Hz, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 39.0 (CH2), 
121.2 (Ar), 122.9 (Ar), 125.5 (Ar), 126.2 (Ar), 127.0 (Ar), 128.0 (Ar), 128.3 (Ar), 132.3 (Ar), 
133.0 (Ar), 134.6 (Ar), 135.1 (Ar), 137.9 (Ar), 159.1 (C=O). 19F-NMR (564.7 MHz, CDCl3) 
δ -57.34 (s, CF3). Anal. Calcd for C15H10F3NO3S: C, 52.79; H, 2.95; N, 4.10. Found: C, 
52.55 ; H, 3.17; N, 3.91. 
 
 
2-(2-nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (III): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 2-Nitrobenzyl chloride (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C for 24 h. The mixture was 
poured on ice and the resulting suspension was filtered. Purification by column 
chromatography on silica gel (ethyl acetate:n-hexane 1:2) gave title compound  as a 
white solid (78% yield); mp 173-178 °C; IR νmax 3086 (ν Csp2-H), 1721 (ν C=O), 1526 (νas 
N-O), 1333 (νas SO2), 1302 (νs N-O), 1259 (ν C-N), 1178 (νs SO2), 723 (δ Csp2-H), 670 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 5.33 (s, 2H, CH2), 7.63-7.65 (m, 2H, 2 x 
Ar), 7.75-7.76 (m, 1H, Ar), 8.04-8.18 (m, 4H, 4 x Ar), 8.37-8.38 (m, 1H, Ar); 13C-NMR 
(101 MHz, DMSO-d6): δ 122.18 (Ar), 125.63 (Ar), 125.82 (Ar), 126.72 (Ar), 129.77 (Ar), 
129.97 (Ar), 130.36 (Ar), 134.72 (Ar), 135.83 (Ar), 136.45 (Ar), 137.34 (Ar), 148.16 (Ar), 
159.28 (C=O), (CH2 signal missing due to overlap with DMSO-d6). 
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2-(2-bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (IV): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 2-Bromobenzyl bromide (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C overnight. The mixture 
was poured on ice and the resulting suspension was filtered and washed with n-
hexane and diethyl ether to give the title compound as a white solid (46% yield);  mp 
160-161 °C; IR νmax 3095 (ν Csp2-H), 1730 (ν C=O), 1334 (νas SO2), 1259 (ν C-N), 1173 (νs 
SO2), 746 (δ Csp2-H), 673 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 4.98 (s, 2H, 
CH2), 7.25-7.31 (m, 1H, Ar), 7.37-7.45 (m, 2H, Ar), 7.68 (d, J = 8.0 Hz, 1H, Ar), 8.01-8.11 
(m, 2H, 2 x Ar), 8.16 (d, J = 7.6 Hz, 1H, Ar), 8.35 (d, J = 7.6 Hz, 1H, Ar); 13C-NMR (101 
MHz, DMSO-d6): δ 42.48 (CH2), 122.13 (Ar), 122.70 (Ar), 125.79 (Ar), 126.69 (Ar), 128.52 
(Ar), 129.72 (Ar), 130.41 (Ar), 133.15 (Ar), 134.02 (Ar), 135.81 (Ar), 136.44 (Ar), 137.35 
(Ar), 159.08 (C=O). 
 
 
2-(3-Methylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (V): anhydrous 
potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. 3-Methylbenzyl bromide (1.1 eq.) was added and 
the reaction stirred at 80 °C for 48 h. The mixture was poured on ice and the resulting 
suspension was filtered. Purification via column chromatography on silica gel (ethyl 
acetate:n-hexane, 1:2) gave the title compound as a white solid (72% yield); mp 94-96 
°C; IR νmax 3065 (ν Csp2-H), 1729 (ν C=O), 1329 (νas S=O), 1260 (ν C-N), 1178 (νs S=O), 
748 (δ Csp2-H), 676 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.37 (3H, s, CH3), 4.90 
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(2H, s, CH2), 7.14 (d, J = 7.6 Hz, 1H, Ar), 7.24-7.33 (m, 3H, Ar), 7.82-7.88 (m, 2H, Ar), 
7.95 (d, J = 7.2 Hz, 1H, Ar), 8.08 (d, J = 8.0 Hz, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 
21.4 (CH3), 42.7 (CH2), 121.0 (Ar), 125.2 (Ar), 125.8 (Ar), 127.3 (Ar), 128.6 (Ar), 129.1 
(Ar), 129.4 (Ar), 134.3 (Ar), 134.4 (Ar), 134.8 (Ar), 137.8 (Ar), 138.4 (Ar), 158.9 (C=O). 
Anal. Calcd for C15H13NO3S: C, 62.70; H, 4.56; N, 4.87. Found: C, 62.99; H, 4.28; N, 4.69. 
 
 
8.2.4. 2-(3-Trifluoromethylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (VI): 
anhydrous potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin 
(1.0 eq.) in 10 mL of N,N-dimethylformamide. 3-Trifluoromethylbenzyl bromide (1.1 
eq.) was added and the reaction stirred at 80 °C for 48 h. The mixture was poured on 
ice and the resulting suspension was filtered.. Purification via column chromatography 
on silica gel (ethyl acetate:n-hexane, 1:2) gave the title compound as a white solid (79% 
yield); mp 128-130 °C; IR νmax 3092 (ν Csp2-H), 1720 (ν C=O), 1332 (νas S=O), 1263 (ν C-
N), 1175 (νs S=O), 752 (δ Csp2-H), 680 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.97 
(2H, s, CH2), 7.49-7.52 (m, 1H, Ar), 7.60 (d, J = 8.0 Hz, 1H, Ar), 7.72 (d, J = 7.6 Hz, 1H, 
Ar), 7.79 (s, 1H, Ar), 7.84-7.97 (m, 3H, Ar), 8.09 (d, J = 7.6 Hz, 1H, Ar); 13C-NMR (101 
MHz, CDCl3) δ 42.1 (CH2), 121.1 (Ar), 125.3 (Ar), 125.4 (Ar), 125.6 (Ar), 127.1 (Ar), 129.3 
(Ar), 131.0 (Ar), 132.1 (Ar), 134.5 (Ar), 135.0 (Ar), 135.5 (Ar), 137.7 (Ar), 158.9 (C=O). 
19F-NMR (564.7 MHz, CDCl3) δ -60.08 (s, CF3). Anal. Calcd for C15H10F3NO3S: C, 52.79; 
H, 2.95; N, 4.10. Found: C, 52.98; H, 2.76; N, 4.32. 
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2-(3-nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (VII): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 3-Nitrobenzyl bromide (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C for 72 h. The mixture was 
poured on ice and extracted with dichloromethane. The organics were reunited, dried 
over sodium sulfate and concentrated in vacuo. Purification by column 
chromatography on silica gel (ethyl acetate:n-hexane 1:1) gave the title compound as a 
white solid (37 % yield); mp 179-181 °C; IR νmax 3091 (ν Csp2-H), 1734 (ν C=O), 1529 (νas 
N-O), 1324 (νas SO2), 1294 (νs N-O), 1263 (ν C-N), 1180 (νs SO2), 751 (δ Csp2-H), 696 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CD2Cl2): δ 4.83 (s, 2H, CH2), 7.39-7.43 (m, 1H, Ar), 
7.68-7.82 (m, 4H, 4 x Ar), 7.91 (d, J = 7.2 Hz, 1H, Ar), 8.01 (d, J = 7.2 Hz, 1H, Ar), 8.18 (s, 
1H, Ar); 13C-NMR (101 MHz, CD2Cl2): δ 41.58 (CH2), 121.13 (Ar), 123.16 (Ar), 123.40 
(Ar), 125.30 (Ar), 127.03 (Ar), 129.76 (Ar), 134.59 (Ar), 134.69 (Ar), 135.27 (Ar), 136.94 
(Ar), 137.55 (Ar), 148.10 (Ar), 158.94 (C=O). 
 
 
2-(3-fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (VIII): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 3-Fluorobenzyl chloride (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C for 48 h. The mixture was 
poured on ice and the resulting suspension was filtered and washed with petroleum 
ether to give compound 18a as a white solid (34% yield); mp 105-107 °C; IR νmax 3075 
(ν Csp2-H), 1735 (ν C=O), 1316 (νas SO2), 1264 (ν C-N), 1179 (νs SO2), 752 (δ Csp2-H), 673 
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(δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 4.96 (s, 2H, CH2), 7.12-7.17 (m, 1H, 
Ar), 7.26-7.28 (m, 2H, 2 x Ar), 7.39-7.44 (m, 1H, Ar), 7.94-8.18 (m, 3H, Ar), 8.35 (d, J = 
7.2 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 41.47 (CH2), 114.98 (Ar), 115.19 (Ar), 
122.12 (Ar), 124.28 (Ar), 125.71 (Ar), 126.72 (Ar), 131.04 (Ar), 135.77 (Ar), 136.37 (Ar), 
137.26 (Ar), 138.54 (Ar), 159.12 (C=O), 162.57 (d, J = 244.42 Hz, Ar). 
 
 
2-(3-bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (IX): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 3-Bromobenzyl bromide (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C for 72 h. The mixture was 
poured on ice and extracted with dichloromethane. The organics were reunited, dried 
over sodium sulfate, and evaporated in vacuo. Purification by column chromatography 
on silica gel (ethyl acetate:petroleum ether 1:2) gave the title compounds as a white 
solid (86% yield); mp 92-95 °C; IR νmax 1720 (ν C=O), 1330 (νas SO2), 1265 (ν C-N), 1180 
(νs SO2), 705 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 4.95 (s, 2H, CH2), 7.31-
7.35 (m, 1H, Ar), 7.43-7.45 (m, 1H, Ar), 7.49-7.51 (m, 1H, Ar), 7.65 (s, 1H, Ar), 7.98-8.12 
(m, 3H, Ar), 8.34 (d, J = 7.2 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 41.35 (CH2), 
122.13 (Ar), 125.73 (Ar), 126.70 (Ar), 127.38 (Ar), 131.03 (Ar), 131.16 (Ar), 135.79 (Ar), 
136.38 (Ar), 137.25 (Ar), 138.42 (Ar), 159.13 (C=O) (two aromatic carbon missing due to 
signals overlapping). 
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2-(4-Methylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (X): anhydrous 
potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. 4-Methylbenzyl bromide (1.1 eq.) was added and 
the reaction stirred at 80 °C for 48 h. The mixture was poured on ice and the resulting 
suspension was filtered. Purification via column chromatography on silica gel (ethyl 
acetate:n-hexane, 1:2) gave the title compound as a white solid (67% yield); mp 111-
113 °C; IR νmax 2920 (ν Csp3-H), 1732 (ν C=O), 1329 (νas S=O), 1257 (ν C-N), 1174 (νs S=O), 
747 (δ Csp2-H), 674 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.35 (3H, s, CH3), 4.89 
(2H, s, CH2), 7.18 (d, J = 8.0 Hz, 2H, Ar), 7.42 (d, J = 8.0 Hz, 2H, Ar), 7.81-7.88 (m, 3H, 
Ar), 8.06 (d, J = 8.0 Hz, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 21.2 (CH3), 42.5 (CH2), 
121.0 (Ar), 125.2 (Ar), 127.4 (Ar), 128.8 (Ar), 129.4 (Ar), 131.5 (Ar), 134.3 (Ar), 134.7 (Ar), 
137.8 (Ar), 138.1 (Ar), 158.9 (C=O). Anal. Calcd for C15H13NO3S: C, 62.70; H, 4.56; N, 
4.87. Found: C, 62.57; H, 4.34; N, 4.58. 
 
 
2-(4-Trifluoromethylbenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XI): 
anhydrous potassium carbonate (1.1 eq.) were added to a stirring solution of saccharin 
(1.0 eq.) in 10 mL of N,N-dimethylformamide. 4-Trifluoromethylbenzyl bromide (1.1 
eq.) was added and the reaction stirred at 80 °C for 48 h. The mixture was poured on 
ice and the resulting suspension was filtered. Purification via column chromatography 
on silica gel (ethyl acetate:n-hexane, 1:2) gave the title compound as a white solid (57% 
yield); mp 119-121 °C; IR νmax 2963 (ν Csp3-H), 1741 (ν C=O), 1319 (νas S=O), 1264 (ν C-
N), 1167 (νs S=O), 750 (δ Csp2-H), 679 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.97 
(2H, s, CH2), 7.64 (bs, 4H, Ar), 7.84-7.98 (m, 3H, Ar), 8.08 (d, J = 8.0 Hz, 1H, Ar); 13C-
NMR (101 MHz, CDCl3) δ 42.0 (CH2), 121.2 (Ar), 125.4 (Ar), 125.6 (Ar), 125.7 (Ar), 127.1 
(Ar), 129.0 (Ar), 134.5 (Ar), 135.0 (Ar), 137.7 (Ar), 138.4 (Ar), 158.9 (C=O). 19F-NMR 
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(564.7 MHz, CDCl3) δ -60.12 (s, CF3). Anal. Calcd for C15H10F3NO3S: C, 52.79; H, 2.95; 
N, 4.10. Found: C, 53.04; H, 2.78; N, 3.95. 
 
 
4-((1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)methyl)benzonitrile (XII): 
anhydrous potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin 
(1.0 eq.) in 10 mL of N,N-dimethylformamide at room temperature. 4-
(Bromomethyl)benzonitrile (1.1 eq.) was added and the reaction mixture was stirred 
at 80 °C for 72 h. The mixture was poured on ice and the resulting suspension was 
filtered. Purification by column chromatography on silica gel (ethyl acetate:petroleum 
ether 1:1) gave compound 10a as a white solid (71% yield); mp 178-180 °C; IR νmax 3096 
(ν Csp2-H), 2227 (ν C≡N), 1723 (ν C=O), 1334 (νas SO2), 1254 (ν C-N), 1181 (νs SO2), 751 
(δ Csp2-H), 673 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 5.05 (s, 2H, CH2), 7.62 
(d, J = 7.2 Hz, 2H, 2 x Ar), 7.85 (d, J = 7.2 Hz, 2H, 2 x Ar), 8.01-8.16 (m, 3H, 3 x Ar), 8.37 
(d, J = 7.6 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 41.57 (CH2), 111.05 (CN), 119.08 
(Ar), 122.18 (Ar), 125.77 (Ar), 126.69 (Ar), 129.03 (Ar), 132.94 (Ar), 135.85 (Ar), 136.45 
(Ar), 137.26 (Ar), 141.37 (Ar), 159.15 (C=O). 
 
 
2-(4-Nitrobenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XIII): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. Then 4-nitrobenzyl bromide (1.1 eq.) was added 
and the reaction mixture was stirred at 80 °C for 24 h. The mixture was poured on ice 
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and the resulting suspension was filtered and washed with water and n-hexane. 
Purification by column chromatography on silica gel (ethyl acetate:petroleum ether, 
1:3) gave the title compound as a yellow powder (91% yield); mp 178-180 °C; IR νmax 
3092 (ν Csp2-H), 1727 (ν C=O), 1516 (νas N-O), 1338 (νas S=O), 1299 (νs N-O), 1248 (ν C-
N), 1197 (νs S=O), 755 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 5.10 (s, 2H, CH2), 
7.69-7.71 (m, 2H, Ar), 8.03-8.36 (m, 6H, Ar); 13C-NMR (101 MHz, DMSO-d6) δ 41.3 (CH2), 
122.2 (Ar), 124.1 (Ar), 125.7 (Ar), 126.7 (Ar), 129.3 (Ar), 135.8 (Ar), 136.4 (Ar), 137.2 (Ar), 
143.3 (Ar), 147.5 (Ar), 159.1 (C=O). Anal. Calcd for C14H10N2O5S: C, 52.83; H, 3.17; N, 
8.80. Found: C, 52.56; H, 3.41; N, 9.04. 
 
 
2-(4-Fluorobenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XIV): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. Then 4-fluorobenzyl bromide (1.5 eq.) was added 
and the reaction mixture was stirred at 80 °C for 72 h. The mixture was poured on ice 
and the resulting suspension was filtered and washed with water and petroleum ether. 
Purification by column chromatography on silica gel (ethyl acetate:n-hexane, 1:3) gave 
the title compound as a white powder (89% yield);  mp 125-126 °C; IR νmax 1726 (ν 
C=O), 1335 (νas S=O), 1295 (ν C-N), 1180 (νs S=O), 1158 (ν Csp2-F), 838 (δ Csp2-H) cm-1; 
1H-NMR (400 MHz, DMSO-d6) δ 4.92 (s, 2H, CH2), 7.18 (t, J = 8.8 Hz, 2H, Ar), 7.47-7.50 
(m, 2H, Ar), 7.97-8.11 (m, 3H, Ar), 8.31 (d, J = 7.6 Hz, 1H, Ar); 13C-NMR (101 MHz, 
DMSO-d6) δ 41.4 (CH2), 115.6 (Ar), 115.9 (Ar), 122.1 (Ar), 125.6 (Ar), 126.7 (Ar), 130.6 
(Ar), 130.7 (Ar), 131.8 (Ar), 135.7 (Ar), 136.3 (Ar), 137.3 (Ar), 159.1 (C=O), 162.2 (d, JC-F 
= 244.9 Hz, Ar). 19F-NMR (564.7 MHz, CDCl3) δ -111.04 (tt, JF-H = 8.6 Hz (ortho), 5.2 Hz 
(meta), CF). Anal. Calcd for C14H10FNO3S: C, 57.72; H, 3.46; N, 4.81. Found: C, 57.99; H, 
3.67; N, 4.55. 
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2-(4-Chlorobenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XV): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. Then 4-chlorobenzyl bromide (1.1 eq.) was added 
and the reaction mixture was stirred at 80 °C for 48 h. The mixture was poured on ice 
and the resulting suspension was filtered and washed with water, petroleum ether and 
diethyl ether. Purification by column chromatography on silica gel (ethyl 
acetate:petroleum ether, 1:3) gave the title compound as a white powder (89% yield); 
mp 153-155 °C; IR νmax  3092 (ν Csp2-H), 1726 (ν C=O), 1331 (νas S=O), 1307 (ν C-N), 1197 
(νs S=O), 749 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.93 (s, 2H, CH2), 7.41-
7.45 (m, 4H, Ar), 7.98-8.08 (m, 3H, Ar), 8.30-8.32 (m, 1H, Ar); 13C-NMR (101 MHz, 
DMSO-d6) δ 41.4 (CH2), 122.1 (Ar), 125.6 (Ar), 126.7 (Ar), 128.9 (Ar), 130.3 (Ar), 133.0 
(Ar), 134.6 (Ar), 135.6 (Ar), 136.3 (Ar), 137.2 (Ar), 159.1 (C=O). Anal. Calcd for 
C14H10ClNO3S: C, 54.64; H, 3.28; N, 4.55. Found: C, 54.90; H, 3.47; N, 4.27. 
 
 
2-(4-Bromobenzyl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XVI): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide. Then 4-bromobenzyl bromide (1.5 eq.) was added 
and the reaction mixture was stirred at 80 °C for 72 h. The mixture was poured on ice 
and the resulting suspension was filtered and washed with water and petroleum ether. 
Purification by column chromatography on silica gel (ethyl acetate:petroleum ether, 
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1:3) gave the title compound  as a white powder (89% yield); mp 158-160 °C; IR νmax 
1725 (ν C=O), 1332 (νas S=O), 1303 (ν C-N), 1180 (νs S=O or ν C-Br), 861 (δ Csp2-H) cm-1; 
1H-NMR (400 MHz, CDCl3) δ 4.87 (s, 2H, CH2), 7.40 (d, J = 8.4 Hz, 2H, Ar), 7.49 (d, J = 
8.4 Hz, 2H, Ar), 7.81-7.95 (m, 3H, Ar), 8.06 (d, J = 7.2 Hz, 1H, Ar); 13C-NMR (101 MHz, 
CDCl3) δ 42.0 (CH2), 121.1 (Ar), 122.4 (Ar), 125.3 (Ar), 127.1 (Ar), 130.5 (Ar), 131.9 (Ar), 
133.6 (Ar), 134.5 (Ar), 134.9 (Ar), 137.6 (Ar), 158.9 (C=O). Anal. Calcd for C14H10BrNO3S: 
C, 47.74; H, 2.86; N, 3.98. Found: C, 47.92; H, 3.01; N, 4.15. 
 
 
2-(2,6-difluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (XVII): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 ml of N,N-dimethylformamide at room temperature. 2,6-Difluorbenzyl bromide 
(1.1 eq.) was added and the reaction mixture was stirred at 80 °C overnight. The 
mixture was poured on ice and the resulting suspension was filtered and washed with 
petroleum ether to give compound 20a as a white solid (81% yield); mp 173-175 °C; IR 
νmax 1733 (ν C=O), 1338 (νas SO2), 1295 (ν Csp2-F), 1252 (ν C-N), 1181 (νs SO2), 753 (δ Csp2-
H), 673 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 5.01 (s, 2H, CH2), 7.13-7.17 (m, 
2H, 2 x Ar), 7.46-7.50 (m, 1H, Ar), 8.01-8.06 (m, 2H, 2 x Ar), 8.15 (d, J = 7.2 Hz, 1H, Ar), 
8.28 (d, J = 7.2 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 30.27 (CH2), 110.81 (Ar), 
112.02 (Ar), 121.93 (Ar), 125.78 (Ar), 126.45 (Ar), 131.82 (Ar), 135.82 (Ar), 136.48 (Ar), 
137.17 (Ar), 158.21 (C=O), 161.52 (d, J = 258.36 Hz, Ar). 
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2-(3,4-dichlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (XVIII): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. 3,4-Dichlorobenzyl chloride 
(1.1 eq.) was added and the reaction mixture was stirred at 80 °C for 48 h. The mixture 
was poured on ice and the resulting suspension was filtered and washed with 
petroleum ether and diethyl ether to give the title compound as a white solid (46% 
yield); mp 135-137 °C; IR νmax 3079 (ν Csp2-H), 1726 (ν C=O), 1312 (νas SO2), 1263 (ν C-
N), 1182 (νs SO2), 749 (δ Csp2-H), 675 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 
4.76 (s, 2H, CH2), 7.22 (d, J = 7.6 Hz, 1H, Ar), 7.43 (d, J = 8.0 Hz, 1H, Ar), 7.51 (s, 1H, 
Ar), 7.81-7.93 (m, 3H, 3 x Ar), 8.15 (d, J = 7.2 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-
d6): δ 40.83 (CH2), 122.14 (Ar), 125.74 (Ar), 126.74 (Ar), 128.66 (Ar), 130.39 (Ar), 130.98 
(Ar), 131.17 (Ar), 131.54 (Ar), 135.79 (Ar), 136.38 (Ar), 136.89 (Ar), 137.22 (Ar), 159.12 
(C=O). 
 
 
2-(naphthalen-1-ylmethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (XIX): 
anhydrous potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin 
(1.0 eq.) in 10 mL of N,N-dimethylformamide at room temperature. 1-
(Chloromethyl)naphthalene (1.1 eq.) was added and the reaction mixture was stirred 
at 80 °C for 72 h. The mixture was poured on ice and extracted with dichloromethane. 
The organics were reunited, dried over sodium sulfate and evaporated in vacuo. 
Purification by column chromatography on silica gel (ethyl acetate:petroleum ether 
1:2) gave the title compound as a white solid (19% yield); mp 142-145 °C; IR νmax 3047 
(ν Csp2-H), 1726 (ν C=O), 1336 (νas SO2), 1298 (ν C-N), 1171 (νs SO2), 748 (δ Csp2-H), 675 
(δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 5.43 (s, 2H, CH2), 7.49-7.63 (m, 4H, 4 
x Ar), 7.92-8.09 (m, 4H, 4 x Ar), 8.18-8.24 (m, 2H, Ar), 8.33-8.35 (m, 1H, Ar); 13C-NMR 
(101 MHz, DMSO-d6): δ 122.05 (Ar), 123.53 (Ar), 125.81 (Ar), 125.85 (Ar), 126.54 (Ar), 
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126.65 (Ar), 127.12 (Ar), 129.07 (Ar), 129.16 (Ar), 130.48 (Ar), 130.94 (Ar), 133.71 (Ar), 
135.80 (Ar), 136.45 (Ar), 137.46 (Ar), 159.27 (C=O), (CH2 signal missing due to overlap 
with DMSO-d6). 
 
 
2-(2-oxo-2-phenylethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (XX): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. α-Bromoacetophenone (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C overnight. The mixture 
was poured on ice and the resulting suspension was filtered and washed with 
petroleum ether and diethyl ether to give the title compound as a yellow solid (89% 
yield); mp 192-194 °C; IR νmax 3070 (ν Csp2-H), 1735 (ν C=O), 1698 (ν C=O), 1332 (νas 
SO2), 1296 (ν C-N), 1180 (νs SO2), 744 (δ Csp2-H), 673 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, 
DMSO-d6): δ 5.49 (s, 2H, CH2), 7.60 (t, J = 7.4 Hz, 2H, 2 x Ar), 7.74 (t, J = 7.2 Hz, 1H, Ar), 
8.03-8.07 (m, 1H, Ar), 8.09-8.12 (m, 3H, 3 x Ar), 8.17 (d, J = 7.6 Hz, 1H, Ar), 8.37 (d, J = 
7.6 Hz, 1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 45.32 (CH2), 122.22 (Ar), 125.64 (Ar), 
126.67 (Ar), 128.86 (Ar), 129.43 (Ar), 134.28 (Ar), 134.77 (Ar), 135.86 (Ar), 136.50 (Ar), 
137.72 (Ar), 159.35 (C=O), 190.61 (C=O). 
 
 
2-[2-(3-Methoxyphenyl)-2-oxoethyl]-1,2-benzothiazol-3(2H)-one 1,1-dioxide (XXI): 
anhydrous potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin 
(1.0 eq.) in 10 mL of N,N-dimethylformamide. 2-bromo-3’-methoxyacetophenone (1.1 
eq.) was added and the reaction mixture was stirred at 80 °C for 72 h. The mixture was 
poured on ice and the resulting suspension was filtered and washed with water and 
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petroleum ether. Purification by column chromatography on silica gel (ethyl 
acetate:petroleum ether, 1:3) gave the title compound as a yellow powder (58% yield); 
mp 167-169 °C; mp 167-169 °C; IR νmax 1736 (ν C=O), 1694 (ν C=O), 1328 (νas S=O), 1258 
(ν C-N), 1182 (νs S=O), 864 (δ Csp2-H) 752 (δo Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 
3.86 (s, 3H, OCH3), 5.14 (s, 2H, CH2), 7.18-7.20 (m, 1H, Ar), 7.41-7.58 (m, 3H, Ar), 7.87-
7.96 (m, 3H, Ar), 8.11 (s, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 44.6 (CH2), 55.5 (OCH3), 
112.4 (Ar), 120.7 (Ar), 120.9 (Ar), 121.2 (Ar), 125.5 (Ar), 127.3 (Ar), 129.9 (Ar), 134.5 (Ar), 
134.9 (Ar), 135.3 (Ar), 137.9 (Ar), 159.1 (Ar), 160.0 (C=O), 188.7 (C=O). Anal. Calcd for 
C16H13NO5S: C, 58.00; H, 3.95; N, 4.23. Found: C, 58.22; H, 4.11; N, 4.02. 
 
 
2-(Hydroxymethyl)-N-(2-methylbenzyl)benzenesulfonamide (1): (2-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 2 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:4). The title compound was a white solid (52% yield); mp 64-66 °C; IR νmax 
3459 (ν O-H), 3237 (ν N-H), 3065 (ν Csp2-H), 1319 (νas S=O), 1167 (νs S=O), 712 (δ Csp2-
H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.25 (s, 3H, CH3), 2.77 (bs, 1H, OH, D2O exch.), 
4.08 (s, 2H, CH2), 5.01 (s, 2H, CH2), 5.43 (bs, 1H, NH, D2O exch.), 7.09-7.19 (m, 4H, Ar), 
7.47-7.61 (m, 3H, Ar), 8.01-8.04 (m, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 18.7 (CH3), 
45.5 (CH2), 64.2 (CH2), 126.2 (Ar), 128.2 (Ar), 128.5 (Ar), 128.9 (Ar), 129.6 (Ar), 129.9 
(Ar), 130.5 (Ar), 131.6 (Ar), 133.2 (Ar), 134.1 (Ar), 136.6 (Ar), 138.2 (Ar). 
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2-(Hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)benzenesulfonamide (2): (2-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was 
suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 
was added portionwise and the reaction monitored by TLC. After 4 h the reaction was 
quenched with water and the aqueous phase was extracted with dichloromethane (3 x 
30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated 
in vacuo to give a crude product that was purified by column chromatography 
(EtOAc/n-hexane, 1:3). The title compound was a white solid (47% yield);  mp 66-68 
°C; IR νmax 3446 (ν O-H), 3214 (ν N-H), 1310 (νas S=O), 1157 (νs S=O), 714 (δ Csp2-H) cm-
1; 1H-NMR (400 MHz, CDCl3) δ 2.81 (t, 1H, J = 5.4 Hz, OH, D2O exch.), 4.17 (d, 2H, J = 
6.0 Hz, CH2), 4.91 (s, 2H, CH2), 5.83 (m, 1H, NH, D2O exch.), 7.27 (t, 1H, J = 7.6 Hz, Ar), 
7.35-7.41 (m, 3H, Ar), 7.46-7.50 (m, 3H, Ar), 7.89-7.91 (m, 1H, Ar); 13C-NMR (101 MHz, 
CDCl3) δ 43.7 (CH2), 63.9 (CH2), 124.2 (C-F, 1JC-F =274.8 Hz, CF3), 125.9 (Ar), 126.0 (Ar), 
127.9 (Ar), 128.6 (Ar), 129.7 (Ar), 130.6 (Ar), 131.6 (Ar), 132.3 (Ar), 133.3 (Ar), 135.0 (Ar), 
138.0 (Ar), 138.1 (Ar); 19F-NMR (564.7 MHz, CDCl3) δ -56.89 (s, CF3). 
 
 
2-(Hydroxymethyl)-N-(2-nitrobenzyl)benzenesulfonamide (3): (2-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
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to give the title compound as a light brown solid (37% yield); mp 103-105 °C; IR νmax 
3498 (ν O-H), 3238 (ν N-H), 2973 (ν Csp3-H), 1522 (ν N-O), 1327 (νas S=O), 1165 (νs S=O), 
698 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.34 (d, 2H, J = 5.6 Hz, CH2), 4.88 
(s, 2H, CH2), 5.45 (bs, 1H, OH, D2O exch.), 7.39 (t, 1H, J = 7.2 Hz, Ar), 7.50 (t, 1H, J = 7.6 
Hz, Ar), 7.60-7.68 (m, 3H, 3 x Ar), 7.74-7.79 (m, 2H, 2 x Ar), 7.96 (d, 1H, J = 8.4 Hz, Ar), 
8.29 (bs, 1H, NH, D2O exch.); 13C-NMR (101 MHz, DMSO-d6) δ 43.4 (CH2), 60.0 (CH2), 
125.1 (Ar), 127.3 (Ar), 128.2 (Ar), 128.5 (Ar), 129.1 (Ar), 130.7 (Ar), 133.0 (Ar), 133.4 (Ar), 
134.1 (Ar), 137.0 (Ar), 141.6 (Ar), 148.1 (Ar). 
 
 
N-(2-Bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (4): (2-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 2:1). The title compound was a white solid (0.05 g, 11% yield);  mp 162-164 °C; 
IR νmax 3273 (ν O-H and ν N-H), 2920 (ν Csp3-H), 1402 (νas S=O), 1065 (νs S=O), 676 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 3.45 (bs, 1H, OH, D2O exch.), 4.14 (d, 2H, J 
= 6.4 Hz, CH2), 4.93 (s, 2H, CH2), 6.18 (m, 1H, NH, D2O exch.), 7.03 (t, 1H, J = 7.6 Hz, 
Ar), 7.15 (t, 1H, J = 7.4 Hz, Ar), 7.28 (d, 1H, J = 6.8 Hz, Ar), 7.33-7.49 (m, 4H, Ar), 7.87 
(d, 1H, J = 8.0 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 47.4 (CH2), 63.5 (CH2), 123.4 (Ar), 
127.6 (Ar), 128.3 (Ar), 129.4 (Ar), 129.6 (Ar), 130.3 (Ar), 131.3 (Ar), 132.7 (Ar), 133.1 (Ar), 
135.6 (Ar), 137.8 (Ar), 138.4 (Ar). 
 
47 
 
 
2-(Hydroxymethyl)-N-(3-methylbenzyl)benzenesulfonamide (5): (3-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:4). The title compound was a white solid (51% yield); mp 79-80 °C; IR νmax 
3431 (ν O-H), 3161 (ν N-H), 2936 (ν Csp3-H), 1316 (νas S=O), 1152 (νs S=O), 694 (δ Csp2-
H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.27 (s, 3H, CH3), 2.80 (bs, 1H, OH, D2O exch.), 
4.07 (bs, 2H, CH2), 4.99 (s, 2H, CH2), 5.72 (bs, 1H, NH, D2O exch.), 6.96 (d, 2H, J = 7.6 
Hz, Ar), 7.04 (d, 1H, J = 8.0 Hz, Ar), 7.14 (t, 1H, J = 7.4 Hz, Ar), 7.44-7.49 (m, 2H, Ar), 
7.55-7.59 (m, 1H, Ar), 7.98 (d, 1H, 7.8 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 21.3 (CH3), 
47.5 (CH2), 63.8 (CH2), 124.9 (Ar), 128.4 (Ar), 128.5 (Ar), 128.6 (Ar), 128.7 (Ar), 129.8 
(Ar), 131.5 (Ar), 133.1 (Ar), 136.1 (Ar), 138.1 (Ar), 138.2 (Ar), 138.3 (Ar). 
 
 
2-(Hydroxymethyl)-N-(3-(trifluoromethyl)benzyl)benzenesulfonamide (6): (3-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was 
suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 
was added portionwise and the reaction monitored by TLC. After 8 h the reaction was 
quenched with water and the aqueous phase was extracted with dichloromethane (3 x 
30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated 
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in vacuo to give a crude product which was purified by column chromatography 
(EtOAc/n-hexane, 1:3). The title compound was a white solid (71% yield); mp 76-78 °C; 
IR νmax 3430 (ν O-H), 3278 (ν N-H), 1317 (νas S=O), 1160 (νs S=O), 700 (δ Csp2-H) cm-1; 
1H-NMR (400 MHz, CDCl3) δ 2.98 (t, 1H, J = 4.8 Hz, OH, D2O exch.), 4.06 (d, 2H, J = 6.4 
Hz, CH2), 4.91 (d, 2H, J = 4.0 Hz, CH2), 6.07 (m, 1H, NH, D2O exch.), 7.24-7.37 (m, 6H, 
Ar), 7.42-7.46 (m, 1H, Ar), 7.82 (d, 1H, J = 7.6 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 
46.9 (CH2), 63.9 (CH2), 123.9 (C-F, 1JC-F =273.4 Hz, CF3), 124.5 (Ar), 124.6 (Ar), 128.6 (Ar), 
129.1 (Ar), 129.7 (Ar), 130.7 (Ar), 131.3 (Ar), 131.7 (Ar), 133.3 (Ar), 137.4 (Ar), 137.8 (Ar), 
138.0 (Ar); 19F-NMR (564.7 MHz, CDCl3) δ -60.09 (s, CF3). 
 
 
2-(Hydroxymethyl)-N-(3-nitrobenzyl)benzenesulfonamide (7):  (3-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. Excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product that was purified by column chromatography (EtOAc/n-
hexane, 2:1). The title compound was a white solid (37% yield); mp 109-111 °C; mp 
109-111 °C; IR νmax 3491 (ν O-H), 3164 (ν N-H), 2958 (ν Csp3-H), 1536 (ν N-O), 1326 (νas 
S=O), 1162 (νs S=O), 695 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.16 (s, 2H, 
CH2), 4.87 (s, 2H, CH2), 5.47 (bs, 1H, OH, D2O exch.), 7.33-7.37 (m, 1H, Ar), 7.51-7.60 
(m, 2H, Ar), 7.64 (d, 1H, J = 7.6 Hz, Ar), 7.73-7.75 (m, 2H, Ar), 8.04 (s, 1H, Ar), 8.06 (s, 
1H, Ar), 8.35 (bs, 1H, NH, D2O exch.); 13C-NMR (101 MHz, DMSO-d6) δ 45.4 (CH2), 59.9 
(CH2), 122.5 (Ar), 122.6 (Ar), 127.1 (Ar), 127.9 (Ar), 128.5 (Ar), 130.2 (Ar), 132.9 (Ar), 
134.6 (Ar), 137.2 (Ar), 140.8 (Ar), 141.5 (Ar), 148.1 (Ar). 
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N-(3-Fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (8): (3-
fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 5 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:1). The title compound was a light yellow oil (67% yield);  IR νmax 3492 (ν O-
H), 3283 (ν N-H), 2895 (ν Csp3-H), 1318 (νas S=O), 1252 (ν Csp2-F), 1175 (νs S=O), 689 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.84 (bs, 1H, OH, D2O exch.), 4.05 (s, 2H, 
CH2), 4.97 (s, 2H, CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.85-6.94 (m, 3H, Ar), 7.17-7.20 
(m, 1H, Ar), 7.39-7.55 (m, 3H, Ar), 7.92 (d, 1H, J = 7.6 Hz, Ar); 13C-NMR (101 MHz, 
CDCl3) δ 46.6 (CH2), 63.6 (CH2), 114.6 (Ar-F, 2JC-F = 21.1 Hz), 114.8 (Ar-F, 2JC-F = 22.0 Hz), 
123.4 (Ar-F, long-rangeJC-F = 2.7 Hz), 128.5 (Ar), 129.7 (Ar), 130.1 (Ar-F, 3JC-F = 8.2 Hz), 131.6 
(Ar), 133.2 (Ar), 137.9 (Ar), 138.1 (Ar), 139.0 (Ar-F, 3JC-F = 7.3 Hz), 162.7 (Ar-F, 1JC-F = 
247.45 Hz); 19F-NMR (564.7 MHz, CDCl3) δ -110.03 (ddd, JF-H = 9.5 Hz, 8.6 Hz, 5.2 Hz, 
CF). 
 
 
N-(3-Bromobenzyl)-2-(hydroxymethyl)-benzenesulfonamide (9): (3-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
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portionwise and the reaction monitored by TLC. After 5 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in 
vacuo to give a crude product which was purified by column chromatography 
(EtOAc/n-hexane, 1:1). The title compound was a white solid (70% yield); mp 75-76 °C; 
IR νmax 3454 (ν O-H), 3214 (ν N-H), 2955 (ν Csp3-H), 1319 (νas S=O), 1156 (νs S=O), 694 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.00 (d, 2H, J = 6 Hz, CH2), 4.87 (d, 2H, J 
= 5.2 Hz, CH2), 5.42 (bs, 1H, OH, D2O exch.), 7.20 (bs, 2H, Ar), 7.38 (bs, 3H, Ar), 7.59-
7.63 (m, 1H, Ar), 7.75-7.78 (m, 2H, Ar), 8.23 (bs, 1H, NH, D2O exch.); 13C-NMR (101 
MHz, DMSO-d6) δ 45.6 (CH2), 59.9 (CH2), 122.0 (Ar), 127.0 (Ar), 127.2 (Ar), 127.9 (Ar), 
128.5 (Ar), 130.4 (Ar), 130.7 (Ar), 130.8 (Ar), 132.9 (Ar), 137.2 (Ar), 141.2 (Ar), 141.5 (Ar). 
 
 
2-(Hydroxymethyl)-N-(4-methylbenzyl)benzenesulfonamide (10): (4-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in 
vacuo to give a crude product which was purified by column chromatography 
(EtOAc/n-hexane, 1:4). The title compound was a white solid (56% yield); mp 100-102 
°C; IR νmax 3437 (ν O-H), 3130 (ν N-H), 2930 (ν Csp3-H), 1310 (νas S=O), 1151 (νs S=O), 
701 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.31 (s, 3H, CH3), 2.80 (bs, 1H, OH, 
D2O exch.), 4.07 (d, 2H, J = 5.2 Hz, CH2), 4.99 (s, 2H, CH2), 5.60 (bs, 1H, NH, D2O exch.), 
7.06 (bs, 4H, Ar), 7.44-7.50 (m, 2H, Ar), 7.55-7.60 (m, 1H, Ar), 8.00 (d, 1H, 7.6 Hz, Ar); 
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13C-NMR (101 MHz, CDCl3) δ 21.1 (CH3), 47.3 (CH2), 63.8 (CH2), 127.9 (Ar), 128.5 (Ar), 
129.3 (Ar), 129.9 (Ar), 131.6 (Ar), 133.1 (Ar), 133.2 (Ar), 137.6 (Ar), 138.1 (Ar), 138.2 (Ar). 
 
 
2-(Hydroxymethyl)-N-(4-(trifluoromethyl)benzyl)benzenesulfonamide (11): (4-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was 
suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 
was added portionwise and the reaction monitored by TLC. After 8 h the reaction was 
quenched with water and the aqueous phase was extracted with dichloromethane (3 x 
30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated 
in vacuo to give a crude product which was purified by column chromatography 
(EtOAc/n-hexane, 1:3). The title compound was a white solid (79% yield); mp 78-80 °C; 
IR νmax 3417 (ν O-H), 3161 (ν N-H), 3065 (ν Csp2-H), 1321 (νas S=O), 1157 (νs S=O), 688 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 3.03 (bs, 1H, OH, D2O exch.), 4.15 (d, 2H, J 
= 6.4 Hz, CH2), 5.02 (d, 2H, J = 5.2 Hz CH2), 6.14 (t, 1H, J = 6.4 Hz, NH, D2O exch.), 7.32 
(d, 2H, J = 8.0 Hz, Ar), 7.40-7.49 (m, 4H, Ar), 7.54-7.58 (m, 1H, Ar), 7.91 (s, 1H, Ar); 13C-
NMR (101 MHz, CDCl3) δ 46.9 (CH2), 63.9 (CH2), 124.0 (C-F, 1JC-F= 273.1 Hz, CF3), 125.4 
(Ar), 125.5 (Ar), 128.1 (Ar), 128.6 (Ar), 129.7 (Ar), 129.8 (Ar), 130.1 (Ar), 131.7 (Ar), 133.3 
(Ar), 137.8 (Ar), 138.0 (Ar), 140.4 (Ar); 19F-NMR (564.7 MHz, CDCl3) δ -60.08 (s, CF3). 
 
 
N-(4-Cyanobenzyl)-2-(hydroxymethyl)benzenesulfonamide (12): (4-
cyanobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
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mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate and concentrated in vacuo 
to give a crude product, which was purified by column chromatography (EtOAc/n-
hexane, 2:1). The title compound was a white solid (67% yield); mp 93-95 °C; IR νmax 
3481 (ν O-H), 3187 (ν N-H), 2949 (ν Csp3-H), 2235 CN, 1325 (νas S=O), 1156 (νs S=O), 703 
(δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.09 (s, 2H, CH2), 4.88 (s, 2H, CH2), 
5.46 (bs, 1H, OH, D2O exch.), 7.35-7.41 (m, 3H, Ar), 7.59-7.62 (m, 1H, Ar), 7.70-7.77 (m, 
4H, Ar), 8.33 (bs, 1H, NH, D2O exch.); 13C-NMR (101 MHz, DMSO-d6) δ 45.9 (CH2), 59.9 
(CH2), 110.3 (Ar), 119.3 (CN), 127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 128.7 (Ar), 132.6 (Ar), 
132.9 (Ar), 137.1 (Ar), 141.6 (Ar), 144.3 (Ar). 
 
 
2-(Hydroxymethyl)-N-(4-nitrobenzyl)benzenesulfonamide (13): (4-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product, which was purified by column chromatography (EtOAc/n-
hexane, 1:1). The title compound was a yellow solid (57% yield); mp 98-99 °C; IR νmax 
3493 (ν O-H), 3243 (ν N-H), 1515 (ν N-O), 1318 (νas S=O), 1160 (νs S=O), 690 (δ Csp2-H) 
cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.74 (bs, 1H, OH, D2O exch.), 4.21 (bs, 2H, CH2), 5.08 
(s, 2H, CH2), 6.13 (bs, 1H, NH, D2O exch.), 7.40-7.59 (m, 5H, Ar), 7.96-7.97 (m, 1H, Ar), 
8.11-8.13 (m, 2H, Ar); 13C-NMR (101 MHz, CDCl3) δ 46.7 (CH2), 64.3 (CH2), 123.7 (Ar), 
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128.5 (Ar), 128.8 (Ar), 129.8 (Ar), 131.6 (Ar), 133.4 (Ar), 137.6 (Ar), 138.7 (Ar), 144.0 (Ar), 
147.2 (Ar). 
 
 
N-(4-Fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (14): (4-
fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:3). The title compound was a light brown solid (79% yield); mp 99-100 °C; IR 
νmax 3439 (ν O-H), 3140 (ν N-H), 1312 (νas S=O), 1151 (νs S=O), 696 (δ Csp2-H) cm-1; 1H-
NMR (400 MHz, CDCl3) δ 3.18 (bs, 1H, OH, D2O exch.), 4.04 (d, 2H, J = 6.4 Hz, CH2), 
4.98 (s, 2H, CH2), 6.00 (bs, 1H, NH, D2O exch.), 6.88-6.93 (m, 2H, Ar), 7.12-7.15 (m, 2H, 
Ar), 7.41-7.57 (m, 3H, Ar), 7.93 (d, 1H, J = 8.0 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 
46.7 (CH2), 63.7 (CH2), 115.4 (Ar-F, 2JC-F =21.2 Hz), 128.5 (Ar), 129.6 (Ar), 129.7 (Ar), 131.6 
(Ar), 132.0 (Ar), 132.1 (Ar), 133.2 (Ar), 138.0 (Ar), 138.1 (Ar), 135.4 (Ar-F, 1JC-F =247.3 
Hz); 19F-NMR (564.7 MHz, CDCl3) δ -111.71 (tt, JF-H = 8.7 Hz (ortho), 5.3 Hz (meta), CF). 
 
 
N-(4-Chlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (15): (4-
chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq) was suspended in 20 
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mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:1). The title compound was a white solid (70% yield); mp 103-105 °C; IR νmax 
3458 (ν O-H), 3236 (ν N-H), 2876 (ν Csp3-H), 1314 (νas S=O), 1152 (νs S=O), 690 (δ Csp2-
H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.90 (bs, 1H, OH, D2O exch.), 4.06 (d, 2H, J = 6.0 
Hz, CH2), 5.01 (s, 2H, CH2), 5.88 (bs, 1H, NH, D2O exch.), 7.11 (d, 2H, J = 8.4 Hz, Ar), 
7.21 (d, 2H, J = 8.4 Hz, Ar), 7.43-7.49 (m, 2H, Ar), 7.56-7.60 (m, 1H, Ar), 7.95 (d, 1H, J = 
7.6 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 46.8 (CH2), 63.9 (CH2), 128.6 (Ar), 128.7 (Ar), 
129.3 (Ar), 129.8 (Ar), 131.6 (Ar), 133.2 (Ar), 133.7 (Ar), 134.8 (Ar), 137.9 (Ar), 138.1 (Ar). 
 
 
N-(4-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (16): (4-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:2). The title compound was a white solid (53% yield); mp 124-125 °C; IR νmax 
3461 (ν O-H), 3234 (ν N-H), 3064 (ν Csp2-H), 1314 (νas S=O), 1152 (νs S=O), 690 (δ Csp2-
H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.71 (bs, 1H, OH, D2O exch.), 4.06 (bs, 2H, CH2), 
5.03 (s, 2H, CH2), 5.78 (bs, 1H, NH, D2O exch.), 7.06-7.08 (m, 2H, Ar), 7.37-7.59 (m, 5H, 
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Ar), 7.96-7.97 (m, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 46.9 (CH2), 64.1 (CH2), 121.9 
(Ar), 128.6 (Ar), 129.6 (Ar), 129.8 (Ar), 131.7 (Ar), 133.2 (Ar), 137.9 (Ar), 138.3 (Ar). 
 
 
N-(2,6-Difluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (17): (2,6-
difluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 1:1). The title compound was a white solid (67% yield); mp 128-130 °C; IR νmax 
3495 (ν O-H), 3159 (ν N-H), 2958 (ν Csp3-H), 1320 (νas S=O), 1159 (νs S=O), 693 (δ Csp2-
H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.72 (bs, 1H, OH, D2O exch.), 4.23 (s, 2H, CH2), 
4.89 (bs, 2H, CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.79-6.73 (m, 2H, Ar), 7.10-7.14 (m, 1H, 
Ar), 7.26 (s, 1H, Ar), 7.33-7.48 (m, 2H, Ar), 7.92-7.94 (m, 1H, Ar); 13C-NMR (101 MHz, 
CDCl3) δ 35.1 (CH2), 63.6 (CH2), 111.2 (Ar-F, 2JC-F = 24.8 Hz), 128.3 (Ar), 129.7 (Ar), 129.9 
(Ar), 130.0 (Ar), 130.1 (Ar), 131.2 (Ar), 133.1 (Ar), 137.8 (Ar), 138.2 (Ar), 161.2 (Ar-F, 1JC-
F = 246.9 Hz); 19F-NMR (564.7 MHz, CDCl3) δ -112.08 (t, JF-H = 6.9 Hz, CF). 
 
 
N-(3,4-Dichlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (18): (3,4-
chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 
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mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 2:1). The title compound was a light brown solid (81% yield); mp 83-84 °C; IR 
νmax 3463 (ν O-H), 3192 (ν N-H), 2947 (ν Csp3-H), 1319 (νas S=O), 1158 (νs S=O), 690 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.88 (bs, 1H, OH, D2O exch.), 3.96 (d, 2H, J 
= 6.4 Hz, CH2), 4.93 (bs, 2H, CH2), 6.00 (t, 1H, J = 6.0 Hz NH, D2O exch.), 6.94-6.96 (bs, 
1H, Ar), 7.17-7.22 (m, 2H, Ar), 7.33-7.39 (m, 2H, Ar), 7.46-7.48 (m, 1H, Ar), 7.83 (d, 1H, 
J = 7.6 Hz, Ar); 13C-NMR (101 MHz, CDCl3) δ 46.3 (CH2), 64.0 (CH2), 127.2 (Ar), 128.6 
(Ar), 129.7 (Ar), 129.8 (Ar), 130.5 (Ar), 131.7 (Ar), 131.8 (Ar), 132.6 (Ar), 133.3 (Ar), 136.7 
(Ar), 137.7 (Ar), 138.1 (Ar). 
 
 
2-(Hydroxymethyl)-N-(naphthalen-1-ylmethyl)benzenesulfonamide (19): 2-
(naphthalen-1-ylmethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was 
suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 
was added portionwise and the reaction monitored by TLC. After 6 h the reaction was 
quenched with water and the aqueous phase was extracted with dichloromethane (3 x 
30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated 
in vacuo to give a crude product which was purified by column chromatography 
(EtOAc/n-hexane, 1:1). The title compound was a white solid (57% yield); mp 80-81 °C; 
IR νmax 3517 (ν O-H), 3347 (ν N-H), 3061 (ν Csp2-H), 1318 (νas S=O), 1157 (νs S=O), 690 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.68 (bs, 1H, OH, D2O exch.), 4.51 (s, 2H, 
CH2), 4.91 (s, 2H, CH2), 5.69 (bs, 1H, NH, D2O exch.), 7.29-7.55 (m, 7H, Ar), 7.74-7.86 
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(m, 3H, Ar), 8.05 (s, 1H, Ar); 13C-NMR (101 MHz, CDCl3) δ 45.6 (CH2), 63.7 (CH2), 123.2 
(Ar), 125.2 (Ar), 126.0 (Ar), 126.6 (Ar), 127.0 (Ar), 128.4 (Ar), 128.7 (Ar), 129.0 (Ar), 130.0 
(Ar), 131.1 (Ar), 131.4 (Ar), 131.5 (Ar), 133.2 (Ar), 133.7 (Ar), 137.6 (Ar), 138.3 (Ar). 
 
 
N-(2-Hydroxy-2-phenylethyl)-2-(hydroxymethyl)benzenesulfonamide (20): 2-(2-
oxo-2-phenylethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended 
in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched 
with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). 
The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo 
to give a crude product which was purified by column chromatography (EtOAc/n-
hexane, 2:1). The title compound was a light yellow oil (49% yield); IR νmax 3291 (ν O-
H and ν N-H), 2923 (ν Csp3-H), 1316 (νas S=O), 1153 (νs S=O), 696 (δ Csp2-H) cm-1; 1H-
NMR (400 MHz, CDCl3) δ 2.94 (bs, 1H, CH2), 3.15 (bs, 1H, CH2), 3.42 (bs, 1H, OH, D2O 
exch.), 4.56-4.64 (m, 2H, CH2), 4.91-5.03 (m, 1H, CH), 5.28 (bs, 1H, OH, D2O exch.), 6.57 
(bs, 1H, NH, D2O exch.), 7.13-7.20 (m, 5H, Ar), 7.38-7.47 (m, 3H, Ar), 7.91 (d, 1H, J = 6.4 
Hz, Ar); 13C NMR (101 MHz, CDCl3) δ 50.4 (CH2), 62.7 (CH2), 72.4 (CH), 125.8 (Ar), 
127.9 (Ar), 128.2 (Ar), 128.5 (Ar), 129.5 (Ar), 131.3 (Ar), 133.3 (Ar), 137.3 (Ar), 138.6 (Ar), 
140.8 (Ar). 
 
 
N-(2-Hydroxy-2-(3-methoxyphenyl)ethyl)-2-(hydroxymethyl)benzenesulfonamide 
(21): 2-(2-hydroxy-2-(3-methoxyphenyl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-
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dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. 
An excess of NaBH4 was added portionwise and the reaction monitored by TLC. After 
8 h the reaction was quenched with water and the aqueous phase was extracted with 
dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium 
sulfate, and concentrated in vacuo to give a crude product which was purified by 
column chromatography (EtOAc/n-hexane, 1:2). The title compound was a yellow oil 
(88% yield); IR νmax 3477 (ν O-H), 3295 (ν N-H), 2935 (ν Csp3-H), 1317 (νas S=O), 1160 (νs 
S=O), 697 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, CDCl3) δ 2.89-2.95 (m, 1H, CH2), 3.13-
3.17 (m, 1H, CH2), 3.64 (s, 3H, OCH3), 4.41 (bs, 2H, CH2), 4.58 (bs, 1H, OH), 4.87-4.91 
(m, 1H, CH), 4.97 (bs, 1H, OH, D2O exch.), 6.48 (bs, 1H, NH, D2O exch.), 6.67-6.71 (m, 
3H, Ar), 7.07-7.11 (m, 1H, Ar), 7.32-7.47 (m, 3H, Ar), 7.87 (d, 1H, J = 7.6 Hz, Ar); 13C-
NMR (101 MHz, CDCl3) δ 50.4 (CH2), 55.1 (OCH3), 60.6 (CH2), 72.2 (CH), 111.4, (Ar), 
113.3 (Ar), 118.1 (Ar), 128.2 (Ar), 129.5 (Ar), 129.6 (Ar), 131.2 (Ar), 133.2 (Ar), 137.3 (Ar), 
138.6 (Ar), 142.5 (Ar), 159.5 (ArO). 
 
Enzyme inhibition assays 
An Applied Photophysics stopped-flow instrument has been used for assaying the 
CA-catalyzed CO2 hydration activity. Phenol red (0.2 mM) has been used as indicator, 
working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5, for α-
CAs) as buffer, and 20 mM NaClO4 (for maintaining constant the ionic strength), 
following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 
10-100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of 
the kinetic parameters and inhibition constants. For each inhibitor at least six traces of 
the initial 5-10% of the reaction have been used for determining the initial velocity. The 
uncatalyzed rates were determined in the same manner and subtracted from the total 
observed rates. Stock solutions of each inhibitor (1 µM) were prepared in distilled-
deionized water and dilutions up to 0.1 nM were done thereafter with the assay buffer. 
Inhibitor and enzyme solutions were preincubated together for 15 min at room 
temperature prior to assay, in order to allow for the formation of the E-I complex or 
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for the eventual active site mediated hydrolysis of the inhibitor. The inhibition 
constants were obtained by non-linear least-squares methods using PRISM 3 and the 
Cheng-Prusoff equation, and represent the average from at least three different 
determinations. All recombinant CA isoforms were obtained in-house as previously 
reported[97]. 
 
Molecular modelling studies 
Preparation of saccharin-based structures 
The saccharin-based analogs 1-21 were prepared in 3D with the MOE software 
package (v2013.08.02, Chemical Computing Group Inc., Montreal, Canada) as 
previously reported28. All possible structural isomers of compounds were constructed. 
Strong acids were deprotonated and strong bases were protonated. Finally, the ligands 
were energy minimized using a steepest-descent protocol (MMFF94x force field). 
 
Preparation of hCA crystal  structures for docking studies  
The structures of hCA I (PDB: 3LXE, 1.90 Å), hCA II (PDB: 4E3D, 1.60 Å), hCA IX (PDB: 
3IAI, 2.20 Å) and hCA XII (PDB: 1JD0, 1.50 Å) were obtained from the protein databank 
(PDB). The protein atoms, the active site zinc ions and the zinc-bound water molecule 
of hCA II were retained and all other atoms were omitted. The remaining structure 
was protonated using the MOE software package and subsequently the obtained 
structure was energy-minimized (AMBER99 force field). Finally, the obtained protein 
models were superposed on the hCA I structure using the backbone Cα-atoms. The 
zinc-bound water molecule of hCA II coordinated well to the zinc ions of the other 
hCAs. 
Docking studies  
The GOLD Suite software package (v5.2, CCDC, Cambridge, UK) and the GoldScore 
scoring function were used to dock the derivatives into the hCA structures with and 
without the zinc-bound water molecule (25 dockings per ligand). The binding pocket 
was defined as all residues within 13 Å of a centroid (x: -17.071, y: 35.081, 43.681; 
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corresponding approximately to the position of the thiadiazole ring of acetazolamide 
in the 1JD0 structure). 
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Chapter 3 
Design, synthesis and biological activity of saccharin/isoxazole and 
saccharin/isoxazoline derivatives as selective inhibitors of carbonic 
anhydrase IX and XII isoforms 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
3.1 Saccharin/isoxazoline and saccharin/isoxazoles derivatives: aim of the work 
In one of our first work regarding saccharin inhibitors of hCAs, we reported a 
compound obtained from 1,3-dipolar cycloaddition reaction between N-propargyl 
substituted saccharin and N-hydroxy-4-nitrobenzimidoyl chloride (Figure 3.1) [109]. 
This compound, the first endowed with a heterocyclic “linker” between the methylene 
of benzyl group and phenyl ring, showed activity in the nanomolar range only 
towards tumor-related isoforms, being ineffective against the two off-targets. 
 
 
Figure 3.1. Design of new saccharin/isoxazole and saccharin/isoxazoline compounds. 
 
In the light of the above, I designed the new inhibitors evaluating the insertion of two 
different systems as linker group: isoxazole and isoxazoline. The two chosen linkers 
possess some identical characteristic, e.g. both are five-membered rings with same 
heteroatoms, identical connection and position of substituents. However, there are 
also differences which are noteworthy. Indeed, isoxazole ring is a flat-aromatic system 
that could give п-stacking interaction inside the active site; on the other hands, 
isoxazoline, the 4,5-dihydrogenated form of isoxazole, loss aromaticity and possess 
two tetrahedral carbon atoms inside the ring, that alter the flat conformation (п-
interaction could be established with double bond ring, yet). Furthermore, the 
presence of four different substituents on one of the two tetrahedral carbon (C(5) of 
isoxazoline), account for the existence of a stereocenter. So, all the 
saccharin/isoxazoline compounds exist as couple of enantiomers, that could be 
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resolved and tested in the future with the aim to determine the preferred configuration 
chosen by the enzymes and, in conclusion, the eutomer. 
 
3.2 Chemistry 
For the synthesis of new saccharin derivatives, we followed a multi-step approach 
[122,123], useful to obtain reagents for the final 1,3-dipolar cycloaddition reaction 
between olefin substituted saccharins and hydroximinoyl acid chlorides (chloro 
oximes), leading to final products (Scheme 3.1, a-d).  
 
 
Scheme 3.1. Synthetic approach for the synthesis of new derivatives 1a-9a and 1b-9b. 
 
N-alkylated saccharins were obtained following our previously reported procedure 
[109], through nucleophilic substitution reaction between saccharin and 
allyl/propargyl bromide (Scheme 3.1, a). The hydroximinoyl acid chlorides (chloro 
oximes) were synthesised in two steps from the corresponding benzaldehydes 
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[109,124]. The first step (Scheme 3.1, b) involved the reaction between the selected 
aldehyde and hydroxylamine hydrochloride, in the presence of triethylamine in 
methanol (80 °C) to obtain oximes [109]. At a later time, the freshly synthesised oxime 
was reacted with N-chlorosuccinimide (NCS) in N,N-dimethylformamide (DMF), 
adding gaseous hydrogen chloride (HCl(g)) to promote the beginning of reaction 
(Scheme 3.1, c). In fact, Howe et al. observed that the reaction of NCS with 
benzaldoximes exhibited an induction period that could be reduced through the 
addition of small amounts of gaseous HCl. In this way, we avoided the fairly 
exothermic behaviour observed when the reaction initiates in the presence of  
considerable portion of the NCS [124]. The resulting chloro oximes were not 
contaminated by side-products (i.e. ring chlorinated products) and could be used 
without purification in the next 1,3-dipolar cycloaddition. In this reaction the 1,3-
dipole, that is the nitrile oxides generated in situ by dehydrohalogenation of the chloro 
oxime with triethylamine, reacted with the dipolarophile (N-allyl/propargyl 
saccharins) in ethyl acetate. Regioselectivities in isoxazoline ring synthesis are 
controlled by the energy of the atomic orbitals involved (frontiers molecular orbitals, 
FMO), although in some reactions electronically preferred orientations may be 
disfavoured by steric effects [125]. However, the reaction of nitrile oxides with 
monosubstituted olefins are quite exclusive, giving only or predominantly the 5-
substituted isoxazoline, regardless the nature of the substituent on the dipolarophile. 
On the other hand, cycloaddition of nitrile oxides to acetylenic dipolarophiles leads 
directly to 5-substituted isoxazoles [123,125]. 
 
3.3 Two-dimensional nuclear Overhauser enhancement spectroscopy (2D-NOESY 
NMR) 
Compound 3b synthesised from N-hydroxy-pyridine-2-carbimidoyl chloride and N-
propargyl saccharin, was subjected 2D-NMR using NOESY approach. This analysis 
was able to reveal spatial relationships among proximal protons, in order to confirm 
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the regioselectivity of the 1,3-dipolar cycloaddition reaction, to give 5-substituted 
isoxazoles instead of 4-substituted ones (Figure 3.2).  
 
 
Figure 3.2. (a) Compound 3b containing 5-substituted isoxazoline, proximal protons were 
depicted in red; (b) compound 3b containing unattended 4-substituted isoxazoline and 
without proximal protons.  
 
3.4 Biological evaluation 
All the synthesized saccharin/isoxazoline and saccharin/isoxazole derivatives were 
tested to evaluate their inhibitory activity towards the ubiquitous off-target isoforms, 
hCA I and II, and the cancer-related ones, hCA IX and XII, by a stopped-flow, CO2 
hydrase assay method and their CA inhibition data (Ki) are summarized in Table 3.1. 
 
3.5 Results and discussion 
3.5.1 Inhibition of hCA I, II, IX, and XII.  
Comparing the activity of compounds 1a-9a and 1b-9b with the N-alkyl/propargyl 
saccharins parent drugs, it is possible to asses that the insertion of 
isoxazoline/isoxazole ring, connected with aromatic or heteroaromatic system, 
improved both activity and selectivity.  Data reported in Table 3.1 show that all the 
synthesised compounds are selective inhibitors of tumor-related isoforms (hCA IX and 
hCA XII), being devoid of any activity towards the two ubiquitously expressed 
isoforms hCA I and hCA II, their off-target. Except for compound 9a, all derivatives 
showed preferred affinity for isoform XII with Ki spanning from 7.0 nM obtained for 
compound 6b, to 240 nM exhibited by 2b. The nature of the linker (isoxazoline rather 
than isoxazole) or the substituents on phenyl ring, as well as heterocyclic type system, 
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influenced the inhibitory activity against the tested isoforms. These compounds did 
not show a general trend; however, an important evidence was obtained. Compounds 
1a and 1b, substituted with NO2 on meta position of phenyl ring, showed a similar 
inhibitory activity towards isoform XII (1a, Ki hCA XII = 76.5 nM; 1b, Ki hCA XII = 57.3 
nM), while compound 1a was more effective than 1b against isoform IX (1a, KI hCA IX 
= 102.9 nM; 1b, KI hCA IX = 230.2 nM). Compounds 2a and 2b, possessing a p-NO2 
substituted phenyl ring, displayed a similar trend for hCA IX inhibition, while 
compound 2b containing the isoxazole linker, showed impaired activity towards 
isoform XII (2a, Ki hCA XII = 77 nM; 2b, Ki hCA XII = 240 nM). For these four derivatives 
it was possible to note that starting from 1a, containing a m-NO2 substituted phenyl 
ring bound to the isoxazoline ring, to compound 2b endowed with p-NO2 substituted 
phenyl ring connected to isoxazole system, there was a decrease of activity against 
hCA IX (Table 3.1). This trend was opposite compared with derivatives ranking from 
6a to 7b, possessing methoxy substituent (OMe). Indeed, compound 7b endowed with 
isoxazole linker and p-OMe substituted phenyl ring, showed a good activity against 
isoform IX (KI hCA IX = 22.1 nM). The other derivatives possessing a methoxy group 
were inactive (5a, 5b, 6a), or less effective (6b, 7a) towards isoform IX, compared to 7b. 
However, all the molecules containing methoxy group on phenyl ring were good 
inhibitors of hCA XII (7.0 < Ki hCA XII (nM) < 9.4) with the best activity exhibited by 
compound 6b. From these data it seems that the nature of the linker not favoured one 
isoform instead of the other or influenced in a specific manner the enzyme inhibition. 
In fact, the isoxazoline variation of 1a with isoxazole of 1b, increased the activity 
against hCA XII while reduced that towards hCA IX. For the couple 2a-2b, we 
observed impairment of activity towards both the tumor-related isoforms passing 
from isoxazoline linker to isoxazole one. The changing of the linker type for couples 
6a-6b and 7a-7b influenced only the inhibitory activity towards hCA IX, while hCA 
XII was not affected, showing almost constant inhibition data. Albeit further 
substitution patterns have to be evaluated, these preliminary outcomes showed that 
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was the combination of the substituent type/position on phenyl ring along with linker 
combination, rather than the single feature, which affect the inhibitory activity.  
Heterocyclic systems bound to the linker moiety were also evaluated. Compounds 3a 
and 3b were endowed with pyridin-2-yl moiety bound respectively to isoxazoline and 
isoxazole ring. These molecules showed similar activity against hCA IX (3a, KI hCA IX 
= 258.2 nM; 3b, KI hCA IX = 245.4 nM), whereas compound 3a exhibited better activity 
against hCA XII (3a, Ki hCA XII = 9.7 nM; 3b, Ki hCA XII = 66.5 nM). Derivatives 4a and 
4b whit pyridin-3-yl system showed comparable activity towards isoform XII, while 
differed for activity on hCA IX (4a, KI hCA IX = 273.5 nM; 4b, KI hCA IX = 86.2 nM). 
These data confirmed the absence of the univocal influence of linker. These data 
confirmed the absence of the univocal influence of linker. Compounds endowed with 
unsubstituted phenyl ring bound on the isooxazoline linker 8a showed the inhibition 
of only hCA XII; the isoxazole counterpart 8b was effective against both the tumor-
related isoforms (8b, Ki hCAIX = 50.9 nM; Ki hCAXII = 7.5 nM). Finally, compounds 
containing thiophene 9a and 9b showed the best inhibitory profile with low nanomolar 
activity towards both hCAIX (9a, Ki hCA IX = 7.2 nM; 9b, Ki hCA IX = 9.0 nM) and XII 
(9a, Ki hCA XII = 9.0 nM; 9b, Ki hCA XII = 8.2 nM).  
So, the five-membered heterocyclic system seems to be the best tolerated group bound 
to the linker moiety 
 
Table 3.1. Inhibition data of selected human CA isoforms (hCA I, II, IX and XII) with 
compounds 1a-9a and 1b-9b reported here and the standard sulfonamide inhibitor 
acetazolamide (AAZ) by a stopped flow CO2 hydrase assay. 
Compound Structure 
Ki (nM) 
hCA I hCA II hCA IX hCA XII 
S1 
 
>10000 86 140 94 
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S2 
 
>10000 58 210 570 
1a 
 
>10000 >10000 102.9 76.5 
1b 
 
>10000 >10000 230.2 57.3 
2a 
 
>10000 >10000 235.1 77.0 
2b 
 
>10000 >10000 310 240 
3a 
 
>10000 >10000 258.2 9.7 
3b 
 
>10000 >10000 245.4 66.5 
4a 
 
>10000 >10000 273.5 9.2 
4b 
 
>10000 >10000 86.2 8.0 
5a 
 
>10000 >10000 >10000 9.4 
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5b 
 
>10000 >10000 >10000 9.3 
6a 
 
>10000 >10000 >10000 7.6 
6b 
 
>10000 >10000 247.1 7.0 
7a 
 
>10000 >10000 139.1 8.1 
7b 
 
>10000 >10000 22.1 8.0 
8a 
 
>10000 >10000 >10000 8.5 
8b 
 
>10000 >10000 50.9 7.5 
9a 
 
>10000 >10000 7.2 9.0 
9b 
 
>10000 >10000 7.5 8.2 
AAZ  250 12 25 5.7 
*Mean from 3 different assay, by a stopped flow technique (errors were in the range of  5-10 
% of the reported values). 
 
3.5.2 2D-NOESY NMR of compound 3b  
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2D-NOESY NMR spectra reported in Figure 3.3, displayed the presence of the 
interaction between the two protons previously showed in Figure 3.2. 
 
 
Figure 3.3. 2D-NOESY NMR of compound 3b. 
 
The presence of the interaction between protons with spatial proximity, was confirmed 
by the presence of the “green” circles present along an ideal line which connect the 
proton C4(H) of the isoxazole ring (singlet at ~7.06), with pyridine signals between 7.90 
and 8.10 ppm containing the one of the proton at C3 position of pyridine ring. This 
outcome showed the interaction between the red depicted hydrogens of Figure 3.2, a 
confirming the regioselectivity of the reactions.  
 
3.6 Conclusion 
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The design, synthesis, characterization and in vitro pharmacological evaluation of 
several new saccharin/isoxazoline and saccharin/isoxazole derivatives have been 
reported. They shown to be ineffective towards the two cytosolic off-target hCA I and 
II (Kis > 10 µM); conversely, most of these compounds inhibited both the tumor related 
isoforms hCA IX and XII in the low nanomolar range with Kis ranging between 7.0 and 
310 nM. The majority of molecules 1a-9a and 1b-9b showed preferred activity for hCA 
XII, with the best result observed for compound 6b (Ki hCA XII = 7.0 nM), although 
also hCA IX were inhibited in the low nanomolar range by some derivatives. The 
analysis of the Ki values showed the absence of an explicit correlation between the 
linker type and the activity/selectivity profile; rather, the activity of compounds was 
likely affected by the arrangement of phenyl ring substituent and linker type.  
The results will be rationalized by means docking studies in order to evaluate the 
interactions whose affect the activity and selectivity. Furthermore, some of the 
saccharin/isoxazoline derivatives will be exposed to chiral resolution to obtain the 
enantiomers and evaluate as chiral properties affect the inhibitory activity. 
 
3.7 Experimental section 
General 
Unless otherwise indicated, all reactions were carried out under a positive pressure of 
nitrogen (balloon pressure) in washed and oven-dried glassware. Solvents were used 
as supplied without further purification. Where mixtures of solvents are specified, the 
stated ratios are volume:volume. Reagents were used directly as supplied by Sigma-
Aldrich® Italy. All melting points were measured on a Stuart® melting point apparatus 
SMP1, and are uncorrected. Temperatures are reported in °C. 1H and 13C NMR spectra 
were recorded at 400 and 101 MHz, respectively, on a Bruker spectrometer using 
CDCl3, DMSO-d6, MeOD and CD3CN, as the solvents at room temperature. The 
samples were analysed with a final concentration of ~30 mg/mL. Chemical shifts are 
expressed as δ units (parts per millions) relative to the solvent signal. 1H spectra are 
reported as follows: δH (spectrometer frequency, solvent): chemical shift/ppm (multiplicity, 
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J-coupling constant(s), number of protons, assignment). 13C spectra are reported as follows: 
δC (spectrometer frequency, solvent): chemical shift/ppm (assignment). Multiplets are 
abbreviated as follows: br – broad; s – singlet; d – doublet; t – triplet; q – quartet; m – 
multiplet. Coupling constants J are valued in Hertz (Hz). The processing and analyses 
of the NMR data were carried out with MestreNova. Infra-red spectra were recorded 
on a Bruker Tensor 27 FTIR spectrometer equipped with an attenuated total reflectance 
attachment with internal calibration. Absorption maxima (νmax) are reported in 
wavenumbers (cm-1). Column chromatography was carried out using Sigma-Aldrich® 
silica gel (high purity grade, pore size 60 Å, 230–400 mesh particle size). All the 
purifications and reactions were monitored by TLC performed on 0.2 mm thick silica 
gel-aluminium backed plates (60 F254, Merck). Visualization was carried out under 
ultra-violet irradiation (254 nm). Where given, systematic compound names are those 
generated by ChemBioDraw Ultra 12.0 following IUPAC conventions. 
 
Synthesis and characterization data of saccharin derivatives S1-S2 
 
 
2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide (S1): anhydrous potassium 
carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 10 mL of 
N,N-dimethylformamide (DMF) at room temperature. Allyl chloride (4.0 eq.) was 
added portionwise and the reaction mixture was stirred at 80°C for 48 h. The mixture 
was poured on ice and extracted with chloroform. The organics were reunited, dried 
over sodium sulfate and concentrated in vacuo. Purification by column 
chromatography on silica gel (ethyl acetate:petroleum ether 1:2) gave title compound 
as a white solid (76% yield); mp 73-75 °C; IR νmax 3094 (ν Csp2-H), 1731 (ν C=O), 1331 
(νas SO2), 1262 (ν C-N), 1180 (νs SO2), 751 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-
d6): δ 4.34 (s, 2H CH2), 5.25 (d, J = 10.0 Hz, 1H, =CH2), 5.36 (d, J = 16.8 Hz, 1H, =CH2), 
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5.89-5.95 (m, 1H, CH=), 7.98-8.12 (m, 3H, 3 x Ar), 8.32 (d, J = 7.6 Hz, 1H, Ar); 13C-NMR 
(101 MHz, DMSO-d6): δ 40.99 (CH2), 118.95 (CH2=), 122.03 (Ar), 125.60 (Ar), 126.71 (Ar), 
131.75 (CH=), 135.73 (Ar), 136.31 (Ar), 137.36 (Ar), 158.71 (C=O). 
 
 
2-(Prop-2-yn-1-yl)-1,2-benzothiazol-3(2H)-one 1,1-dioxide (S2): anhydrous 
potassium carbonate (1.1 eq.) was added to a stirring solution of saccharin (1.0 eq.) in 
10 mL of N,N-dimethylformamide at room temperature. Propargyl bromide (4.0 eq.) 
was added portionwise and the reaction mixture was stirred at room temperature for 
48 h. The mixture was poured on ice and extracted with dichloromethane. The organics 
were reunited, dried over sodium sulfate and concentrated in vacuo. Purification by 
column chromatography on silica gel (ethyl acetate:petroleum ether 1:1) gave 
compound 2a as a white solid (60% yield); mp 112-116 °C; IR νmax 3273 (ν Csp-H), 3093 
(ν Csp2-H), 2126 (ν C≡C), 1737 (ν C=O), 1332 (νas SO2), 1258 (ν C-N), 1177 (νs SO2), 751 (δ 
Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 3.39 (s, 1H, CH≡), 4.57 (s, 2H, CH2), 7.97-
8.’01 (m, 1H, Ar), 8.03-8.07 (m, 1H, Ar), 8.11 (d, J = 7.6 Hz, 1H, Ar), 8.32 (d, J = 7.6 Hz, 
1H, Ar); 13C-NMR (101 MHz, DMSO-d6): δ 27.95 (CH2), 75.68 (CH≡), 77.49 (C≡CH), 
122.16 (Ar), 125.75 (Ar), 126.43 (Ar), 135.84 (Ar), 136.56 (Ar), 137.37 (Ar), 158.36 (C=O). 
 
Synthesis and characterization data of oximes O1-O9 
 
 
3-nitrobenzaldehyde oxime (O1): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
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anhydrous methanol and stirred for 5 minutes at room temperature. 3-
nitrobenzaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C until 
complete consumption of starting material. The reaction was cooled down to room 
temperature and the solvent removed in vacuo. 20 mL of ice-cold water were added to 
the residue and the resulting suspension was kept at 0-4 °C overnight in order to obtain 
oximes precipitate, which was filtered and washed with mixture of petroleum 
ether/diethyl ether, obtaining the title compound as a light yellow solid (85.0 % yield); 
mp 108-111 °C; IR νmax 3267 (ν O-H), 1618 (ν C=N), 1531 (νas N-O), 1348 (νs N-O), 976 
(N-O, oxime), 733 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 7.66-7.70  (m, 1H, 
Ar), 8.02 (d, J = 7.6 Hz, 1H, Ar), 8.19 (d, J = 8.0 Hz, 1H, Ar), 8.30 (s, 1H, OH), 8.39 (s, 1H, 
Ar), 11.63 (s, 1H, HC=N-) . 13C-NMR (101 MHz, DMSO-d6): δ 121.3 (Ar), 124.1 (Ar), 
130.8 (Ar), 132.8 (Ar), 135.4 (Ar), 147.1 (Ar), 148.6 (HC=N-). 
 
 
4-nitrobenzaldehyde oxime (O2): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
anhydrous methanol and stirred for 5 minutes at room temperature. 4-
nitrobenzaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C until 
complete consumption of starting material. The reaction was cooled down to room 
temperature and the solvent removed in vacuo. 20 mL of ice-cold water were added to 
the residue and the resulting suspension was kept at 0-4 °C overnight in order to obtain 
oximes precipitate, which was filtered and washed with mixture of petroleum 
ether/diethyl ether, obtaining the title compound as a yellow solid (95.9% yield); mp 
99-102 °C; IR νmax 3292 (ν O-H), 1604 (ν C=N), 1532 (νas N-O), 1346 (νs N-O), 942 (N-O, 
oxime), 747 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 7.83 (d, J = 7.6 Hz, 2H, 
Ar), 8.23 (d, J = 8 Hz, 2H, Ar), 8.28 (s, 1H, OH), 11.83 (s, 1H, HC=N-). 13C-NMR (101 
MHz, DMSO-d6): δ 124.4 (2 x Ar), 127.8 (2 x Ar), 140.0 (Ar), 147.3 (Ar), 148.0 (HC=N-). 
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Pyridine-2-aldoxime (O3): in an oven dried flask hydroxylamine hydrochloride (1.5 
eq) and triethylamine (2.25 eq) were dissolved in 10 mL of anhydrous methanol and 
stirred for 5 minutes at room temperature. Pyridine-2-carboxaldehyde (1.0 eq) was 
added and the reaction mixture stirred at 80 °C until complete consumption of starting 
material. The reaction was cooled down to room temperature and the solvent removed 
in vacuo. 20 mL of ice-cold water were added to the residue and the resulting 
suspension was kept at 0-4 °C overnight in order to obtain oximes precipitate, which 
was filtered and washed with mixture of petroleum ether/diethyl ether, obtaining the 
title compound as a white solid (70% yield); mp 64-67 °C; IR νmax 2696 (ν O-H), 1519 (ν 
C=N), 1410 (δ O-H), 982 (N-O, oxime), 702 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-
d6): δ 7.34-7.37 (m, 1H, pyr), 7.78-7.82 (m, 2H, pyr), 8.06-8.07 (m, 1H, pyr), 8.55-8.56 (m, 
1H, OH), 11.67 (s, 1H, HC=N-). 13C-NMR (101 MHz, DMSO-d6): δ 120.2 (pyr), 124.4 
(pyr), 137.2 (pyr), 149.4 (pyr), 149.8 (HC=N-), 152.5 (pyr). 
 
 
Pyridine-3-aldoxime (O4): in an oven dried flask hydroxylamine hydrochloride (1.5 
eq) and triethylamine (2.25 eq) were dissolved in 10 mL of anhydrous methanol and 
stirred for 5 minutes at room temperature. Pyridine-3-carboxaldehyde (1.0 eq) was 
added and the reaction mixture stirred at 80 °C until complete consumption of starting 
material, the reaction was cooled down to room temperature and the solvent removed 
in vacuo. 20 mL of ice-cold water were added to the residue and the resulting 
suspension was kept at 0-4 °C overnight in order to obtain oximes precipitate, which 
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was filtered and washed with mixture of petroleum ether/diethyl ether, obtaining the 
title compound as a white solid (92 % yield); mp 122-123 °C; IR νmax 2773 (ν O-H), 1592 
(ν C=N), 1434 (δ O-H), 975 (N-O, oxime), 735 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, 
DMSO-d6): δ 7.40-7.42 (m, 2H, pyr), 7.96-7.98 (m, 1H, pyr), 8.18 (s, 1H, pyr), 8.53-8.54 
(m, 1H, OH), 11.51 (s, 1H, HC=N-). 13C-NMR (101 MHz, DMSO-d6): δ 124.3 (pyr), 129.5 
(pyr), 133.5 (pyr), 146.2 (pyr), 148.3 (HC=N-), 150.5 (pyr). 
 
 
2-methoxybenzaldehyde oxime (O5): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
anhydrous methanol and stirred for 5 minutes at room temperature. 2-
methoxybenzaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C 
until complete consumption of starting material. The reaction was cooled down to 
room temperature and the solvent removed in vacuo. 20 mL of ice-cold water were 
added to the residue and the resulting suspension was kept at 0-4 °C overnight in order 
to obtain oximes precipitate, which was filtered and washed with mixture of 
petroleum ether/diethyl ether, obtaining the title compound as a light yellow solid 
(89.17 % yield); mp 73-76 °C; 1H-NMR (400 MHz, CDCl3): δ 3.90 (s, 3H, CH3), 6.94-7.01 
(m, 2H, Ar), 7.36-7.40 (m, 1H, Ar), 7.66-7.68 (m, 1H, Ar), 8.50 (s, 1H, HC=N-), 9.37 (s, 
1H, OH).  
 
 
3-methoxybenzaldehyde oxime (O6): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
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anhydrous methanol and stirred for 5 minutes at room temperature. 3-
methoxybenzaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C 
until complete consumption of starting material. The reaction was cooled down to 
room temperature and the solvent removed in vacuo. 20 mL of ice-cold water were 
added to the residue and the resulting suspension was extracted with ethyl acetate (3 
x 20 mL). The organics were reunited, dried over sodium sulphate and evaporated in 
vacuo to give the title compound as thick oil (89.2% yield); 1H-NMR (400 MHz, 
CD3CN): δ 3.80 (s, 3H, CH3), 6.96-6.98 (m, 2H, Ar), 7.21-7.24 (m, 2H, Ar), 7.31-7.35 (m, 
1H, Ar), 8.20 (s, 1H, HC=N-), 9.45 (br, 1H, OH).  
 
 
4-methoxybenzaldehyde oxime (O7): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
anhydrous methanol and stirred for 5 minutes at room temperature. 4-
methoxybenzaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C 
until complete consumption of starting material. The reaction was cooled down to 
room temperature and the solvent removed in vacuo. 20 mL of ice-cold water were 
added to the residue and the resulting suspension was kept at 0-4 °C overnight in order 
to obtain oximes precipitate, which was filtered and washed with mixture of 
petroleum ether/diethyl ether, obtaining the title compound as a white solid (89.2% 
yield); mp 31-33 °C; 1H-NMR (400 MHz, CD3CN): δ 3.81 (s, 3H, CH3), 6.95-7.0 (m, 2H, 
Ar), 7.53-7.55 (m, 2H, Ar), 8.07 (s, 1H, OH), 8.95 (s, 1H, HC=N-).  
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Benzaldehyde oxime (O8): in an oven dried flask hydroxylamine hydrochloride (1.5 
eq) and triethylamine (2.25 eq) were dissolved in 10 mL of anhydrous methanol and 
stirred for 5 minutes at room temperature. Benzaldehyde (1.0 eq) was added and the 
reaction mixture stirred at 80 °C until complete consumption of starting materials. The 
reaction was cooled down to room temperature and the solvent removed in vacuo. 20 
mL of ice-cold water were added to the residue and the resulting suspension was 
extracted with ethyl acetate (3 x 20 mL). The organics were reunited, dried over sodium 
sulphate and evaporated in vacuo to give the title compound as colourless oil (75% 
yield); 1H-NMR (400 MHz, CDCl3): δ 7.41 (m, 3H, Ar), 7.61 (br, 2H, Ar), 8.21 (s, 1H, 
HC=N-), 9.38 (s, 1H, OH).  
 
 
Thiophene-2-carbaldehyde oxime (O9): in an oven dried flask hydroxylamine 
hydrochloride (1.5 eq) and triethylamine (2.25 eq) were dissolved in 10 mL of 
anhydrous methanol and stirred for 5 minutes at room temperature. Thiophene-2-
carbaldehyde (1.0 eq) was added and the reaction mixture stirred at 80 °C until 
complete consumption of starting materials. The reaction was cooled down to room 
temperature and the solvent removed in vacuo. 20 mL of ice-cold water were added to 
the residue and the resulting suspension was kept at 0-4 °C overnight in order to obtain 
oximes precipitate, which was filtered and washed with mixture of petroleum 
ether/diethyl ether, obtaining the title compound as a light brown solid (63% yield); 
1H-NMR (400 MHz, CD3CN): δ 7.13-7.15 (m, 1H, thiophene), 7.44-7.66 (m, 2H, 
thiophene), 7.76 (s, 1H, OH), 9.70 (s, 1H, HC=N-).  
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Synthesis and characterization data of chloro oximes C1-C9 
 
 
N-hydroxy-3-nitrobenzimidoyl chloride (C1): in an oven dried flask m-
nitrobenzaldoxime O1 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. N-
chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at room 
temperature. The solution was purged with 20 mL of HCl(g) and the reaction stirred 
for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide were 
added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as a yellow-orange solid (49 % yield); mp 99-100 °C; IR νmax 3293 (ν 
O-H), 1523 (νas N-O), 1349 (νs N-O), 979 (N-O, oxime), 728 (δ Csp2-H) cm-1; 1H-NMR (400 
MHz, DMSO-d6): δ 7.74-7.78 (m, 1H, Ar), 8.19-8.31 (m, 2H, Ar),  8.47 (s, 1H, Ar), 12.81 
(s, 1H, OH)  . 13C-NMR (101 MHz, DMSO-d6): δ 121.3 (Ar), 125.3 (Ar), 131.0 (Ar), 133.0 
(Ar), 134.1 (Ar), 134.5 (Ar), 148.4 (ClC=N-).  
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N-hydroxy-4-nitrobenzimidoyl chloride (C2): in an oven dried flask p-
nitrobenzaldoxime O2 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. N-
chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at room 
temperature. The solution was purged with 20 mL of HCl(g) and the reaction stirred 
for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide were 
added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as light yellow solid (85% yield); mp 107-110 °C; IR νmax 3266 (ν O-
H), 1598 (ν C=N), 1519 (νas N-O), 1349 (νs N-O, NO2), 941 (N-O, oxime), 842 (ν C sp2-Cl), 
(752 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 8.08.02 (m, 2H, Ar), 8.26-8.28 (m, 
2H, Ar), 12.93 (s, 1H, OH). 13C-NMR (101 MHz, DMSO-d6): δ 124.4 (2 x Ar), 128.2 (2 x 
Ar), 134.5 (Ar), 138.7 (Ar), 148.7 (ClC=N-).  
 
 
N-hydroxy- pyridine-2-carbimidoyl chloride (C3): in an oven dried flask pyridine-2-
aldoxime O3 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. N-chlorosuccinimide 
(0.2 eq) were added and the reaction stirred for 10 minutes at room temperature. The 
solution was purged with 20 mL of HCl(g) and the reaction stirred for 10 additional 
minutes and then heated up to 50 °C. N-chlorosuccinimide were added portion wise 
(0.2 eq at the time, up to 1.5 total eq.) over half an hour. The progression of the reaction 
was monitored using iodine starch paper. When the iodine starch paper was not 
turning brown anymore, the reaction was quenched with 4 volumes of ice-cold water. 
The aqueous phase was extracted with diethyl ether, the organics reunited were dried 
over sodium sulphate and evaporated in vacuo to give the title compound as a light 
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brown solid (76.6 % yield); mp 110-110 °C; 1H-NMR (400 MHz, DMSO-d6): δ 7.46-7.49 
(m, 1H, pyr), 7.86-7.88 (m, 2H, pyr), 8.64-8.65 (m, 1H, pyr), 12.64 (m, 1H, OH). 13C-NMR 
(101 MHz, DMSO-d6): δ 122.0 (pyr), 125.4 (pyr), 137.1 (pyr), 137.59 (pyr), 149.8 (ClC=N-
), 150.2 (pyr). 
 
 
N-hydroxy-pyridine-3-carbimidoyl chloride (C4): in an oven dried flask pyridine-3-
aldoxime O4 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. N-chlorosuccinimide 
(0.2 eq) were added and the reaction stirred for 10 minutes at room temperature. The 
solution was purged with 20 mL of HCl(g) and the reaction stirred for 10 additional 
minutes and then heated up to 50 °C. N-chlorosuccinimide were added portion wise 
(0.2 eq at the time, up to 1.5 total eq.) over half an hour. The progression of the reaction 
was monitored using iodine starch paper. When the iodine starch paper was not 
turning brown anymore, the reaction was quenched with 4 volumes of ice-cold water. 
The aqueous phase was extracted with diethyl ether, the organics reunited were dried 
over sodium sulphate and evaporated in vacuo to give the title compound as brown 
solid (8.85 % yield); mp 126-128 °C; IR νmax 2517 (ν O-H), 1525 (ν C=N), 1417 (δ O-H), 
949 (N-O, oxime), 805 (ν C sp2-Cl), 693 (δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 
7.50-7.53 (m, 1H, pyr), 8.13-8.14 (m, 1H, pyr), 8.66 (s, 1H, pyr), 8.95 (s, 1H, pyr), 12.69 
(s, 1H, OH). 13C-NMR (101 MHz, DMSO-d6): δ 124.3 (pyr), 129.4 (pyr), 133.6 (pyr), 134.9 
(pyr), 147.4 (ClC=N-), 151.3 (pyr). 
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N-hydroxy-2-methoxybenzimidoyl chloride (C5): in an oven dried flask 2-
methoxybenzaldehyde oxime O5 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. 
N-chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at 
room temperature. The solution was purged with 20 mL of HCl(g) and the reaction 
stirred for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide 
were added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as a white solid (81 % yield); mp 105-112 °C; 1H-NMR (400 MHz, 
CDCl3): δ 3.94 (s, 3H, CH3), 7.00-7.06 (m, 2H, Ar), 7.42-7.46 (m, 1H, Ar), 7.63-7.65 (m, 
1H, Ar), 9.88 (br, 1H, OH).  
 
 
N-hydroxy-3-methoxybenzimidoyl chloride (C6): in an oven dried flask 3-
methoxybenzaldehyde oxime O6 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. 
N-chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at 
room temperature. The solution was purged with 20 mL of HCl(g) and the reaction 
stirred for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide 
were added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as a yellow oil (81% yield); 1H-NMR (400 MHz, CDCl3): 1H-NMR 
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(400 MHz, CDCl3): δ 3.81 (s, 3H, CH3), 6.93-6.98 (m, 1H, Ar), 7.25-7.30 (m, 2H, Ar), 7.38-
7.44 (m, 1H, Ar), 10.84 (br, 1H, OH).  
 
 
N-hydroxy-4-methoxybenzimidoyl chloride (C7): in an oven dried flask 4-
methoxybenzaldehyde oxime O7 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. 
N-chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at 
room temperature. The solution was purged with 20 mL of HCl(g) and the reaction 
stirred for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide 
were added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as a yellow solid (58.8% yield); mp 70 °C; 1H-NMR (400 MHz, 
CDCl3): 1H-NMR (400 MHz, CDCl3): δ 3.97 (s, 3H, CH3), 6.93-6.95 (m, 2H, Ar), 7.79-7.81 
(m, 2H, Ar), 8.20 (br, 1H, OH). 
 
 
N-hydroxybenzimidoyl chloride (C8): in an oven dried flask benzaldoxime O8 (1.0 
eq) was dissolved in 10 mL of anhydrous DMF. N-chlorosuccinimide (0.2 eq) were 
added and the reaction stirred for 10 minutes at room temperature. The solution was 
purged with 20 mL of HCl(g) and the reaction stirred for 10 additional minutes and 
then heated up to 50 °C. N-chlorosuccinimide were added portion wise (0.2 eq at the 
time, up to 1.5 total eq.) over half an hour. The progression of the reaction was 
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monitored using iodine starch paper. When the iodine starch paper was not turning 
brown anymore, the reaction was quenched with 4 volumes of ice-cold water. The 
aqueous phase was extracted with diethyl ether, the organics reunited were dried over 
sodium sulphate and evaporated in vacuo to give the title compound as a yellow oil 
(65% yield); 1H-NMR (400 MHz, CDCl3): δ 7.27-7.34 (m, 3H, Ar), 7.77-7.80 (m, 2H, Ar), 
11.44 (br, 1H, OH).  
 
 
N-hydroxythiophene-2-carbimidoyl chloride (C9): in an oven dried flask thiophene-
2-carbaldehyde oxime O9 (1.0 eq) was dissolved in 10 mL of anhydrous DMF. N-
chlorosuccinimide (0.2 eq) were added and the reaction stirred for 10 minutes at room 
temperature. The solution was purged with 20 mL of HCl(g) and the reaction stirred 
for 10 additional minutes and then heated up to 50 °C. N-chlorosuccinimide were 
added portion wise (0.2 eq at the time, up to 1.5 total eq.) over half an hour. The 
progression of the reaction was monitored using iodine starch paper. When the iodine 
starch paper was not turning brown anymore, the reaction was quenched with 4 
volumes of ice-cold water. The aqueous phase was extracted with diethyl ether, the 
organics reunited were dried over sodium sulphate and evaporated in vacuo to give 
the title compound as a green solid (34.0% yield); mp 100-102 °C; 1H-NMR (400 MHz, 
MeOD): δ 5.51-5.52 (m, 1H, thiophene), 5.92-5.94 (m, 1H, thiophene), 6.42 (m, 1H, 
thiophene), 10.44 (br, 1H, OH).  
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Synthesis and characterization data of saccharin/isoxazoline derivatives 1a-9a  
 
 
2-((3-(3-nitrophenyl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-
one 1,1-dioxide (1a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
hydroxy-3-nitrobenzimidoyl chloride C1 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo to give the title compound as a light yellow solid (7% yield); mp 175–177 °C; IR 
νmax 3088 (ν Csp2-H), 1744 (ν C=O), 1593 (ν C=N), 1525 (νas N-O, NO2), 1343 (νs N-O, 
NO2), 1323 (νas S=O), 1302 (ν N-O), 1263 (ν C-N), 1177 (νs S=O), 719 (δ Csp2-H), 674 (δ 
Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): δ 3.44 (dd, 2J = 17.2 Hz, 3J = 6.6 Hz, 1H 
C(4)H2-isoxazoline), 3.68 (dd, 2J = 17.0 Hz, 3J = 11.0 Hz, 1H, C(4)H2-isoxazoline), 3.90 
(dd, 2J = 15.2 Hz, 3J = 4.4 Hz, 1H, CH2), 4.03 (dd, 2J = 15.2 Hz, 3J = 7.2 Hz,  1H, CH2), 5.14-
5.21 (m, 1H, C(5)H-isoxazoline), 7.73-7.77 (m, 1H, Ar), 7.98-8.13 (m, 4H, Ar), 8.29- 8.33 
(m, 2H, Ar), 8.37 (s, 1H, Ar). 13C (101 MHz, CDCl3): δ 38.3 (C(4)H2-isoxazoline), 41.5 
(CH2), 78.3 (C(5)H-isoxazoline), 121.2 (Ar), 121.7 (Ar), 124.8 (Ar), 125.5 (Ar), 126.9 (Ar), 
129.9 (Ar), 130.9 (Ar), 132.4 (Ar), 134.6 (Ar), 135.2 (Ar), 137.5 (Ar), 148.5 (Ar), 154.9 
(C=N, isoxazoline), 159.4 (C=O). 
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2-((3-(4-nitrophenyl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-
one 1,1-dioxide (2a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
hydroxy-4-nitrobenzimidoyl chloride C2 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was filtered to give title compound as a 
light yellow solid (64% yield); mp 210-213 °C; IR νmax 3076 (ν Csp2-H), 1735 (ν C=O), 
1580 (ν C=N), 1509 (νas N-O), 1326 (νas S=O), 1308 (νs N-O), 1247 (ν C-N), 1181 (νs S=O), 
849 (δ Csp2-H), 749 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): δ 3.41 (dd, 2J = 16.2 
Hz, 3J = 7.2 Hz, 1H C(4)H2-isoxazoline), 3.66 (dd, 2J =17.6 Hz, 3J = 10.8 Hz, 1H, C(4)H2-
isoxazoline), 3.91 (dd, 2J = 15.4 Hz, 3J = 4.6 Hz, 1H, CH2), 4.04 (dd, 2J = 15.2 Hz, 3J = 7.2 
Hz,  1H, CH2), 5.17-5.19 (m, 1H, C(5)H-isoxazoline), 7.90 (d, 3J = 8.4 Hz, 2H, Ar), 8.00-
8.12 (m, 3H, Ar), 8.27-8.32 (m, 3H, Ar). 13C (101 MHz, DMSO-d6): δ 38.0 (C(4)H2, 
isoxazoline), 42.1 (CH2), 79.0 (C(5)H-isoxazoline), 122.1 (Ar), 124.5 (2xAr), 125.7 (Ar), 
126.6 (Ar), 128.3 (2xAr), 135.7 (Ar), 135.8 (Ar), 136.4 (Ar), 137.2 (Ar), 148.5 (Ar), 156.4 
(C=N, isoxazoline), 159.4 (C=O). 
 
 
2-((3-(pyridin-2-yl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 
1,1-dioxide (3a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
hydroxy- pyridine-2-carbimidoyl chloride C3 (1.25 eq) were dissolved in 20 mL of 
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anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo to give the title compound as a light orange solid (99% yield); mp 133-135 °C; IR 
νmax 2928 (ν Csp2-H), (1739 (ν C=O), 1578 (ν C=N), 1320 (νas S=O), 1300 (ν N-O), 1288 (ν 
C-N), 1173 (νs S=O), 778 (δ Csp2-H), 745 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): 
δ 3.39-3.45 (m, 1H C(4)H2-isoxazoline), 3.59-3.66 (m, 1H, C(4)H2-isoxazoline), 3.89-3.94 
(m, 1H, CH2), 3.99-4.04 (m, 1H, CH2), 5.11-5.12 (m, 1H, C(5)H-isoxazoline), 7.42-7.45 
(m, 1H, pyr), 7.84-7.92 (m, 1H Ar + 1H pyr), 7.97-8.11 (m, 2H Ar + 1H pyr), 8.30-8.32 
(m, 1H, Ar), 8.61 (s, 1H, pyr). 13C (101 MHz, DMSO-d6): δ 38.4 (C(4)H2-isoxazoline), 42.2 
(CH2), 78.5 (C(5)H-isoxazoline), 121.8 (pyr), 122.1 (Ar), 125.2 (pyr), 125.7 (Ar), 126.6 
(pyr), 135.8 (Ar), 136.4 (Ar), 137.1 (Ar), 137.4 (pyr), 148.9 (Ar), 149.9 (pyr), 158.9 (C=N, 
isoxazoline), 159.4 (C=O). 
 
 
2-((3-(pyridin-3-yl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 
1,1-dioxide (4a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
hydroxy- pyridine-3-carbimidoyl chloride C4 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:1) 
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gave the title compound as a light orange solid (32% yield); mp 98-100 °C; IR νmax 3041 
(ν Csp2-H), 1733 (ν C=O), 1596 (ν C=N), 1335 (νas S=O), 1301 (ν N-O), 1260 (ν C-N), 1180 
(νs S=O), 748 (δ Csp2-H), 673 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.31 (dd, 2J = 
17.0 Hz, 3J = 6.6 Hz, 1H, C(4)H2-isoxazoline), 3.45 (dd, 2J =17.0 Hz, 3J = 10.6 Hz, 1H, 
C(4)H2-isoxazoline), 3.86 (dd, 2J = 14.8 Hz, 3J = 6.8 Hz, 1H, CH2), 3.99 (dd, 2J = 15.0 Hz, 
3J = 5.8 Hz,  1H, CH2), 5.16-5.23 (m, 1H, C(5)H-isoxazoline), 7.24-7.27 (m, 1H, pyr), 7.76-
7.88 (m, 2H Ar + 1 H pyr), 7.86-7.98 (m, 1H Ar + 1H pyr), 8.53-8.54 (m, 1H, Ar), 8.74-
8.75 (m, 1H, pyr). 13C (101 MHz, CDCl3): δ 38.4 (C(4)H2-isoxazoline), 41.6 (CH2), 79.2 
(C(5)H-isoxazoline), 121.1 (Ar), 123.6 (pyr), 125.3 (pyr), 125.4 (Ar), 126.8 (Ar), 133.9 
(pyr), 134.6 (Ar), 135.2 (pyr), 137.3 (Ar), 147.8 (Ar), 151.1 (pyr), 154.3 (C=N, isoxazoline), 
159.3 (C=O). 
 
 
2-((3-(2-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-
3(2H)-one 1,1-dioxide (5a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) 
and N-hydroxy-2-methoxybenzimidoyl chloride C5 (1.25 eq) were dissolved in 20 mL 
of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:1) 
gave the title compound as a white solid (36% yield); mp 138-140 °C; IR νmax 2940 (ν 
Csp2-H), 1735 (ν C=O), 1333 (νas S=O), 1599 (ν C=N), 1302 (ν N-O), 1256 (ν C-N), 1174 
(νs S=O), 770 (δ Csp2-H), 753 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.51 (dd, 2J = 
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17.8 Hz, 3J = 6.2 Hz, 1H C(4)H2-isoxazoline), 3.60 (dd, 2J =17.8 Hz, 3J = 10.2 Hz, 1H, 
C(4)H2-isoxazoline), 3.86-3.93 (m, 3H OCH3 + 1H CH2), 4.05 (dd, 2J = 14.8 Hz, 3J = 6.0 
Hz, 1H, CH2), 5.16-5.23 (m, 1H, C(5)H-isoxazoline), 6.93-7.00 (m, 2H, Ar), 7.37-7.41 (m, 
1H, Ar), 7.73- 7.75 (m, 1H, Ar), 7.84-7.96 (m, 3H, Ar), 8.08 (d, 3J = 7.6 Hz, 1H, Ar). 13C 
(101 MHz, CDCl3): δ 41.4 (C(4)H2-isoxazoline), 41.9 (CH2), 55.5 (OCH3), 77.2 (C(5)H-
isoxazoline), 111.4 (Ar), 118.3 (Ar), 120.8 (Ar), 121.1 (Ar), 125.4 (Ar), 127.1 (Ar), 129.6 
(Ar), 131.5 (Ar), 134.5 (Ar), 135.1 (Ar), 137.5 (Ar), 156.1 (C=N, isoxazoline), 157.6 (Ar), 
159.3 (C=O). 
 
 
2-((3-(3-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-
3(2H)-one 1,1-dioxide (6a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) 
and N-hydroxy-3-methoxybenzimidoyl chloride C6 (1.25 eq) were dissolved in 20 mL 
of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:petroleum 
ether 1:3) gave the title compound as a highly thick oil (31% yield); IR νmax 2938 (ν Csp2-
H), 1727 (ν C=O), 1595 (ν C=N), 1330 (νas S=O), 1301 (ν N-O), 1254 (ν C-N), 1183(νs 
S=O), 765 (δ Csp2-H), 673 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.32-3.36 (m, 1H 
C(4)H2-isoxazoline), 3.43-3.50 (m, 1H C(4)H2-isoxazoline), 3.78-3.80 (m, 3H, OCH3), 
3.87-3.92 (m, 1H CH2), 4.02-4.06 (m, 1H, CH2), 5.20 (br, 1H, C(5)H-isoxazoline), 6.93-
6.95 (m, 1H, Ar), 7.18-7.28 (m, 3H, Ar), 7.83- 7.91 (m, 3H, Ar), 8.02-8.04 (m, 1H, Ar). 13C 
(101 MHz, CDCl3): δ 38.8 (C(4)H2-isoxazoline), 41.8 (CH2), 55.4 (OCH3), 77.2 (C(5)H-
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isoxazoline), 111.5 (Ar), 116.6 (Ar), 119.5 (Ar), 121.1 (Ar), 125.4 (Ar), 126.9 (Ar), 129.8 
(Ar), 130.3 (Ar), 134.6 (Ar), 135.2 (Ar), 137.4 (Ar), 156.5 (C=N, isoxazoline), 159.3 (Ar), 
159.7 (C=O). 
 
 
2-((3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-
3(2H)-one 1,1-dioxide (7a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) 
and N-hydroxy-4-methoxybenzimidoyl chloride C7 (1.25 eq) were dissolved in 20 mL 
of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was filtered to give title compound as a 
white solid (62% yield); mp 148-153 °C; IR νmax 3069 (ν Csp2-H), 1740 (ν C=O), 1607 (ν 
C=N), 1321 (νas S=O), 1301 (ν N-O), 1248 (ν C-N), 1178 (νs S=O), 752 (δ Csp2-H), 672 (δ 
Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): δ 3.32 (dd, 2J = 17.2 Hz, 3J = 6.8 Hz, 1H 
C(4)H2-isoxazoline), 3.56 (dd, 2J = 17.2 Hz, 3J = 10.4 Hz, 1H, C(4)H2-isoxazoline), 3.79 (s, 
3H, OCH3), 3.85 (dd, 2J = 15.2 Hz, 3J = 4.8 Hz, 1H, CH2), 3.97 (dd, 2J = 15.2 Hz, 3J = 7.6 
Hz,  1H, CH2), 5.02-5.10 (m, 1H, C(5)H-isoxazoline), 7.00 (d, 3J = 8.8 Hz, 2H, Ar), 7.60 
(d, 3J = 8.8 Hz, 2H, Ar),  7.99-8.13 (m, 3H, Ar), 8.30 (d, 3J = 7.6 Hz, 2H, Ar). 13C (101 MHz, 
DMSO-d6): δ 38.9 (C(4)H2-isoxazoline), 42.5 (CH2), 55.8 (OCH3), 77.5 (C(5)H-
isoxazoline), 114.7 (2 x Ar), 115.7 (Ar), 121.9 (Ar), 122.0 (Ar), 126.6 (Ar), 128.7 (2 x Ar), 
135.8 (Ar), 136.2 (Ar), 137.1 (Ar), 157.0 (C=N, isoxazoline), 159.6 (Ar),  161.8 (C=O). 
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2-((3-phenyl-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-
dioxide (8a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
hydroxybenzimidoyl chloride C8 (1.25 eq) were dissolved in 20 mL of anhydrous ethyl 
acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in ethyl acetate were 
added dropwise over 30 mins. A white suspension was formed, and the reaction 
stirred overnight at room temperature. The reaction was quenched with 40 mL of 
water and the resulting suspension was extracted with dichloromethane (3x20mL). 
The organics reunited were dried over sodium sulphate and evaporated in vacuo. 
Purification by column chromatography on silica gel (ethyl acetate:petroleum ether 
1:3) gave the title compound as a thick oil (60% yield); IR νmax 2935 (ν Csp2-H), 1729 (ν 
C=O), 1594 (ν C=N), 1331 (νas S=O), 1302 (ν N-O), 1256 (ν C-N), 1175 (νs S=O), 748 (δ 
Csp2-H), 675 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.32-3.36 (m, 1H, C(4)H2-
isoxazoline), 3.42-3.49 (m, 1H, C(4)H2-isoxazoline), 3.85-3.90 (m, 1H, CH2), 4.01-4.05 (m, 
1H, CH2), 5.19 (br, 1H, C(5)H-isoxazoline), 7.35 (br, 3H, Ar), 7.64 (br, 2H, Ar), 7.77-7.86 
(m, 3H, Ar), 7.96-7.98 (m, 1H, Ar). 13C (101 MHz, CDCl3): δ 38.7 (C(4)H2-isoxazoline), 
41.8 (CH2), 77.7 (C(5)H-isoxazoline), 121.1 (Ar), 125.3 (Ar), 126.9 (2 x Ar), 128.8 (2 x Ar), 
129.1 (Ar), 130.3 (Ar), 134.6 (Ar), 135.3 (Ar), 137.3 (Ar), 156.6 (C=N, isoxazoline), 159.3 
(C=O). 
 
 
2-((3-(thiophen-2-yl)-4,5-dihydroisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-
one 1,1-dioxide (9a): 2-allylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide S1 (1.0 eq) and N-
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hydroxythiophene-2-carbimidoyl chloride C9 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:3) 
gave the title compound as a brown highly thick oil (16% yield); IR νmax 3091 (ν Csp2-
H), 1730 (ν C=O), 1636 (ν C=N), 1332 (νas S=O), 1311 (ν N-O), 1260 (ν C-N), 1178 (νs 
S=O), 752 (δ Csp2-H), 698 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.38 (dd, 2J = 16.4 
Hz, 3J = 6.4 Hz, 1H, C(4)H2-isoxazoline), 3.51 (dd, 2J = 16.8 Hz, 3J = 10.4 Hz, 1H, C(4)H2-
isoxazoline), 3.90 (dd, 2J = 14.8 Hz, 3J = 7.2 Hz, 1H, CH2), 4.05 (dd, 2J = 14.8 Hz, 3J = 5.6 
Hz,  1H, CH2), 5.18-5.22 (m, 1H, C(5)H-isoxazoline), 7.04-7.06 (m, 1H, thiophene), 7.04-
7.06 (m, 1H, thiophene), 7.22-7.23 (m, 1H, thiophene), 7.39-7.40 (m, 1H, thiophene), 
7.84-7.95 (m, 3H, Ar), 8.06 (d, 3J = 7.2 Hz, 1H, Ar). 13C (101 MHz, CDCl3): δ 39.6 (C(4)H2-
isoxazoline), 41.6 (CH2), 77.8 (C(5)H-isoxazoline), 121.2 (Ar), 125.4 (thiophene), 126.9 
(thiophene), 127.4 (Ar), 128.7 (thiophene), 129.0 (thiophene), 131.3 (Ar), 134.7 (Ar), 
135.2 (Ar), 137.4 (Ar), 152.3 (C=N, isoxazoline), 159.3 (C=O). 
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Synthesis and characterization data of saccharin/isoxazole derivatives 1b-9b 
 
2-((3-(3-nitrophenyl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
(1b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
hydroxy-3-nitrobenzimidoyl chloride C1 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:1) 
gave the title compound as a white solid (26% yield); mp 191-193 °C; IR νmax 1731 (ν 
C=O), 1605 (ν C=N), 1539 (νas N-O, NO2), 1334 (νas S=O), 1303 (νs N-O, NO2), 1262 (ν C-
N), 1185 (νs S=O), 755 (δ Csp2-H), 670 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): δ 
5.23 (s, 2H, CH2), 7.37 (s, 1H, C(4)H, isoxazole), 7.79-7.81 (m, 1H, Ar), 8.02-8.10 (m, 2H, 
Ar), 8.15-8.17 (m, 1H, Ar), 8.31-8.33 (m, 2H, Ar), 8.35-8.37 (m, 1H, Ar), 8.61 (br, 1H, Ar). 
13C (101 MHz, DMSO-d6): δ 33.9 (CH2), 102.7 (C(4)H-isoxazole), 121.6 (Ar), 122.3 (Ar), 
125.4 (Ar), 125.9 (Ar), 126.6 (Ar), 130.2 (Ar), 131.4 (Ar), 133.4 (Ar), 135.9 (Ar), 136.6 (Ar), 
137.3 (Ar), 148.8 (Ar), 158.7 (C(5)-isoxazole), 161.1 (C=N, isoxazole), 168.2 (C=O). 
 
 
2-((3-(4-nitrophenyl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
(2b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
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hydroxy-4-nitrobenzimidoyl chloride C2 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was filtered to give title compound as a 
white solid (40% yield); mp 260-262 °C; IR νmax 3145 (ν Csp2-H), 1597 (ν C=N), 1720 (ν 
C=O), 1511 (νas N-O, NO2), 1334 (νas S=O), 1303 (νs N-O), 1268 (ν C-N), 1184 (νs S=O), 
755 (δ Csp2-H), 677 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): δ 5.23 (s, 2H, CH2), 
7.31 (s, 1H, C(4)H-isoxazole), 8.02-8.10 (m, 2H, Ar), 8.13-8.17 (m, 3H, Ar), 8.31-8.37 (m, 
3H, Ar). 13C (101 MHz, DMSO-d6): δ 33.8 (CH2), 102.9 (C(4)H-isoxazole), 122.3 (Ar), 
124.8 (2 x Ar), 125.9 (Ar), 126.6 (Ar), 128.4 (2 x Ar), 134.6 (Ar), 135.9 (Ar), 136.6 (Ar), 
137.3 (Ar), 148.9 (Ar), 155.2 (C=N, isoxazole), 158.7 (C(5)-isoxazole), 168.3 (C=O). 
 
 
2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
(3b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
hydroxy- pyridine-2-carbimidoyl chloride C3 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was filtered to give title compound as a 
light brown solid (22% yield); mp 161-164 °C; IR νmax 3101 (ν Csp2-H), 1735 (ν C=O), 1593 
(ν C=N), 1326 (νas S=O), 1303 (ν N-O) 1269 (ν C-N), 1180 (νs S=O), 785 (δ Csp2-H), 749 (δ 
Csp2-H) cm-1. 1H-NMR (400 MHz, DMSO-d6): 5.25 (s, 2H, CH2), 7.06 (s, 1H, C(4)H-
isoxazole), 7.48-7.50 (m, 1H, pyr), 7.92-8.08 (m, 2H Ar + 2H pyr), 8.14-8.16 (m, 1H, Ar), 
8.35-8.37 (m, 1H, Ar), 8.68 (s, 1H, pyr). 13C (101 MHz, DMSO-d6): δ 33.8 (CH2), 103.0 
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(C(4)H-isoxazole), 121.8 (pyr), 122.2 (Ar), 125.7 (Ar), 125.9 (pyr), 135.9 (Ar), 136.6 (Ar), 
137.3 (Ar), 138.0 (Ar), 147.5 (pyr), 147.7 (pyr), 150.5 (pyr), 158.7 (C(5)-isoxazole), 163.5 
(C=N, isoxazole), 167.7 (C=O). 
 
 
2-((3-(pyridin-3-yl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
(4b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
hydroxy- pyridine-3-carbimidoyl chloride C4 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:1) 
gave the title compound as a light brown solid (34% yield); mp 140-143 °C; IR νmax 3084 
(ν Csp2-H), 1736 (ν C=O), 1610 (ν C=N), 1327(νas S=O), 1292 (ν N-O), 1260 (ν C-N), 1173 
(νs S=O), 747 (δ Csp2-H), 671 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): 5.11 (s, 2H, 
CH2), 6.74 (s, 1H, C(4)H-isoxazole), 7.37-7.40 (m, 1H, pyr), 7.87-7.99 (m, 2H Ar + 1H 
pyr), 8.11-8.13 (d, J = 7.6, 2H, Ar), 8.67-8.68 (m, 1H, pyr), 8.98 (s, 1H, pyr). 13C (101 MHz, 
CDCl3): δ 33.6 (CH2), 101.9 (C(4)H-isoxazole), 121.3 (Ar), 123.8 (pyr), 125.6 (Ar), 126.1 
(pyr), 126.8 (Ar), 134.2 (pyr), 134.7 (Ar), 135.4 (Ar), 137.7 (Ar), 146.9 (pyr), 147.9 (pyr), 
151.1 (C=N, isoxazole), 158.4 (C(5)-isoxazole), 166.6 (C=O). 
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2-((3-(2-methoxyphenyl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-
dioxide (5b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) 
and N-hydroxy-2-methoxybenzimidoyl chloride C5 (1.25 eq) were dissolved in 20 mL 
of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:1) 
gave the title compound as a white solid (27% yield); mp 126-131 °C; IR νmax 1733 (ν 
C=O), 1603 (ν C=N), 1337 (νas S=O), 1300 (ν N-O), 1250 (ν C-N), 1185 (νs S=O), 760 (δ 
Csp2-H), 671 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 3.88 (s, 3H, OCH3), 5.10 (s, 
2H, CH2), 6.93 (s, 1H, C(4)H-isoxazole), 6.97-7.04 (m, 2H, Ar), 7.39-7.42 (m, 1H, Ar), 
7.86-7.91 (m, 3H, Ar), 7.94-7.96 (m, 1H, Ar), 8.08-8.10 (m, 1H, Ar). 13C (101 MHz, CDCl3): 
δ 33.6 (CH2), 55.6 (OCH3), 105.8 (C(4)H-isoxazole), 111.4 (Ar), 117.6 (Ar), 120.9 (Ar), 
121.2 (Ar), 125.5 (Ar), 126.9 (Ar), 129.5 (Ar), 131.4 (Ar), 134.6 (Ar), 135.2 (Ar), 137.6 (Ar), 
157.2 (Ar), 158.5 (C(5)-isoxazole), 160.4 (C=N, isoxazole),  164.3 (C=O). 
 
 
2-((3-(3-methoxyphenyl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-
dioxide (6b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) 
and N-hydroxy-3-methoxybenzimidoyl chloride C6 (1.25 eq) were dissolved in 20 mL 
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of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:petroleum 
ether 1:3) gave the title compound as a pale yellow solid (21% yield); mp 144-149 °C; 
IR νmax 2937 (ν Csp2-H), 1740 (ν C=O), 1603 (ν C=N), 1328 (νas S=O), 1300 (ν N-O), 1255 
(ν C-N), 1163 (νs S=O), 755 (δ Csp2-H), 675 (δ Csp2-H) cm-1.1H-NMR (400 MHz, DMSO-
d6): δ 3.80 (s, 3H, OCH3), 5.22 (s, 2H, CH2), 7.05-7.07 (m, 1H, Ar), 7.18 (s, 1H, C(4)H-
isoxazole), 7.39-7.45 (m, 3H, Ar), 8.02 (t, 3J = 7.6 Hz, 1H, Ar), 8.07-8.11 (m, 1H, Ar), 8.16 
(d, 3J = 7.6 Hz, 1H, Ar), 8.37 (d, 3J = 7.6 Hz, 1H, Ar). 13C (101 MHz, DMSO-d6): δ 33.8 
(CH2), 55.7 (OCH3), 102.6 (C(4)H-isoxazole), 112.2 (Ar), 116.6 (Ar), 119.4 (Ar), 122.4 
(Ar), 125.8 (Ar), 126.6 (Ar), 129.9 (Ar), 130.7 (Ar), 135.8 (Ar), 136.5 (Ar), 137.3 (Ar), 158.7 
(C(5)-isoxazole), 160.1 (Ar),  162.5 (C=N, isoxazole), 167.3 (C=O). 
 
 
2-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-
dioxide (7b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) 
and N-hydroxy-4-methoxybenzimidoyl chloride C7 (1.25 eq) were dissolved in 20 mL 
of anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was filtered to give the title compound 
as a white solid (69% yield); mp 179-185 °C; IR νmax 3127 (ν Csp2-H), 1739 (ν C=O), 1614 
(ν C=N), 1333 (νas S=O), 1294 (ν N-O), 1248 (ν C-N), 1169 (νs S=O), 834 (δ Csp2-H), 752 
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(δ Csp2-H) cm-1; 1H-NMR (400 MHz, DMSO-d6): δ 3.80 (s, 3H, OCH3), 5.18 (s, 2H, CH2), 
7.03-7.06 (m, 2H Ar + 1H C(4)H-isoxazole), 7.78-7.80 (m, 2H, Ar), 8.03-8.09 (m, 2H, Ar), 
8.16-8.17 (m, 1H, Ar), 8.35-8.36 (m, 1H, Ar). 13C (101 MHz, DMSO-d6): δ 33.8 (CH2), 55.7 
(OCH3), 102.1 (C(4)H-isoxazole), 115.0 (2 x Ar), 121.0 (Ar), 122.2 (Ar), 124.8 (Ar), 125.9 
(Ar), 128.6 (2 x Ar), 135.9 (Ar), 136.6 (Ar), 137.2 (Ar), 156.0 (Ar), 158.7 (C(5)-isoxazole), 
161.5 (C=N, isoxazole), 166.9 (C=O). 
 
 
2-((3-phenylisoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (8b): 2-
(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
hydroxybenzimidoyl chloride C8 (1.25 eq) were dissolved in 20 mL of anhydrous ethyl 
acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in ethyl acetate were 
added dropwise over 30 mins. A white suspension was formed, and the reaction 
stirred overnight at room temperature. The reaction was quenched with 40 mL of 
water and the resulting suspension was extracted with dichloromethane (3x20mL). 
The organics reunited were dried over sodium sulphate and evaporated in vacuo. 
Purification by column chromatography on silica gel (ethyl acetate:petroleum ether 
1:3) gave the title compound as a pale yellow solid (23% yield); mp 126-130 °C; IR νmax 
3129 (ν Csp2-H), 1741 (ν C=O), 1608 (ν C=N), 1333 (νas S=O), 1292 (ν N-O), 1256 (ν C-N), 
1181 (νs S=O), 754 (δ Csp2-H), 694 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 5.10 (s, 
2H, CH2), 6.71 (s, 1H, CH-isoxazole), 7.42-7.44 (m, 3H, Ar), 7.77-7.79 (m, 2H, Ar), 7.83-
7.92 (m, 2H, Ar), 7.96 (d, 3J = 7.2 Hz, 1H, Ar), 8.09 (d, 3J = 7.6 Hz, 1H, Ar). 13C (101 MHz, 
CDCl3): δ 33.7 (CH2), 102.2 (C(4)H-isoxazole), 121.3 (Ar), 125.6 (Ar), 126.8 (Ar), 126.9 (2 
x Ar), 128.6 (Ar), 128.9 (2 x Ar), 130.2 (Ar), 134.7 (Ar), 135.3 (Ar), 137.6, 158.5 (C(5)-
isoxazole), 162.7 (C=N, isoxazole), 165.9 (C=O). 
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2-((3-(thiophen-2-yl)isoxazol-5-yl)methyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
(9b): 2-(prop-2-yn-1-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide S2 (1.0 eq) and N-
hydroxythiophene-2-carbimidoyl chloride C9 (1.25 eq) were dissolved in 20 mL of 
anhydrous ethyl acetate. 1.0 mL of a solution of 0.2 mL of triethylamine (1.25 eq) in 
ethyl acetate were added dropwise over 30 mins. A white suspension was formed, and 
the reaction stirred overnight at room temperature. The reaction was quenched with 
40 mL of water and the resulting suspension was extracted with dichloromethane 
(3x20mL). The organics reunited were dried over sodium sulphate and evaporated in 
vacuo. Purification by column chromatography on silica gel (ethyl acetate:n-hexane 1:3) 
gave the title compound as a white solid, mp 140-146 °C, 27% yield; IR νmax 3136 (ν 
Csp2-H), 1724 (ν C=O), 1612 (ν C=N), 1332 (νas S=O), 1300 (ν N-O), 1268 (ν C-N), 1175 
(νs S=O), 752 (δ Csp2-H), 706 (δ Csp2-H) cm-1. 1H-NMR (400 MHz, CDCl3): δ 5.09 (s, 2H, 
CH2), 6.63 (s, 1H, C(4)H-isoxazole), 7.09-7.12 (m, 1H, thiophene), 7.42-7.46 (m, 2H, 
thiophene), 7.90-7.99 (m, 3H, Ar), 8.01-8.15 (m, 1H, Ar). 13C (101 MHz, CDCl3): δ 33.6 
(CH2), 102.2 (C(4)H, isoxazole), 121.3 (Ar), 125.6 (Ar), 126.8 (Ar), 127.6 (Ar, thiophene), 
127.8 (Ar, thiophene), 127.9 (Ar, thiophene), 130.2 (Ar, thiophene), 134.7 (Ar), 135.3 
(Ar), 137.6 (Ar), 157.9 (C=N, isoxazole), 158.5 (C(5)-isoxazole), 165.9 (C=O). 
 
CA Inhibition Screening Assay  
An Applied Photophysics stopped-flow instrument has been used for assaying the 
CA-catalyzed CO2 hydration activity. Phenol red (at a concentration of 0.2 mM) has 
been used as an indicator, working at the maximum absorbance of 557 nm, with 20 
mM Hepes (pH 7.5 for α-CAs) as buffer, and 20 mM Na2SO4 (for maintaining constant 
the ionic strength). The initial rates of the CA-catalysed CO2 hydration reaction were 
followed for a period of 10−100 s. The CO2 concentrations ranged from 1.7 to 17 mM 
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for the determination of the kinetic parameters and inhibition constants. For each 
inhibitor, at least six traces of the initial 5−10% of the reaction have been used for 
determining the initial velocity. The uncatalyzed rates were determined in the same 
manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 
mM) were prepared in distilled−deionized water, and dilutions up to 0.01 nM were 
done thereafter with distilled−deionized water. Inhibitor and enzyme solutions were 
preincubated together for 15 min at room temperature prior to assay to allow for the 
formation of the E−I complex. The inhibition constants were obtained by nonlinear 
least-squares methods using the Cheng−Prusoff equation and represent the mean from 
at least three different determinations. Errors were in the range of ± 5−10% of the 
reported KI values. CA isoforms were recombinant enzymes obtained in house as 
reported earlier [97]. The enzyme concentrations in the assay system were: hCA I, 13.2 
nM; hCA II, 8.4 nM; hCA IX, 7.9 nM; hCA XII, 15.2 nM. 
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I have spent the last part of my PhD in the discovery and synthesis of new inhibitors based on 
benzo[b]thiophen-3-ole scaffold effective against human monoamine oxidases. 
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Chapter 4 
Human monoamine oxidases (hMAOs) 
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4.1 Introduction 
Monoamine oxidases (MAOs; EC 1.4.3.4) are mitochondrial bound flavoenzymes 
which catalyse the oxidative degradation of amines. In human have been observed 
two different isoforms called respectively A and B (hMAO-A / hMAO-B). The initial 
discovery of mammalian MAOs was done in 1928 by Hare, who observed a tyramine 
oxidase activity in rabbit liver, not explainable with tyrosinase function [126]. The 
presence of these enzymes in the main organ addicted to the chemical inactivation of 
xenobiotics, prompted Hare to postulate that they were mainly involved in the 
metabolism of potentially toxic exogenous amines. Follow-up studies showed that 
these enzymes are effective to catalyse the oxidative deamination of some 
neurologically important amine substrates, including dopamine, norepinephrine, 
epinephrine, serotonin and phenethylamine [127]. This reaction occurs due to the 
presence of flavin adenine dinucleotide cofactor (FAD, depicted in yellow in Figure 
4.1) that works as electron acceptor for the oxidation of amines, forming iminium ion 
and FADH2. The regeneration of FAD active form is then accomplished through the 
electron transfer to an oxygen molecule producing hydrogen peroxide (Figure 4.1). 
 
 
 
Figure 4.1. Chemical reaction catalysed by hMAOs using dopamine as an example of 
neurotransmitter substrate. The flavin cofactor is reported in yellow and undergoes a two-
104 
 
electron reduction substrate oxidation. Regeneration to its functional form is accomplished by 
molecular oxygen, leading to hydrogen peroxide production [128]. 
The fate of iminium ion is determined by the aqueous medium which provokes its 
hydrolysis to ammonium ion and aldehyde.The latter is then oxidized to carboxylic 
acids by aldehyde dehydrogenase (ALDH) or reduced to alcohol by aldehyde 
reductase (ALR) [129]. The preferred substrates for hMAOs enzymes are primary 
amines, albeit they also can catalyse the oxidation of secondary amines. On the other 
hand, they have little or no activity in the oxidation of tertiary amines, with few 
exceptions as the bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). MPTP was an impurity of synthetic heroin, which once converted in 1-
methyl-4-phenylpyridinium ion (MPP+), led to the development of symptoms 
resembling those of Parkinson’s patients (Figure 4.2) [130].  
 
 
 
Figure 4.2. Bioactivation of MPTP to MPP+, favoured by MAO B. 
 
The discovery that these symptoms could be stopped by the administration of the 
acetylenic MAO-B inhibitor pargyline, confirmed the implication of this enzyme in 
MPTP bioactivation [131], and set in motion the quest for new MAO-B inhibitors as 
potential anti-Parkinson drugs. 
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4.2. Structural properties and catalytic mechanism of hMAOs  
The two isoforms of human monoamine oxidase are quite similar sharing ~70% 
sequence identity [132,133]. Both the enzymes possess a dimeric organization 
structure. Each monomeric unit comprises a membrane binding domain anchoring the 
enzyme to the outer mitochondrial membrane, and a “globular” part which extends 
out of the membrane. The “globular” part contains the flavin-binding domain and a 
substrate-binding domain [128] (Figure 4.3). 
 
                
 
Figure 4.3. Overall crystal structure of human MAO A (I) and MAO B (II) represented as 
models of the protein dimer inserted in the phospholipid bilayer. FAD cofactor is reported in 
yellow and the active site cavity surface in pink [128,134,135]. 
 
Among the two isoforms, only hMAO-B has been purified as a dimer, while hMAO-A 
was separated only as monomer because of the lower biochemical stability of the two 
monomers that dissociate upon detergent-mediated extraction from the membrane. 
Nevertheless, there are some evidences which confirmed the dimeric organization of 
hMAO-A on the membrane [136].  
The membrane binding domains of hMAOs are located in the C-terminal region of the 
proteins. These sites have an α-helix organization containing residues able to create an 
I II 
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apolar surface that facilitate their insertion into the membrane, and aminoacidic side 
chains positively-charged (e.g. arginine, lysine) which bind the phospholipidic heads 
[134,135]. The globular cores comprise two domains, one that contain the covalently-
bound FAD cofactor and the other involved in substrate binding (Figure 4.4, [128]). 
 
       
Figure 4.4. Detailed representation of substrate-binding site of hMAO-A (I) and hMAO-B 
(II). 
 
The two substrate-binding domains of hMAOs share some conserved aminoacidic 
residues which line the cavity, like Phe 352 of hMAO-A corresponding to the Phe 343 
of hMAO-B. The two aminoacids Tyr 407 / Tyr 444 are disposed in a face to face manner 
in order to create an “aromatic caged environment” that is responsible for the correct 
alignment of the substrate toward the catalytic FAD (similar to the couple of Tyr398 / 
Tyr 435 of hMAO-B). Furthermore, the three residues Pro 113, Phe 112 and Trp 128 of 
hMAO-A (corresponding to Pro 104, Phe 103 and Trp 119 of hMAO-B), located at the 
bottom of the protein near the membrane surface, constitute the “cap” of a loop that 
seals the active site from the exterior and may serve as “gating switch”, because the 
movement of this loop permits the access to the entrance cavity.  
Both the isoforms share a substrate binding cavity of ~ 400 Å3. However, hMAO-B is 
endowed with a further small hydrophobic cavity of 290 Å3. This additional chamber, 
named “entrance cavity”, can be coupled (producing a single cavity with a total 
I II 
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volume of ~ 700 Å3) or not with the substrate cavity depending on Ile 199 side chain 
conformation, which works as a “gate” existing in either a “closed” or “open” 
conformations. The Ile 199 controlled connection of the two pockets in a single cavity, 
can be exploited to design selective inhibitors for hMAO-B [137]. 
FAD cofactor is covalently-bound via a thioether linkage by means a Cys residue of the 
enzyme (Cys 406 for hMAO-A; Cys 397 for hMAO-B) to the 8a-methylene of 
isoalloxazine ring and is involved in the oxidative deamination.  
In the last years two proposals have been suggested to explain the mechanism of 
electron transfer from the amine to the flavin ring. The first is the single electron 
transfer (SET) mechanism proposed by Silverman [138–140] (Scheme 4.1). 
 
 
Scheme 4.1. Single electron transfer (SET) mechanism of action of monoamine oxidases [141]. 
 
Attempts to provide any experimental support for SET mechanism failed, enforcing 
the conclusion that this “route” is both kinetically and thermodynamically 
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improbable. In 1999 Edmonson proposed the polar nucleophilic mechanism (Scheme 
4.2) which is more in accordance with experimental evidences [142]. 
 
 
Scheme 4.2. Polar nucleophilic mechanism of action of monoamine oxidases [142]. 
 
This hypothesis did not lie on radical mechanism. The nucleophilic attack of amine 
nitrogen on C(4a) position of isoalloxazine ring, produces an adduct with a positively-
charged nitrogen deriving from the amine substrate, and a negatively-charged 
nitrogen N(5) of the FAD. This condition increases the pKa of the α-carbon protons 
that can be easily abstracted due to the proximal distance to the isoalloxazine 
negatively-charged N(5), producing the iminium ion (Scheme 4.2).  
The main by-product of this metabolic pathway is hydrogen peroxide which is 
normally deactivated by glutathione peroxidase (GDO). However, if the levels of 
glutathione (GSH) in the brain are low, hydrogen peroxide can be converted by Fe2+ 
ions (the Fenton reaction) into highly reactive oxygen species (ROS), which have been 
proposed to be involved in the neurotoxicity observed in some neurodegenerative 
disorders [143–146].  
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4.3 Pathological roles and inhibitors of hMAOs 
Physiological and pathological roles of hMAO-A and hMAO-B have been extensively 
studied [127,131,139,147–152]. The two enzymes share similar affinity for some 
substrate as dopamine, epinephrine, norepinephrine, and tyramine. Serotonin is the 
preferred substrate for hMAO-A while benzylamine for hMAO-B [153]. 
hMAOs are coexpressed in almost all human tissues except for placenta, which 
predominantly expresses hMAO-A and platelets and lymphocytes, which 
predominantly express hMAO-B. Furthermore, hMAO-A is prevalent in the intestinal 
tract, while hMAO-B is found mostly in the brain and liver. The localization of these 
proteins reflects their functions. In fact, hMAO in peripheral tissues seems to protect 
the body by oxidizing amines from the blood or by preventing their entry into the 
circulation. hMAO-B in the microvessels of the blood brain barrier (BBB) presumably 
has a similar protective function, acting as a metabolic barrier [154]. In the central 
nervous system (CNS) they affect monoamines concentration controlling in this way 
the physiological and functional concentration of some neurotransmitters as 
dopamine, norepinephrine and serotonin.  So, the use of hMAOs inhibitors able to act 
in the CNS, reduce the degradation of neurotransmitters. This has beneficial effects for 
the treatment of pathologies spanning from mental illness like depression to 
Parkinson’s disease and other neurodegenerative disorders. While hMAO-A 
inhibitors positively affect depression due to the increasing of serotonin and 
norepinephrine levels [151], hMAO-B inhibitors ameliorate neurodegenerative 
disorders conditions raising dopaminergic tone. 
Furthermore, hMAOs inhibition reduces the products (aldehyde and ammonium ion) 
and by-product (hydrogen peroxide, H2O2) amounts. Albeit aldehydes do not appear 
to accumulate in the healthy brain, some studies have shown that elevate 
concentration of this product exert cytotoxic effects [155].  
Concerning H2O2 the cells usually possess some machinery systems able to act as 
defenders against this oxidant molecule. Abnormal expression or increased activity of 
hMAOs lead to excessive production of H2O2 which can corrode all the protective 
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agents of the cells, exposing these to the oxidative damages. The presence of some 
cations as Fe2+ and/or Cu+ affect and increase the rate of production of reactive species 
of oxygen (ROS). ROS are less stable than H2O2 and react suddenly with the 
surrounding protein systems, with structural/functional damage leading to cells 
death. This cellular stress has been associated with different pathologies as 
neurodegenerative disorders and cardiomyopathies [156–158], so hMAOs inhibition 
reduces the amount of produced hydrogen peroxide and so, the exposure to oxidative 
stress.  
The first indication for hMAO inhibitors was for the treatment of depression after the 
serendipitous discovery that the mood elevating properties of antitubercular agent 
isoniazid were related to the inhibition of hMAOs [159]. Iproniazid possessing similar 
structure of isoniazid but with minor toxicity, was the first hMAO inhibitor approved 
for the treatment of major depression [160]. The neurotransmitters involved in 
depressive illness are serotonin and norepinephrine. They undergo the activity of 
hMAO-A in the brain, so one approach for development of antidepressant was the 
design of specific and irreversible inhibitors of the hMAO-A isoform [161,162]. 
Nowadays some irreversibly acting compounds such as tranylcypromine (Figure 4.5) 
are still used for the treatment of major depression, although appropriate dietary 
restrictions must be observed to avoid the “cheese reaction” resulting in hypertensive 
crisis and brain haemorrhages [163–165].  
To avoid the drawbacks of these compounds, reversible inhibitors such as 
moclobemide and toloxatone have been developed and used in the therapy of 
depression. They are safer and better-tolerated, not showing the effect of tyramine on 
blood-pression, likely because the increase of amount of physiological substrate 
displaces the inhibitors that reversibly bound the enzyme [166,167].  
As mentioned before hMAO-A specific inhibitors may find future also as protectants 
against cardiac cellular degeneration [168], while ongoing studies are evaluating the 
involvement of hMAO-A overexpression in cancer [169,170]. 
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Figure 4.5. Irreversible and reverible inhibitors of hMAOs. 
 
hMAO-B inhibitors are useful in the treatment of Parkinson’s disease reducing the 
degradation of central dopamine. They were used both as monotherapy in the early 
phase of disease delaying the need for L-dopa [171], or co-administered with L-dopa 
enhancing the levels of dopamine “artificially” derived from L-dopa [172,173]. 
Increased hMAO-B expression as well as iron levels in other neurodegenerative 
disorders like Alzheimer’s disease have been observed [30]. So, these compounds 
potentially act also as neuroprotective molecules reducing the amount of by-product 
deriving from hMAOs activity, whose expression increase with the age.  
Up to day, two hMAO-B inhibitors are used for the treatment of Parkinson’s disease: 
(R)-deprenyl (also known as selegiline) and rasagiline (Figure 4.5). These compounds 
exhibited irreversible mechanism based on the propargylamine functional group. The 
reversible hMAO-B inhibitor, safinamide, has recently been approved for the 
management of Parkinson´s disease [174,175]. 
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Chapter 5 
Benzo[b]tiophen-3-ol derivatives as effective inhibitors of hMAOs: 
design, synthesis and biological activity 
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5.1 Development of new inhibitors of hMAOs: aim of the work 
An extensive number of natural and synthetic compounds have shown effective 
inhibition of human MAOs [152,157]. Keeping in mind the structure and properties of 
endogenous substrates and reversible inhibitors that bind to hMAOs, Wouters et al. 
[176] proposed that ideal MAO inhibitors should be flat molecules (Figure 5.1) with 
specific dimensions depending on the isoform (11.5 x 5.5 x 1.8 Å for hMAO-A and 8.5 
x 5.1 x 1.8 Å for hMAO-B). 
 
 
Figure 5.1. Molecular properties of the pharmacophore for the inhibition of the hMAOs. The 
part of the structure shown in red corresponds to the chalcone moiety. 
 
The pharmacophore reported in Figure 5.1 was inspired by isatin and indole 
analogues which possess different enzyme specificities, inhibiting respectively 
hMAO-B and hMAO-A [137,177]. Although the dimensions of compounds may 
explain the different affinities for the MAO isoforms (hMAO-A can accommodate 
larger molecule than hMAO-B), the changes of the electron density in the molecules 
play an important role in enzyme selectivity. As a matter of the fact, follow-up studies 
focused on the isosteric substitution of the nitrogen of the indole system with an 
oxygen atom or methylene group, to obtain respectively aurone [178] and indanone 
derivatives [179,180] (Figure 5.2). 
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Figure 2. Structure of aurone (A) and indanone (B) derivatives. Chalcone moiety has been depicted in 
red. 
 
Aurone derivatives (Figure 5.2, A) showed selective inhibition towards rat MAO-B 
(rMAO-B) with IC50 values ranging from 11.6 µM to 26.3 µM, without activity against 
the A isoform of rMAO (IC50 > 100 µM). On the other hand, indanone derivatives 
showed good inhibitory profile in the low micromolar range especially for hMAO-B 
(0.0052 < IC50 hMAO-B (µM) < 2.74). All these structures (indole analogues, aurone and 
indanone derivatives) show a common structural feature, similar to the chalcone 
moiety (highlighted in red), whose ability to bind to hMAO enzymes have been 
reported in the past by our group [181]. With the aim to explore new structures for the 
inhibition of hMAO, I proposed a new scaffold based on benzo[b]thiophen-3-ol 
structure (Figure 5.3). This scaffold retained some similarity with the compounds 
discussed above, for example the presence of bicyclic system connected with a 
“bridge” to aromatic/heteroaromatic ring. The bridge, for indole, aurone and indanone 
derivatives is the β-carbon of the α,β-unsaturated ketone. Conversely, for the structure 
of benzo[b]thiophen-3-ol, the carbonyl moiety of the α,β-unsaturated ketone is the 
“bridge”. 
 
 
 
Figure 5.3. Benzo[b]thiophen-3-ole scaffold. Similarities and differences with previously 
reported scaffolds. 
A B 
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Other important differences among these scaffolds are the isosteric replacement of the 
oxygen atom of aurones with sulphur and the presence of 1,3-diketonic system that, 
via keto-enol tautomerism, generates the corresponding chalcone while also 
possessing the potential for metal chelation [182]. This is a very interesting aspect and 
provides the possibility to obtain multi-target drug in the light of the evidence that 
some cations (e.g. Fe2+ and Cu+) may contribute to neurodegeneration in central 
nervous system tissues. In fact, these ions are implicated in the Fenton reaction [183] 
which catalyse the production of hydroxyl radicals from hydrogen peroxide, a well-
known by-product of MAO enzymatic activity [145,146]. Since hydroxyl radicals 
possess a very short half-life, estimated at 1 ns, they can be highly toxic to biomolecules 
and the use of chelating agents should repair this metal dyshomeostasis leading to 
reduced damage derived from oxidative stress. 
 
5.2 Chemistry 
The structure of benzo[b]thiophen-3-ol has been previously studied from a chemical 
point of view, and several research groups have proposed synthetic strategies to obtain 
this class of compounds [184–186]. Here I propose a new one-step, very simple 
synthetic procedure which allowed us to obtain the desired compounds PM1-PM20 
(Scheme 5.1). Methyl 2-mercaptobenzoate and α-bromo acetophenone in equimolar 
amount, were reacted in methanol in the presence of potassium hydroxide. The 
reaction was performed in a nitrogen atmosphere (to avoid sulphur oxidation) and at 
room temperature for 1-2 h. After this time, an excess of potassium hydroxide was 
added, and the temperature was raised to 60 °C. The completion of reactions was 
usually reached in 4-5 hours producing all the compounds PM1-PM20 in moderate to 
high yields. 
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Scheme 5.1. Synthesis of compounds PM1-PM20. 
 
We proposed a reaction mechanism for the synthesis of the benzo[b]thiophen-3-ol 
derivatives as reported in Scheme 5.2. The reaction starts with the nucleophilic attack 
of deprotonated thiol group on alfa brominated position of the ketone to obtain the 
intermediate W (Scheme 5.2, I). Then, an intramolecular crossed aldolic reaction take 
place (Scheme 5.2, II). The methylene y attacks methyl ester functional group with 
consequent methanol elimination, producing the benzo[b]thiophen-3-ol [187]. 
 
  
Scheme 2. Proposed mechanism of reaction. 
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5.3 Biological assays 
5.3.1 hMAO-A and hMAO-B inhibition studies 
The synthesised compounds PM1-PM20 were evaluated as hMAO inhibitors using the 
recombinant hMAOs as enzyme sources. For these assays, kynuramine was used as 
substrate for both hMAO isoforms. The oxidation of kynuramine by the hMAOs yields 
4-hydroxyquinoline which was measured by fluorescence spectrophotometry. By 
measuring the hMAO-Activities in the presence of a range of different inhibitor 
concentrations (0.003-100 µM), the IC50 values were measured. The inhibitory activities 
of compounds PM1-PM20 are summarized in Table 5.1 along with selectivity index 
(SI) values given as the ratio (IC50 hMAO-A)/(IC50 hMAO-B). 
 
5.3.2 Evaluation of DOPAC/DA ratio and LDH activity 
Compounds that showed the best inhibitory activity towards hMAO (PM4, PM5, 
PM6, PM9, PM10, PM12, PM13) were also been tested with cortex synaptosomes in 
both basal and LPS-induced inflammatory conditions, to estimate the capability of 
reducing DOPAC/DA ratio and LDH activity. DOPAC/DA ratio describes the extent 
of dopamine turnover and could be considered an indirect index of MAO-B activity 
[188]. On the other hand, LDH has long been considered a valuable marker of tissue 
damage [189,190], and thus the neuroprotective effects of the new compounds were 
also evaluated. 
 
5.4 Result and discussion 
5.4.1 In vitro MAO inhibition study 
All the synthesised compounds PM1-PM20 have been evaluated as potential 
inhibitors of hMAO-A and hMAO-B and the activities are given as the IC50 values in 
Table 5.1. Among these derivatives only compounds PM2, PM17 and PM18 were 
superior inhibitors of hMAO-A compared to hMAO-B, although only to a small extent. 
All the other compounds were selective hMAO-B inhibitors with IC50 values in the 
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micromolar/low micromolar range. The simplest compound of this series, PM1, 
containing an unsubstituted phenyl ring bound to the carbonyl “bridge”, showed 
similar inhibition against both the isoforms with poor selectivity (IC50 hMAO-A = 13.27 
µM; IC50 hMAO-B = 7.39 µM; SIPM1 = 1.8). When phenyl ring was substituted, we 
observed different effects depending on the position and chemical nature of the 
substituent. In fact, the presence of a weak electron donor such as the methyl group on 
phenyl ring, improved inhibition activity towards hMAO-B when it was placed on 
meta- (PM3, IC50 hMAO-B = 1.81 µM) or para- (PM4, IC50 hMAO-B = 0.47 µM) positions. 
PM4 also displayed improved inhibition activity towards hMAO-A (PM4, IC50 hMAO-
A = 2.71 µM), accounting for the slightly reduced SI compared with PM3 (PM3, IC50 
hMAO-A = 12.59 µM). On the other hand, when this substituent was located at the 
ortho-position, we observed reduced inhibitory activity against both the isoforms, with 
a slight preference for hMAO-A (PM2, IC50 hMAO-A = 18.66 µM; IC50 hMAO-B = 23.38 
µM; SI = 0.8). A similar trend was observed for compounds substituted with the 
methoxy group, which is considered to be a stronger electron donor than the methyl 
(PM5-PM6). For these two derivatives we also recorded different inhibition activities 
towards hMAO-B, with the best outcome observed when methoxy group was placed 
on the para-position of the phenyl ring (PM6, IC50 hMAO-B = 0.28 µM). Similar to the 
methyl substituted derivatives, the placement of the methoxy substituent on meta-
position negatively affected inhibition activity against hMAO-A (PM5, IC50 hMAO-A 
= 32.97 µM), thus improving the selectivity index (SI = 42.3). In the light of the above, 
it may be concluded that electron donor groups improve inhibitory activity towards 
hMAO-B when they were on meta- and para-positions. Furthermore, when these 
groups are on meta-position, they also led to an increase in selectivity due to the 
reduction of hMAO-A inhibition. A different trend was observed for halogen-
substituted derivatives (PM7-PM13). The data show that when substitution is changed 
from the fluorine, to chlorine and finally to bromine, there is an incremental increase 
of inhibitory activity and selectivity towards hMAO-B, according with the increased 
size and reduced electronegativity of the halogen, with the best inhibition shown by 
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compound PM12 (IC50 hMAO-B = 0.35 µM; SI = 180.4). In the light of the above, we 
conclude that halogens, which represent electron-withdrawing groups, positively 
affect both inhibition activity and selectivity when they are placed in meta-position 
(e.g. PM12, IC50 hMAO-B = 0.35 µM vs. PM13, IC50 hMAO-B = 0.88 µM). This trend 
differs from that observed with the electron donor groups (e.g. methyl or methoxy). 
Other compounds such as PM14 and PM15 which are substituted on para-position 
with CN and NO2, exhibited hMAO-B inhibition in the low micromolar range (PM14, 
IC50 hMAO-B = 4.51 µM; PM15, IC50 hMAO-B = 2.75 µM) with little selectivity between 
the two isoforms (PM14 SI = 4.7; PM15 SI = 6.8). The presence of a heterocyclic ring for 
compounds PM16-PM19 negatively affected the inhibition of hMAO-B. Finally, 
substitution of the phenyl ring with the bulky naphthyl, but not biphenyl, improved 
both activity and selectivity towards hMAO-B (PM20, IC50 hMAO-B = 1.08 µM; SI = 
39.4). 
 
Table 5.1. Inhibitory activity (IC50) and selectivity index (SI) towards hMAO-A and hMAO-B 
of compounds PM1-PM20. 
 
IC50 ± SD (µM)a 
SIb 
Compound Substituent hMAO-A hMAO-B 
PM1 
 
13.27 ± 0.29 7.39 ± 0.15 1.8 
PM2 
 
18.66 ± 2.99 23.38 ± 3.03 0.8 
PM3 
 
12.59 ± 1.58 1.81 ± 0.13 6.9 
PM4 
 
2.71 ± 0.14 0.47 ± 0.02 5.8 
120 
 
PM5 
 
32.97 ± 0.88 0.78 ± 0.07 42.3 
PM6 
 
4.18 ± 0.77 0.28 ± 0.03 14.9 
PM7 
 
25.05 ± 2.17 1.44 ± 0.40 17.4 
PM8 
 
13.40 ± 0.92 2.28 ± 0.18 5.8 
PM9 
 
51.04 ± 1.72 0.55 ± 0.09 92.8 
PM10 
 
13.75 ± 0.51 0.89 ± 0.07 15.4 
PM11 
 
43.36 ± 2.81 37.31 ± 1.01 1.2 
PM12 
 
63.16 ± 3.48 0.35 ± 0.08 180.4 
PM13 
 
21.05 ± 1.98 0.88 ± 0.08 23.9 
PM14 
 
21.21 ± 3.27 4.51 ± 0.13 4.7 
PM15 
 
18.80 ± 1.53 2.75 ± 0.02 6.8 
PM16 
 
50.05 ± 2.56 49.73 ± 1.90 1.0 
PM17 
 
53.75 ± 2.90 56.93 ± 5.62 0.9 
PM18 
 
6.44 ± 0.68 7.56 ± 0.70 0.8 
121 
 
PM19 
 
36.45 ± 1.07 5.59 ± 0.74 6.5 
PM20 
 
42.54 ± 1.88 1.08 ± 0.097 39.4 
aValues are the mean ± SD of triplicate determinations. bSelectivity index for the MAO-B 
isoform, given as the ratio: (IC50 hMAO-A)/(IC50 hMAO-B). 
 
5.4.2 Evaluation of DOPAC/DA ratio and LDH activity 
Figures 5.4-5.7 show that deprenyl, an irreversible and selective MAO-B inhibitor, and 
the new MAO inhibitors PM4, PM5, PM6, PM9, PM10, PM12 and PM13 were able to 
exert modulatory effects on cortex synaptosomes DA/DOPAC ratio and LDH activity, 
in both basal and LPS-induced inflammatory conditions. 
Particularly, in Figure 4 it is possible to observe that deprenyl and PM9 stimulated 
DOPAC/DA ratio, while PM10, PM12 and PM13 inhibited basal DOPAC/DA ratio. On 
the other hand, no significant effect was exerted by PM4, PM5 and PM6. When 
synaptosomes were challenged with inflammatory LPS stimulus (Figure 5.5), we 
observed that deprenyl and all PM inhibitors were able to reduce DOPAC/DA ratio. 
Additionally, the present molecules were more effective than deprenyl, with the 
highest inhibitory effects displayed by PM10, PM12 and PM13. 
DOPAC/DA ratio has long been proposed as an index of MAO-B activity [188], while 
microdialysis studies demonstrated the ability of LPS to increase monoamine 
degradation and extracellular DOPAC levels, in mouse prefrontal cortex [191]. 
Additionally, we have recently reported that the pro-oxidant stimulus induced by 
amyloid β-peptide could reduce monoamine levels, in rat cortex synaptosomes [192]. 
Despite there being agreement between the data reported in Figure 5.5 and the MAO-
B inhibitory activity described in Table 5.1, whereas the contrasting results obtained 
in basal condition (Figure 5.4), following PMs treatment, suggest the possible onset of 
pro-inflammatory/pro-oxidant effects, which could have overcome the intrinsic MAO 
inhibitory activity of these molecules, thus leading to increased DA turnover in rat 
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cortex synaptosomes. In order to test this hypothesis, we performed a second set of 
experiments to evaluate the effect of deprenyl and the PM inhibitors on cortex 
synaptosome LDH activity, in both basal and LPS-induced inflammatory condition 
(Figures 5.6-5.7). 
LDH has long been considered a valuable marker of tissue damage [189,190]. 
Additionally, antioxidants resulted able to downregulate its activity, ex vivo [193]. In 
the present study we observed that, except for compound PM13, most of the PM 
inhibitors upregulated basal LDH activity (Figure 5.6). Conversely, when 
synaptosomes were perfused with Krebs-Ringer buffer added with LPS, deprenyl 
inhibited LDH activity at the lowest concentration (20 nM), which is very close to its 
MAO-B IC50 value (17 nM) [194], despite exerting a stimulatory effect at the highest 
tested concentration (1 µM). We cannot exclude that the highest tested deprenyl 
concentration (1 µM) could be toxic for cortex synaptosomes. Similarly, the PM 
inhibitors displayed a significant LDH inhibitory activity, which is more evident 
around their respective IC50 values, which are included in the range 0.1-1 µM (Table 
5.1). Unlike deprenyl, all the PM molecules inhibited LDH activity in the concentration 
range (0.1-1 μM). Our findings of reduced LPS-induced LDH activity by both deprenyl 
(20 nM) and PMs (0.1-1 μM), in rat cortex synaptosomes, are consistent with the 
reported antioxidant activity of MAO inhibitors, in vivo [195,196]. On the other hand, 
we should consider that the contrasting finding of stimulation of LDH activity (Figure 
5.6), induced by deprenyl and PM inhibitors in basal condition, could be related to the 
employed ex vivo experimental model. Specifically, it is well known that antioxidants 
in the cell medium could exert pro-oxidative effects, by generating hydrogen peroxide 
and thus activating adaptive responses of cells to mild oxidative stress [197]. In this 
context, it is rational to hypothesize that our results of blunted LPS-induced 
DOPAC/DA ratio and LDH activity, in cortex synaptosomes treated with both 
deprenyl and PMs, could be related to both MAO-B inhibition activity and improved 
neuron antioxidant defence system. Taken together, these findings support further 
deepening of PM inhibitor efficacy in in vivo experimental models of 
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neuroinflammation and oxidative stress. Particularly, future studies should involve 
inhibitors PM10, PM12 and PM13 which exerted the highest inhibitory efficacy on 
both LPS-induced DOPAC/DA ratio and LDH activity (Figures 5.5 and 5.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Effect of PMs on DOPAC/DA ratio in rat cortex synaptosomes. ANOVA: P<0.0001; 
post-hoc: ***P<0.001 vs. Vehicle group. 
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Figure 5.5. Effect of PMs on DOPAC/DA ratio in rat cortex synaptosomes challenged with LPS. 
ANOVA: P<0.0001; post-hoc: *P<0.05, ***P<0.001 vs. LPS group. 
 
 
Figure 5.6. Effect of PMs on LDH activity in rat cortex synaptosomes. ANOVA: P<0.0001; post-
hoc: *P<0.05, **P<0.01, ***P<0.001 vs. Vehicle group. 
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Figure 5.7. Effect of PMs on LDH activity in rat cortex synaptosomes challenged with LPS. 
ANOVA: P<0.0001; post-hoc: *P<0.05, **P<0.01, ***P<0.001 vs. LPS group. 
 
5.5 Conclusions 
The design, synthesis, characterization and in vitro biological activity evaluation of 
some novel benzo[b]thiophen-3-ol derivatives as inhibitors of hMAO-B have been 
reported. These compounds have been synthesised through a new simple synthetic 
approach consisting in a one-step reaction, with moderate to high yields. The 
compounds PM1-PM20 showed activity in the micromolar/low micromolar range 
against hMAO-B, with the best activity exhibited by PM6 with Ki = 0.28 µM, however 
possessing only a little selectivity index (SI = 14.9). On the other hand, the halogen-
substituted compounds, showed a better inhibition profile, with increased activity, 
with the best performance obtained for compound PM12, containing meta-bromo 
substituted phenyl ring (Ki hMAO-B = 0.35 µM; SI = 180).  
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Compounds PM1-PM20 have also been tested with cortex synaptosomes in both basal 
and LPS-induced inflammatory conditions to evaluate their ability to affect the 
DOPAC/DA ratio as well as LDH activity. DOPAC/DA ratio is an indirect index of 
MAO-B activity, and all the tested compounds are effective in reducing this value in 
cortex synaptosomes challenged with LPS, showing outcomes better than the reference 
drug deprenyl. Furthermore, all the PM molecules inhibited LDH activity in the 
concentration range 0.1-1 µM, showing potential activity as neuroprotective agents. 
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5.6 Experimental section 
General 
Unless otherwise indicated, all reactions were carried out under a positive nitrogen 
pressure (balloon pressure) in washed and oven-dried glassware. Solvents were used 
as supplied without further purification. Where mixtures of solvents are specified, the 
stated ratios are volume:volume. Reagents were used directly as supplied by Sigma-
Aldrich® (Italy). All melting points were measured on a Stuart® melting point 
apparatus SMP1, and are uncorrected. Temperatures are reported in °C. Fluorescence 
spectrophotometry was carried out with a Varian Cary Eclipse fluorescence 
spectrophotometer. 1H and 13C NMR spectra were recorded at 400 and 101 MHz, 
respectively, on a Bruker spectrometer using CDCl3 and DMSO-d6 as the solvents at 
room temperature. The samples were analysed with a final concentration of ~30 
mg/mL. Chemical shifts are expressed as δ units (parts per millions) relative to the 
solvent signal. 1H spectra are reported as follows: δH (spectrometer frequency, solvent): 
chemical shift/ppm (multiplicity, J-coupling constant(s), number of protons, assignment). 13C 
spectra are reported as follows: δC (spectrometer frequency, solvent): chemical shift/ppm 
(assignment). Multiplets are abbreviated as follows: br – broad; s – singlet; d – doublet; t 
– triplet; q – quartet; m – multiplet. Coupling constants J are valued in Hertz (Hz). The 
processing and analyses of the NMR data were carried out with MestreNova. Column 
chromatography was carried out using Sigma-Aldrich® silica gel (high purity grade, 
pore size 60 Å, 230–400 mesh particle size). All the purifications and reactions were 
monitored by TLC performed on 0.2 mm thick silica gel-aluminium backed plates (60 
F254, Merck). Visualization was carried out under ultra-violet irradiation (254 nm). 
Where given, systematic compound names are those generated by ChemBioDraw 
Ultra 12.0 following IUPAC conventions. Microsomes from insect cells containing 
recombinant hMAO-A and hMAO-B (5 mg protein/mL) and kynuramine 
dihydrobromide were obtained from Sigma–Aldrich. 
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Chemistry 
General procedure for the synthesis of derivatives PM1-PM20: in an oven dried flask 
containing a stirring solution of methyl 2-mercaptobenzoate (1.0 eq.) in methanol (10 
mL), were added freshly ground potassium hydroxide (1.5 eq.) and the appropriate α-
bromoacetophenone (1.0 eq). The reaction was performed at room temperature for 1-
2 hours. After this time, an excess of potassium hydroxide was added (1.5 eq.) and the 
temperature was raised to 60 °C. The progression of reaction was monitored by TLC 
and completion was usually reached in 4-5 hours. The reaction was poured on ice-cold 
water (30 mL) and the pH was adjusted to the value of ~7 to induce the complete 
precipitation of compound. The resulting benzo[b]thiophen-3-ol was collected by 
filtration and washed with hot methanol (20 mL). This procedure was used in order to 
obtain all the compounds PM1-PM20 in moderate to high yields and a good level of 
purity. 
 
Chemical characterization of compounds PM1-PM20 
 
 
(3-hydroxybenzo[b]thiophen-2-yl)(phenyl)methanone (PM1) 
Yellow powder, mp 117-120 °C, 80% yield; 1H NMR (400 MHz, DMSO-d6): δ 7.48-7.52 
(m, 1H, benzothiophene), 7.58-7.72 (m, 3H Ar + 1H benzothiophene), 7.92-7.95 (m, 2H, 
Ar), 7.98 (d, J = 8.2 Hz, 1H, benzothiophene), 8.05 (d, J = 8.0 Hz, 1H, benzothiophene), 
12.02 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, DMSO-d6): δ 112.2 
(benzothiophene), 123.9 (benzothiophene), 124.0 (benzothiophene), 125.5 
(benzothiophene), 128.8 (2 x Ar), 129.1 (2 x Ar), 130.4 (benzothiophene), 131.1 (Ar), 
133.1 (Ar), 138.6 (benzothiophene), 140.0 (benzothiophene), 160.3 (Cbenzothiophene-OH), 
190.9 (C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(o-tolyl)methanone (PM2) 
Yellow powder, mp 131-133 °C, 86% yield; 1H NMR (400 MHz, CDCl3): δ 2.50 (s, 3H, 
CH3), 7.32-7.36 (m, 2H, Ar), 7.43-7.48 (m, 1H Ar + 1H benzothiophene), 7.54-7.58 (m, 
1H, benzothiophene), 7.63-7.65 (m, 1H, Ar), 7.71 (d, J = 8.2 Hz, 1H, benzothiophene), 
8.09 (d, J = 8.0 Hz, 1H, benzothiophene), 12.84 (br, 1H, OH, D2O exch.). 13C NMR (101 
MHz, CDCl3): δ 19.7 (CH3), 112.0 (benzothiophene), 123.1 (benzothiophene), 124.0 
(benzothiophene), 124.7 (benzothiophene), 125.5 (Ar), 127.4 (Ar), 130.0 
(benzothiophene), 130.5 (benzothiophene), 130.9 (Ar), 131.3 (Ar), 136.3 (Ar), 138.3 (Ar), 
141.0 (benzothiophene), 160.3 (Cbenzothiophene -OH), 190.9 (C=O). 
 
 
(3-hydroxybenzo[b]thiophen-2-yl)(m-tolyl)methanone (PM3) 
Yellow powder, mp 122-124 °C, 76% yield; 1H NMR (400 MHz, CDCl3): δ 2.49 (s, 3H, 
CH3), 7.44-7.48 (m, 2H Ar + 1H benzothiophene), 7.56-7.60 (m, 1H, benzothiophene), 
7.76 (d, J = 8.2 Hz, 1H, benzothiophene), 7.87-7.89 (m, 2H, Ar), 8.09 (d, J = 8.0 Hz, 1H, 
benzothiophene), 13.49 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 21.5 
(CH3), 109.7 (benzothiophene), 123.0 (benzothiophene), 124.0 (benzothiophene), 124.7 
(benzothiophene), 125.6 (Ar), 128.6 (Ar), 128.9 (Ar), 130.1 (benzothiophene), 130.3 
(benzothiophene), 133.4 (Ar), 138.3 (Ar), 138.7 (Ar), 140.8 (benzothiophene), 165.3 
(Cbenzothiophene-OH), 192.1 (C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(p-tolyl)methanone (PM4) 
Yellow powder, mp 99-101 °C, 77% yield; 1H NMR (400 MHz, CDCl3): δ 2.49 (s, 3H, 
CH3), 7.35-7.37 (m, 2H, Ar), 7.43-7.47(m, 1H, benzothiophene), 7.55-7.59 (m, 1H, 
benzothiophene), 7.75 (d, J = 8.2 Hz, 1H, benzothiophene), 7.87-7.89 (m, 2H, Ar), 7.99-
8.01 (m, 2H, Ar), 8.09 (d, J = 8.0 Hz, 1H, benzothiophene), 13.6 (br, 1H, OH, D2O exch.). 
13C NMR (101 MHz, CDCl3): δ 21.7 (CH3), 109.5 (benzothiophene), 122.9 
(benzothiophene), 123.9 (benzothiophene), 124.7 (benzothiophene), 128.6 (2 x Ar), 
129.4 (2 x Ar), 130.0 (benzothiophene), 130.3 (benzothiophene), 135.5 (Ar), 140.7 
(benzothiophene), 143.5 (Ar), 165.3 (Cbenzothiophene-OH), 191.4 (C=O). 
 
 
(3-hydroxybenzo[b]thiophen-2-yl)(3-methoxyphenyl)methanone (PM5) 
Yellow powder, mp 100-104 °C, 63% yield; 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H, 
OCH3), 7.16-7.19 (m, 1H, Ar), 7.44-7.49 (m, 1H Ar + 1H benzothiophene), 7.56-7.60 (m, 
1H Ar + 1H benzothiophene), 7.66-7.69 (m, 1H, Ar), 7.76 (d, J = 8.2 Hz, 1H, 
benzothiophene), 7.87-7.89 (m, 2H, Ar), 8.09 (d, J = 8.1 Hz, 1H, benzothiophene), 13.45 
(br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 55.5 (OCH3), 109.7 
(benzothiophene), 119.2 (Ar), 120.8 (Ar), 123.0 (benzothiophene), 124.0 
(benzothiophene), 124.8 (benzothiophene), 129.8 (Ar), 130.2 (benzothiophene), 130.3 
(benzothiophene), 139.5 (Ar), 140.8 (benzothiophene), 159.8 (Ar), 165.4 (Cbenzothiophene-
OH), 191.6 (C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(4-methoxyphenyl)methanone (PM6) 
Yellow powder, mp 181-183 °C, 73% yield; 1H NMR (400 MHz, DMSO-d6): δ 3.88 (s, 
3H, OCH3), 7.13-7.15 (m, 2H, Ar), 7.49-7.53 (m, 1H, benzothiophene), 7.62-7.66 (m, 1H, 
benzothiophene), 7.98-8.01 (m, 2H Ar + 1H benzothiophene), 8.03 (d, J = 8.0 Hz, 1H, 
benzothiophene), 12.76 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, DMSO-d6): δ 56.1 
(OCH3), 111.4 (benzothiophene), 114.6 (2 x Ar), 123.7 (benzothiophene), 123.9 
(benzothiophene), 125.5 (benzothiophene), 130.3 (benzothiophene), 130.7 
(benzothiophene), 130.9 (Ar), 131.3 (2 x Ar), 139.7 (benzothiophene), 160.9 (Ar), 163.5 
(Cbenzothiophene-OH), 189.5 (C=O). 
 
 
(3-fluorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM7) 
Yellow powder, mp 114-118 °C, 82% yield; 1H NMR (400 MHz, CDCl3): δ 7.31-7.36 (m, 
1H, Ar), 7.45-7.49 (m, 1H, benzothiophene), 7.52-7.62 (m, 1H Ar + 1H benzothiophene), 
7.74-7.77 (m, 1H Ar + 1H benzothiophene), 7.88 (d, J = 7.7 Hz, 1H, Ar), 8.09 (d, J = 8.1 
Hz, 1H, benzothiophene), 13.49 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): 
δ 109.4 (benzothiophene), 115.4 (d, JC-F = 23.1 Hz, Ar), 119.5 (d, JC-F = 21.3 Hz, Ar), 123.0 
(benzothiophene), 124.1 (benzothiophene), 124.2 (d, JC-F = 3.2 Hz, Ar), 124.9 
(benzothiophene), 130.2 (benzothiophene), 130.4 (benzothiophene), 130.4 (d, JC-F = 7.8 
Hz, Ar), 140.2 (d, JC-F = 6.8 Hz, Ar), 140.8 (benzothiophene), 162.7 (d, JC-F = 248.5 Hz, Ar), 
165.8 (Cbenzothiophene-OH), 190.2 (C=O). 
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(4-fluorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM8) 
Yellow powder, mp 96-100 °C, 87% yield; 1H NMR (400 MHz, CDCl3): δ 7.12 (t, J = 8.6 
Hz, 2H, Ar), 7.34 (t, J = 7.6 Hz, 1H, benzothiophene), 7.46 (t, J = 7.6 Hz, 1H, 
benzothiophene), 7.63 (d, J = 8.2 Hz, 1H, benzothiophene), 7.95-8.01 (m, 2H Ar + 1H 
benzothiophene), 13.32 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 109.2 
(benzothiophene), 115.9 (d, JC-F = 21.9 Hz, 2 x Ar), 123.0 (benzothiophene), 124.0 
(benzothiophene), 124.8 (benzothiophene), 130.2 (benzothiophene), 130.3 
(benzothiophene), 131.0 (d, JC-F = 9.2 Hz, 2 x Ar), 134.4 (d, JC-F = 3.0 Hz, Ar), 140.6 
(benzothiophene), 165.4 (d, JC-F = 254.7 Hz, Ar), 165.6 (Cbenzothiophene-OH), 190.2 (C=O). 
 
 
(3-chlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM9) 
Yellow powder, mp 148-158 °C, 89% yield; 1H NMR (400 MHz, CDCl3): δ 7.45-7.52 (m, 
1H Ar + 1H benzothiophene), 7.58-7.62 (m, 1H Ar + 1H benzothiophene), 7.76 (d, J = 
8.2 Hz, 1H, benzothiophene), 7.94-7.96 (m, 1H, Ar), 8.03-8.04 (m, 1H, Ar), 8.09 (d, J = 
8.0 Hz, 1H, benzothiophene), 13.29 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, 
CDCl3): δ 109.4 (benzothiophene), 123.0 (benzothiophene), 124.1 (benzothiophene), 
124.9 (benzothiophene), 126.5 (Ar), 128.5 (Ar), 130.0 (Ar), 130.2 (benzothiophene), 130.5 
(benzothiophene), 132.6 (Ar), 135.0 (Ar), 139.8 (Ar), 140.8 (benzothiophene), 165.7 
(Cbenzothiophene-OH), 190.2 (C=O). 
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(4-chlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM10) 
Yellow powder, mp 136-138 °C, 88% yield; 1H NMR (400 MHz, CDCl3): δ 7.44-7.48 (m, 
1H, benzothiophene), 7.52-7.55 (m, 2H, Ar), 7.57-7.61 (m, 1H, benzothiophene), 7.75 (d, 
J = 8.2 Hz, 1H, benzothiophene), 8.00-8.04 (m, 2H, Ar), 8.08 (d, J = 8.1 Hz, 1H, 
benzothiophene), 13.40 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 109.3 
(benzothiophene), 123.0 (benzothiophene), 124.1 (benzothiophene), 124.9 
(benzothiophene), 129.1 (2 x Ar), 129.9 (2 x Ar), 130.2 (benzothiophene), 130.4 
(benzothiophene), 136.5 (Ar), 139.1 (Ar), 140.7 (benzothiophene), 165.7 (Cbenzothiophene-
OH), 190.3 (C=O). 
 
 
(2,4-dichlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM11) 
White powder, mp 138-140 °C, 88% yield; 1H NMR (400 MHz, DMSO-d6): δ 7.44 (t, J = 
7.6 Hz, 1H, benzothiophene), 7.58-7.60 (m, 2H Ar + 1H benzothiophene), 7.78 (s, 1H, 
Ar), 7.94 (d, J = 8.1 Hz, 1H, benzothiophene), 8.06 (d, J = 8.1 Hz, 1H, benzothiophene), 
11.74 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, DMSO-d6): δ 116.5 
(benzothiophene), 124.2 (Ar + benzothiophene), 125.2 (benzothiophene), 128.0 (Ar), 
129.4 (Ar), 130.0 (Ar), 130.1 (benzothiophene), 131.2 (Ar), 132.2 (benzothiophene), 135.1 
(Ar), 139.5 (benzothiophene), 140.0 (benzothiophene), 157.3 (Cbenzothiophene-OH), 186.7 
(C=O). 
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(3-bromophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM12) 
Yellow powder, mp 152-158 °C, 90% yield; 1H NMR (400 MHz, CDCl3): δ 7.42-7.49 (m, 
1H Ar + 1H benzothiophene), 7.58-7.62 (m, 1H, benzothiophene), 7.74-7.77 (m, 1H Ar 
+ 1H benzothiophene), 7.99 (d, J = 7.8 Hz, 1H,  Ar), 8.09 (d, J = 8.0 Hz, 1H, 
benzothiophene), 8.18-8.19 (m, 1H, Ar), 13.27 (br, 1H, OH, D2O exch.). 13C NMR (101 
MHz, CDCl3): δ 109.4 (benzothiophene), 123.0 (Ar), 123.1 (benzothiophene), 124.1 
(benzothiophene), 124.9 (benzothiophene), 126.9 (Ar), 130.1 (benzothiophene), 130.3 
(Ar), 130.5 (benzothiophene), 131.4 (Ar), 135.5 (Ar), 140.0 (Ar), 140.8 (benzothiophene), 
165.7 (Cbenzothiophene-OH), 190.1 (C=O). 
 
 
(4-bromophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM13) 
Yellow powder, mp 142-147 °C, 74% yield; 1H NMR (400 MHz, CDCl3): δ 7.46 (t, J = 7.6 
Hz, 1H, benzothiophene), 7.59 (t, J = 7.6 Hz, 1H, benzothiophene), 7.70 (d, J = 8.5 Hz, 
2H, Ar), 7.75 (d, J = 8.2 Hz, 1H, benzothiophene), 7.94 (d, J = 8.5 Hz, 2H, Ar), 8.08 (d, J 
= 8.0 Hz, 1H, benzothiophene), 13.39 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, 
CDCl3): δ 109.3 (benzothiophene), 123.0 (benzothiophene), 124.1 (benzothiophene), 
124.9 (benzothiophene), 127.7 (Ar), 130.0 (2 x Ar), 130.2 (benzothiophene), 130.4 
(benzothiophene), 132.0 (2 x Ar), 136.9 (Ar), 140.7 (benzothiophene), 165.7 (Cbenzothiophene-
OH), 190.4 (C=O). 
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4-(3-hydroxybenzo[b]thiophene-2-carbonyl)benzonitrile (PM14) 
Orange powder, mp 192-200 °C, 61% yield; 1H NMR (400 MHz, DMSO-d6): δ 7.48 (t, J 
= 7.6 Hz, 1H, benzothiophene), 7.62 (t, J = 7.6 Hz, 1H, benzothiophene), 7.96-8.04 (m, 
4H Ar + 1H benzothiophene), 8.08 (d, J = 8.1 Hz, 1H, benzothiophene), 11.95 (br, 1H, 
OH, D2O exch.). 13C NMR (101 MHz, DMSO-d6): δ 114.2 (Ar), 114.5 (benzothiophene), 
118.8 (CN), 124.1 (benzothiophene), 124.2 (benzothiophene), 125.4 (benzothiophene), 
129.4 (2 x Ar), 130.2 (benzothiophene), 131.8 (benzothiophene), 132.8 (2 x Ar), 140.0 
(benzothiophene), 143.1 (Ar), 158.3 (Cbenzothiophene-OH), 188.9 (C=O). 
 
 
(3-hydroxybenzo[b]thiophen-2-yl)(4-nitrophenyl)methanone (PM15) 
Orange powder, mp 205-207 °C, 79% yield; 1H NMR (400 MHz, DMSO-d6): δ 7.49 (t, J 
= 7.6 Hz, 1H, benzothiophene), 7.58-7.71 (m, 1H, benzothiophene), 7.99 (d, J = 8.1 Hz, 
1H, benzothiophene), 8.06-8.11 (m, 2H Ar + 1H benzothiophene), 8.38 (d, J = 8.1 Hz, 
2H, Ar), 11.94 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, DMSO-d6): δ 114.5 
(benzothiophene), 123.9 (2 x Ar), 124.1(benzothiophene), 124.2 (benzothiophene), 125.4 
(benzothiophene), 130.1 (2 x Ar), 130.2 (benzothiophene), 131.9 (benzothiophene), 
140.0 (benzothiophene), 144.8 (Ar), 149.6 (Ar-NO2), 158.1 (Cbenzothiophene-OH), 188.5 
(C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(pyridin-3-yl)methanone (PM16) 
Orange powder, mp 132-134 °C, 79% yield; 1H NMR (400 MHz, DMSO-d6): δ 7.47-7.51 
(m, 1H, benzothiophene), 7.58-7.64 (m, 1H Pyr + 1H benzothiophene), 7.99 (d, J = 8.1 
Hz, 1H, benzothiophene), 8.10 (d, J = 8.1 Hz, 1H, benzothiophene), 8.21-8.24 (m, 1H, 
Pyr), 8.79-8.80 (m, 1H, Pyr), 9.00-9.01 (m, 1H, Pyr), 11.92 (br, 1H, OH, D2O exch.). 13C 
NMR (101 MHz, DMSO-d6): δ 109.5 (benzothiophene), 123.1 (benzothiophene), 123.8 
(Pyr), 124.2 (benzothiophene), 125.1 (benzothiophene), 130.0 (benzothiophene), 130.7 
(benzothiophene), 136.3 (Pyr), 136.4 (Pyr), 140.8 (benzothiophene), 148.8 (Pyr), 152.4 
(Pyr), 165.9 (Cbenzothiophene-OH), 189.3 (C=O). 
 
 
(3-hydroxybenzo[b]thiophen-2-yl)(pyridin-4-yl)methanone (PM17) 
Orange powder, mp 203-205 °C, 65% yield; 1H NMR (400 MHz, CDCl3): δ 7.46-7.50 (m, 
1H, benzothiophene), 7.60-7.64 (m, 1H, benzothiophene), 7.76 (d, J = 8.2 Hz, 1H, 
benzothiophene), 7.85-7.86 (m, 2H, Pyr), 8.10 (d, J = 8.1 Hz, 1H, benzothiophene), 8.87-
8.89 (m, 1H, Pyr), 13.12 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 109.4 
(benzothiophene), 121.6 (2 x Pyr), 123.1 (benzothiophene), 124.3 (benzothiophene), 
125.1 (benzothiophene), 130.0 (benzothiophene), 130.9 (benzothiophene), 141.0 
(benzothiophene), 144.7 (Pyr), 150.6 (2 x Pyr), 165.4 (Cbenzothiophene-OH), 189.7 (C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(thiophen-3-yl)methanone (PM18) 
Yellow powder, mp 114-116 °C, 63% yield; 1H NMR (400 MHz, CDCl3): δ 7.44-7.48 (m, 
1H thiophene + 1H benzothiophene), 7.57-7.61 (m, 1H, benzothiophene), 7.78 (d, J = 8.2 
Hz, 1H, benzothiophene), 7.80-7.81 (m, 1H, thiophene), 8.07 (d, J = 8.0 Hz, 1H, 
benzothiophene), 8.39-8.40 (m, 1H, thiophene), 13.55 (br, 1H, OH, D2O exch.). 13C NMR 
(101 MHz, CDCl3): δ 109.4 (benzothiophene), 123.0 (benzothiophene), 123.9 
(benzothiophene), 124.8 (benzothiophene), 126.6 (thiophene), 127.6 (thiophene), 130.2 
(benzothiophene), 130.4 (benzothiophene), 132.2 (thiophene), 140.2 (thiophene), 141.0 
(benzothiophene), 165.7 (Cbenzothiophene-OH), 184.6 (C=O). 
 
 
[1,1'-biphenyl]-4-yl(3-hydroxybenzo[b]thiophen-2-yl)methanone (PM19) 
Yellow powder, mp 150-154 °C, 89% yield; 1H NMR (400 MHz, CDCl3): δ 7.44-7.54 (m, 
3H Ar + 1H benzothiophene), 7.57-7.61 (m, 1H, benzothiophene), 7.69-7.71 (m, 2H, Ar), 
7.77-7.80 (m, 2H Ar + 1H benzothiophene), 8.11 (d, J = 8.1 Hz, 1H, benzothiophene), 
8.17-8.19 (m, 2H, Ar), 13.61 (br, 1H, OH, D2O exch.). 13C NMR (101 MHz, CDCl3): δ 
109.6 (benzothiophene), 123.0 (benzothiophene), 124.0 (benzothiophene), 124.8 
(benzothiophene), 127.3 (2 x Ar), 127.4 (2 x Ar), 128.3 (Ar), 129.0 (2 x Ar), 129.1 (2 x Ar), 
130.2 (benzothiophene), 130.3 (benzothiophene), 136.9 (Ar), 139.8 (benzothiophene), 
140.8 (Ar), 145.5 (Ar), 165.6 (Cbenzothiophene-OH), 191.14 (C=O). 
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(3-hydroxybenzo[b]thiophen-2-yl)(naphthalen-2-yl)methanone (PM20) 
Yellow powder, mp 126-128 °C, 60% yield; 1H NMR (400 MHz, CDCl3): δ 7.44-7.49 (m, 
1H, benzothiophene), 7.57-7.68 (m, 2H Ar + 1H benzothiophene), 7.78 (d, 2H, J = 8.2 
Hz, 1H, benzothiophene), 7.93-7.95 (m, 1H, Ar), 7.99-8.05 (m, 2H, Ar), 8.09-8.12 (m, 1H 
Ar + 1H benzothiophene), 8.65 (s, 1H, Ar), 13.58 (br, 1H, OH, D2O exch.). 13C NMR (101 
MHz, CDCl3): δ 109.8 (benzothiophene), 123.0 (benzothiophene), 124.0 
(benzothiophene), 124.4 (Ar), 124.8 (benzothiophene), 127.0 (Ar), 127.9 (Ar), 128.5 (Ar), 
128.7 (Ar), 129.5 (Ar), 129.9 (Ar), 130.2 (benzothiophene), 130.4 (benzothiophene), 132.4 
(Ar), 135.3 (Ar), 135.3 (Ar), 139.8, 140.8 (benzothiophene), 145.5 (Ar), 165.6 (Cbenzothiophene-
OH), 191.14 (C=O). 
 
Biological assays 
hMAO-A and hMAO-B inhibition studies 
IC50 values for the inhibition of hMAO-A and hMAO-B were measured according to 
the literature protocol [198,199] with the commercially available recombinant enzymes 
(Sigma-Aldrich) serving as enzyme sources. The enzyme reactions (200 µL) were 
carried out in white 96-well microtiter plates (Eppendorf) in potassium phosphate 
buffer (pH 7.4, 100 mM) and contained kynuramine (50 µM), the test inhibitors 
spanning at least three order of magnitude (0.003-100 µM) and hMAO-A (0.0075 mg 
protein/mL) or hMAO-B (0.015 mg protein/mL). The reactions were initiated with the 
addition of enzyme, incubated for 20 min at 37 °C, and at endpoint were treated with 
2 N NaOH (80 µL) to terminate the enzyme reactions. The fluorescence intensity of 4-
hydroxyquinoline, the product formed by the MAO-catalyzed oxidation of 
kynuramine, was measured (λex = 310 nm; λem = 400 nm). Sigmoidal plots of catalytic 
rate versus logarithm of inhibitor concentration were constructed and the IC50 values 
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were estimated and reported as the mean ± standard deviation (SD) of triplicate 
measurements. 
 
 
Rat cortex synaptosomes 
Male adult Sprague-Dawley rats (200-250 g) were housed in Plexiglass cages (40 cm × 
25 cm × 15 cm), two rats per cage, in climatized colony rooms (22 ± 1 °C; 60% humidity), 
on a 12 h/12 h light/dark cycle (light phase: 07:00–19:00 h), with free access to tap water 
and food, 24 h/day throughout the study, with no fasting periods. Rats were fed a 
standard laboratory diet (3.5% fat, 63% carbohydrate, 14% protein, 19.5% other 
components without caloric value; 3.20 kcal/g). Housing conditions and 
experimentation procedures were strictly in accordance with the European Union 
ethical regulations on the care of animals for scientific research. According to the 
recognized ethical principles of “Replacement, Refinement and Reduction of Animals 
in Research”, specimens were obtained as residual material from vehicle-treated rats 
randomized in our previous experiments approved by Local Ethical Committee 
(University “G. d’Annunzio” of Chieti-Pescara) and Italian Health Ministry (Project N. 
880 definitely approved by Italian Health Ministry on 24th August 2015). 
Synaptosomes were prepared from a pool of frontal and parietal cortex, which are 
more sensitive to oxidative stress, compared to other areas such as occipital and dorsal 
cortex [200]. Briefly, the frontal and parietal cortex was quickly dissected, 
homogenized in 0.32 M saccharose solution and centrifuged, first at 4000×g for 10 min, 
and then at 12000×g for 20 min, to isolate neuronal endings from cell nuclei and glia. 
The purified synaptosomes were suspended at 37 °C, under O2/CO2 95%/5%, pH 7.35–
7.45, in Krebs-Ringer buffer (mM: NaCl 125, KCl 3, MgSO4 1.2, CaCl2 1.2, Tris–HCl 10, 
glucose 10). Then, the synaptosome suspension was divided into fractions (each 
containing 100 mg of tissue in 3 mL medium) that were incubated at 37 °C, under 
agitation for 30 min (incubation period), and treated with a pharmacological stimulus 
as follows: i) Krebs-Ringer buffer (vehicle); ii) vehicle plus oxidant stimulus [LPS 
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10 μg/mL]; iii) vehicle plus oxidant stimulus and I-MAO inhibitors (20 nM-1μM). After 
the incubation period, synaptosome suspension was centrifuged (12000×g for 20 min) 
and the supernatant assayed for LDH, DA and DOPAC determination. 
LDH activity determination 
LDH activity was measured by evaluating the consumption of NADH in 20 mM 
HEPES-K+ (pH 7.2), 0.05% bovine serum albumin, 20 µM NADH and 2 mM pyruvate 
using a microplate reader (excitation 340 nm, emission 460 nm) according to 
manufacturer’s protocol (Sigma-Aldrich). Extracts were tested at 25 µg/mL. Data were 
obtained from triplicate test and expressed as relative variations compared to vehicle-
treated cells [201]. 
 
Neurotransmitter extraction and high performance liquid chromatography (HPLC) 
determination 
Extracellular DA, 5-HT and NE levels were analysed through HPLC apparatus 
consisting of a Jasco (Tokyo, Japan) PU-2080 chromatographic pump and an ESA 
(Chelmsford, MA, USA) Coulochem III coulometric detector, equipped with 
microdialysis cell (ESA-5014b) porous graphite working electrode and solid state 
palladium reference electrode. The analytical conditions for biogenic amine 
identification and quantification were selected as previously reported [202]. Briefly, 
the analytical cell was set at −0.150 V, for detector 1 and at +0.300 V, for detector 2, with 
a range of 100 nA. The chromatograms were monitored at the analytical detector 2. 
Integration was performed by Jasco Borwin Chromatography software, version 1.5. 
The chromatographic separation was performed by isocratic elution on Phenomenex 
Kinetex reversed-phase column (C18, 150 mm×4.6 mm i.d., 2.6 µm). The mobile phase 
was (10:90, v/v) acetonitrile and 75 mM, pH 3.00 phosphate buffer containing 
octanesulfonic acid 1.8 mM, EDTA 30 µM and triethylamine 0.015% v:v. Flow rate was 
0.6 mL/min and the samples were manually injected through a 20 µL loop. 
Neurotransmitter peaks were identified by comparison with the retention time of pure 
standard. Neurotransmitter concentrations in the samples were calculated by linear 
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regression curve (y = bx + m) obtained with standard. Neither internal nor external 
standard were necessary for neurotransmitter quantification and all tests performed 
for method validation yielded results in accordance to limits indicated in official 
guidelines for applicability in laboratory trials. The standard stock solutions of DA, 
and DOPAC at 2 mg/mL were prepared in bi-distilled water containing 0.004% EDTA 
and 0.010% sodium bisulfite. The stock solutions were stored at 4 °C. Work solutions 
(1.25-20.00 ng/mL) were obtained daily progressively diluting stock solutions in 
mobile phase. 
 
Statistical analysis 
GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA) was 
used as statistical analysis software. Experiments were performed at least in triplicate 
and results are presented as mean ± standard deviation (SD). One-way analysis of 
variance (ANOVA) followed by Newman-Keuls post-hoc test was employed to assess 
significant differences (p<0.05). As regards the animals randomized for each 
experimental group, the number was calculated on the basis of the “Resource 
Equation” N=(E+T)/T [203]. 
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